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Abstract 
Glaucoma is a leading cause of blindness worldwide. Surgical lowering of 
intraocular pressure (IOP) is frequently necessary, although scarring causes failure. 
Chemotherapeutics applied locally increase success but may have blinding 
complications, including hypotony and infections.  Modifications in technique 
reduce risk, though intense monitoring is required postoperatively. 
Matrix metalloproteinase inhibitors (MMPis) may be a less toxic anti-scarring 
alternative. Because the inhibition is reversible multiple injections are needed in 
experiments to maintain efficacy. Injections are uncomfortable, painful and costly 
however. The pharmacokinetic profile also shows concentration spikes and rapid 
drug clearance.  
A sustained release preparation is therefore desirable. Here we show in chambers 
modeling aqueous flow that single pure ilomastat MMPi implants maintained a 
therapeutic concentration between 10 and 23 days. In the in vivo model, bleb 
survival appeared to be significantly prolonged, however a foreign body reaction 
existed to undissolved implants, with significant collagen deposition in the 
conjunctiva. To improve efficacy and reduce the proscarring nature of undissolved 
drug, implants of the more soluble MMPi marimastat and combination implants of 
ilomastat together with hyaluronic acid were formulated. These dissolved faster, but 
failed earlier. A combined implant of the anti-inflammatory dexamethasone and 
ilomastat appeared to prolong survival with less, but still considerable reaction. 
Coating ilomastat implants with a biocompatible polymer caused less reaction, but 
inflammatory foci existed around presumed polymer defects. A more hydrophilic 
polymer caused less reaction, though with macrophage infiltration. 
During these experiments it became apparent that bleb appearance when using 
implants did not necessarily correlate with survival. Thus the notion of ‘bleb 
survival’ as an outcome was questioned and other outcomes tested. Dye to trace 
aqueous movement was too slow. Inducing ocular hypertension in the rabbit caused 
only a temporary, unpredictable pressure rise, and buphthalmos. Pooling IOP data 
from larger numbers after standard surgery appeared to be most accurate.  
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Chapter 1  Introduction 
1.1 Glaucoma in the population 
Glaucoma is a term used to describe a group of conditions with an optic neuropathy, 
characteristic morphological changes in the optic nerve head and visual field defects. 
It remains a leading cause of blindness throughout the world and one of the most 
common neuropathies. It is estimated that 60.5 million people suffered from it in 
2010 and 7 million believed to be bilaterally blind (Quigley and Broman, 2006). The 
number of people with glaucoma is projected to increase to 111.8 million in 2040 
(Tham et al., 2014).  
Over the last century, in fact, the proportion of blindness attributed to glaucoma in 
developed countries has changed very little (10%) (Taylor, 2009). In developed 
countries the main cause of blindness 100 years ago was corneal disease, fifty years 
ago it was cataract and in present day it is macular degeneration.  That there has been 
no reduction in the proportion of blindness due to glaucoma is not simply because 
there have been no advances in treatment. A major factor is the ageing population. 
As a population becomes healthier and people live longer, the incidence of this 
degenerative optic neuropathy that reaches a clinically detectable threshold will 
increase. Furthermore, because screening is not cost effective a high proportion of 
patients remain undiagnosed (Wong et al., 2004). Optometrists perform tests for 
glaucoma of varying number and detail, according to their index of suspicion and 
capability. A recent study found evidence that the incidence of diagnosed patients 
with glaucoma was less than half that expected (Lockwood et al., 2010). 
At present glaucomatous optic neuropathy is irreversible and therefore the mainstay 
of treatments involve trying to slow this degeneration. The biggest risk factor for 
accelerated progression is an increased level of intraocular pressure (IOP) and 
reducing this is the only proven therapy in everyday use.  
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1.2 Intraocular pressure (IOP) 
The eye requires a pressure to maintain its structure and function. Under normal 
conditions aqueous fluid is produced by the ciliary body behind the iris. This flows 
through the pupil, and the majority exits via the trabecular meshwork. A small 
proportion of aqueous fluid uses the uveoscleral pathway to exit via the ciliary 
muscle and sclera (Figure 1-1). In a population with no visual symptoms the mean 
IOP has been determined as 15.5 mm Hg, derived from a study of 10000 individuals 
(20000 eyes) (Leydghecker et al., 1958). 
 
 
Figure 1-1 Aqueous circulation in the eye. 
With an increased resistance to flow, most commonly due to intrinsic changes in the 
trabecular meshwork, the pressure increases. Too high a pressure results in 
accelerated optic nerve degeneration either through a direct mechanical effect or 
through ischaemia (Caprioli et al., 2010) or through a combination mechanism (Li et 
 16 
al., 2015). The optic nerve changes in appearance from a pink healthy ‘ring donut’ 
shape to a deep pale ‘cup’ (Figure 1-2). 
 
Figure 1-2. Healthy nerve (left) and glaucomatous nerve (right). 
The human optic nerve consists of approximately 1.2 million ganglion cells. Even in 
people without glaucoma it degenerates at 0.5 % per year (Harwerth et al., 2008). 
Because the brain accepts a rate of degeneration as normal, the patient with 
glaucoma may only appreciate vision loss when the disease is very advanced. The 
time between awareness and blindness as a consequence can be relatively short. 
Therefore, unsurprisingly, a considerable proportion of patients present late, and to 
maintain lifelong reasonable visual function significant intervention is required.  
 Ultimately the aim of glaucoma management is to lower intraocular pressure (IOP) 
to a level at which optic nerve degeneration is slowed and the progression of vision 
loss minimised. Although the level of IOP that causes optic nerve damage varies 
between patients, studies have shown that reducing IOP consistently to less than 15 
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mm Hg minimises progression in patients with advanced disease (AGIS 7., 2000, 
Heijl et al., 2002).  
Most medical therapy involves topical drop application of a drug to the eye on a 
regular basis, and either inhibits aqueous production or improves aqueous outflow. 
Typically the longest licensed interval between administrations is 24 hours. Systemic 
medications, such as carbonic anhydrase inhibitors, are often only used in the short 
term due to the common deleterious side effects. Despite maximal tolerated medical 
treatment however, a subset of patients’ IOP remains above target, their glaucoma 
continues to progress, and if unchecked this leads to blindness. 
Although the patient that exhibits relentless glaucomatous progression, despite 
medical treatment, has entered the ‘surgical zone’ one temporising measure is laser 
treatment. Historically laser treatment has been used to lower the intraocular pressure 
for many years. In general this has been through reducing aqueous production by 
cyclodestruction or improving outflow by treating the trabecular meshwork. Indeed 
early trials suggested the use of argon laser trabeculoplasty might be superior to 
medical therapy as a first line treatment for primary open angle glaucoma (The 
Glaucoma Laser Trial, 1995). The side effect profile of laser treatments has negated 
this change however. Argon laser trabeculoplasty (ALT) can cause IOP spikes, 
inflammation, peripheral anterior synechiae and a lack of efficacy in the longer term. 
Another form of laser, selective laser trabeculoplasty, allowed more specific 
treatment of the pigmented trabecular meshwork rather than the non-pigmented but 
post operative inflammation, although less than ALT, can still occur (Martinez-de-la-
Casa et al., 2004). Conventional cyclodiode can cause inflammation and IOP spikes 
too, but has also been associated with sympathetic ophthalmia and suprachoroidal 
haemorrhage (Tay et al., 2006; Roberts et al., 2009). Recent promising developments 
in laser therapy are techniques that have fewer side effects including the use of anti-
angiogenic adjuncts as a more effective means to tackle NVG. 
1.3 Glaucoma Filtration Surgery 
The ‘gold standard’ surgical procedure for glaucoma is still the trabeculectomy, 
devised in the late 1960s (Cairns, 1968) and subsequently modified by Watson 
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(Watson and Barnett, 1975). The basic concept involves creation of a guarded fistula 
in the eye, effectively a ‘trap door’ in the sclera. Held in place by sutures, the 
aqueous seeps out at a controlled rate, determined initially by the suture tension. The 
translucent mucosal lining of the eye, the conjunctiva, when replaced over the trap 
door, forms a blister or ‘bleb’. The aqueous fluid drains into the systemic circulation 
via the conjunctival and episcleral veins (Figure 1-3).  
 
Figure 1-3. Guarded sclerostomy and resulting bleb. 
After any surgical procedure of tissue trauma however, there is an intrinsic wound 
healing response that results in the deposition of scar tissue. This scarring process 
after a trabeculectomy can effectively close the ‘trap door’, which results in surgical 
failure (Figure 1-4) (Hitchings and Grierson, 1983). 
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Figure 1-4 Failed bleb. 
In the national trabeculectomy survey 1/3 of patients where surgery was performed, 
further ocular hypotensive treatment was required at the end of 1 year (Edmunds et 
al., 2001). Histological analysis of failed trabeculectomies as compared to 
functioning ones show increased collagen deposition and new capillary formation 
(Addicks et al., 1983) (Figure 1-5). 
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Figure 1-5 Histology of a failed bleb (left) and functioning bleb (right). Capillaries (C) seen in 
dense collagenous connective tissue. Microcystic spaces (M) seen in functioning bleb. Adapted from 
(Addicks et al., 1983). 
 
1.4 Augmentation with Antimetabolites 
 Since the 1980s surgeons have attempted to prolong trabeculectomy survival 
through the use of antimetabolites (Chen et al., 1990; Rothman et al., 2000). 
Mitomycin C is a naturally occurring antibiotic-antineoplastic compound produced 
by Streptomyces caespitosus. It acts as an alkylating agent after enzyme activation 
resulting in DNA cross-linking. 5-fluorouracil (5FU), a pyrimidine analogue inhibits 
cellular proliferation by being converted to 5-fluoro-2’-deoxyuridine 5’-
monophosphate. This interferes with DNA synthesis through its action on 
thymidylate synthetase. Both agents result in greater surgical success though at the 
cost of an increased rate of complications. This was particularly noticeable in early 
reports. Their application can result in tissue thinning and bleb leaks. In the 5FU trial 
33% of cases treated with 5FU had bleb leaks as compared to 20% in the no 
augmentation group (Fluorouracil Filtering Surgery Study Group, 1989).  
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The resulting hypotony causes retinal swelling and disruption of visual function 
(Zacharia et al., 1993). Bindlish and colleagues reported an incidence of late 
hypotony (IOP < 6 mmHg) in 42% of eyes (including both leaking and non leaking 
trabeculectomies) at some point between six months and final follow-up at five 
years, in a series of 123 primary trabeculectomies with MMC (Bindlish et al., 2002). 
Worse still, bleb leaks act as a tract or infection, which can result in the loss of an 
eye (Wolner et al., 1991; DeBry et al., 2002). The incidence of bleb-related 
endophthalmitis in trabeculectomy without antimetabolite ranges from 0.2% to 1.5%. 
With intraoperative 5-FU and MMC, this incidence increases to 1.0 - 5.7% and 0.3 - 
4.9%, respectively (Razeghinejad et al., 2012). 
 
Figure 1-6. Clockwise from top left: bleb thinning, bleb leakage outlined by fluorescent dye, 
infection and hypotony with retinal swelling and retinal folds. 
More recently changes in the surgical technique and anti-metabolite application have 
resulted in improved bleb morphology, good control of IOP with a significant 
reduction in complications. The ‘Moorfields Safer Surgery System’ involves a 
number of modifications such as use of antimetabolite where type, concentration and 
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exposure time are graded according to patient risk (usually at a lower concentration 
than in early studies) (Khaw et al.). There is a wide area of application under the 
conjunctival flap using polyvinyl alcohol sponges (methylcellulose sponges can 
fragment leaving remnants behind (Al-Shahwan and Edward, 2005)). Releaseable 
sutures with or without adjustable sutures are used routinely. Surgeons using this 
technique have reported a success rate of 96.7% (IOP < 21 mmHg) at 3 years in a 
complex case mix (Shah et al., 2011). Stalmans et al reported a success rate of 100% 
(IOP < 21 mmHg) in lower risk patients at 15.7 months mean follow up, with few 
complications (flat AC 1.8%; hypotony beyond 3 weeks 1.5%) (Stalmans et al., 
2006).  
Nonetheless, surgeons are in general agreement that using antimetabolites 
necessitates close monitoring and considerable work post surgery. Suture 
manipulation and postoperative antimetabolite injection require many visits 
sometimes to theatre: “completion of trabeculectomy surgery is just the beginning of 
a process that takes several months to complete” (King et al., 2007). An alternative 
to using an agent that is cytotoxic or antiproliferative would be to use an agent that 
inhibits the scarring mechanism more selectively. Much research has been performed 
to develop an effective anti-scarring agent without the toxic side effects. Part of the 
difficulty in establishing an agent that is both effective and non-toxic is 
understanding the complexity of the wound healing response, and the interplay 
between fibroblasts and other key cells involved (Bruno et al., 2007; Georgoulas et 
al., 2008).  
1.5 Wound Repair 
After surgical trauma to the skin, conjunctiva or other epithelial surface a sequence 
of events occurs that result in either restitution of tissue architecture or scarring 
(Figure 1-7). The process can be divided into 3 major phases: 
1) haemostasis and inflammation 
2) re-epithelisation and granulation tissue formation 
3) tissue remodelling 
 23 
These phases, although histologically and functionally different, overlap temporally 
and involve communication between numerous cell types and in different tissue 
layers (Park and Barbul, 2004; Toriseva and Kähäri, 2009; Eming et al., 2007).  
 
Figure 1-7. The phases of wound repair. Taken from (Toriseva and Kähäri, 2009). 
1.5.1 Haemostasis and inflammation 
A surgical or traumatic wound leads to the release of blood products including 
platelets from disrupted vessels. These activated platelets aggregate and release 
numerous factors that contribute to the coagulation cascade. As a consequence, a 
meshwork of fibrin binds to platelets and wound tissues, acting as a physical ‘plug’ 
to stop further bleeding.  
The coagulation factors, cell fragments and other proteins act as attractants for 
inflammatory cells and fibroblasts (Eming et al., 2007). Neutrophils phagocytose 
infectious agents and necrotic tissue. Monocytes migrate to the wound site and 
become activated to become macrophages. These are not only able to phagocytose 
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but present antigen to other cells for recognition as ‘foreign’, thereby intitating the 
adaptive immune response. Furthermore macrophages release growth factors, such as 
transforming growth factors (TGF-B, TGF-a), platelet-derived growth factors 
(PDGF) and fibroblast growth factor (FGF), which contribute to wound healing 
regulation (Park and Barbul, 2004). 
1.5.2 Re-epithelialisation and granulation tissue formation 
In parallel to the inflammatory phase there is re-epithelialisation and granulation 
tissue formation. The epithelial cells at the wound edge proliferate, lose cell-cell 
contacts, change morphology and begin migration across the wound. Once the 
wound gap is closed, a basement membrane is reformed and the cells return to their 
original morphology. 
The granulation tissue is made up of fibroblasts, endothelial cells and macrophages. 
The fibroblasts, which have either migrated to the wound site or become transformed 
from residential fibrocytes, deposit and remodel wound extracellular matrix (ECM). 
This initially consists of fibronectin and hyaluronan, both of which facilitate cell 
migration. The endothelial cells migrate to the area and are stimulated by hypoxia 
and growth factors to proliferate. These cells coalesce to form a network of primitive 
blood vessels (angiogenesis). It is through the proteolytic activity of plasmin and 
matrix metalloproteinases that ECM vascularisation is allowed.  
1.5.3 Tissue remodelling and contracture 
The final phase of wound maturation is the process of tissue remodeling, contracture 
and the formation of collagenous scar. This process may continue for months and 
during this time the ECM is synthesised, deposited and remodeled. It is the fibroblast 
that is the principal cell involved, depositing and degrading collagen molecules and 
arranging collagen fibres.  
The fibroblasts themselves also differentiate into myofibroblasts, with the formation 
of intracellular actin bundles. Resembling smooth muscle cells, these cells have 
strong intercellular attachments. They contribute to wound contraction as a 
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coordinated group.  With time as the ECM becomes stronger and takes more of the 
mechanical stress, the myofibroblasts undergo apoptosis (Hinz et al., 2007). 
1.5.4 Matrix Metalloproteinases 
Matrix metalloproteinases (MMPs) are key proteins involved in the wound healing 
process. Discovered by identifying the collagenolytic factor that enables tadpoles to 
lose their tales during metamorphosis (Gross and Lapiere, 1962), initially they were 
believed to be simply enzymes that remodeled ECM. However, subsequently they 
have been found to play roles in regulating the inflammatory process as cytokines 
and chemokines as well. 
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1.5.4.1 Matrix metalloproteinase structure  
The general structure of MMPs involves 3 domains: the propeptide, the catalytic and 
a haemopexin-like C-terminal domain that is linked to the catalytic domain via a 
hinge region (Figure 1-8)(Yong et al., 2001).  
 
Figure 1-8 MMP structure. Adapted from (Yong et al., 2001). 
MMPs are initially expressed in an inactive state due to the cysteine “switch” residue 
of the prodomain region interacting with the zinc ion of the catalytic site. They are 
stored as granules within inflammatory cells or anchored to the cell surface and 
extracellular matrix (ECM). Proteolysis by other proteases or cell surface molecules 
can activate the switch and enzyme (Nagase, 1997).  
There are 23 different types (at the time of writing) and are classified into families 
according to substrate specificity: collagenases, gelatinases, stromelysins, 
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matrilysins, membrane bound MMPs and ‘other’ MMPs (Yong et al., 2001). 
Collagenases degrade collagen, unwinding the triple helix to a denatured gelatin 
form. Gelatinases degrade basement membranes. Stromelysins are less specific and 
are able to degrade extracellular compounds such as fibronectin, laminin and 
proteoglycans. Matrilysins can degrade ECM components, but also cleave cell 
surface molecules such as Fas ligand and VE-cadherin to generate soluble forms, 
therefore acting as ‘sheddases’(Ichikawa et al., 2006). The membrane bound MMPs 
are different from other MMPs in that they have a transmembrane domain and 
cytoplasmic tail of 25 amino acids. They contain a cleavage site for furin like 
proteases and are likely to be activated within the secretion pathway. 
They are regulated at 3 levels: 
1) Proteolytic activation (described above). 
2) Biological inhibition - tissue inhibitors of metalloproteinases (TIMPS). There are 
4 known types in mammals, which usually exist as soluble extracellular proteins. 
3) Transcriptional control of genes - growth factors such as FGF can up-regulate 
MMP gene expression via the c-Fos and c-Jun proto-oncogenes. Glucocorticoids 
can down-regulate MMPs. 
MMPs have numerous roles in physiological and pathological processes. These are 
linked to their capacity to digest selective proteins, latent growth factors, cytokines, 
inactivating binding proteins as well as pro-peptidases. The mechanisms involved 
continue to be elicited, however identifying substrates for MMPs is not without 
difficulty. Rarely do in vitro experiments where substrates are incubated with 
purified MMP and analysis of the protein products actually reflect what happens in 
vivo. An alternative method is to perform a proteomic experiment by the creation of 
tissue models without a specific MMP gene and comparing the protein products to 
the wild type (Overall et al., 1987). Traditionally proteins were identified on a 2 D 
SDS PAGE gel, but with the disadvantage of not being able to distinguish longer 
molecules. More recently the use of mass spectrometry has improved detection. 
Further analysis using in vivo models with targeted mutagenisis help to verify MMP 
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function (Parks et al., 2004). Although there is still much to learn it is clear that 
MMPs are involved in all 3 stages of wound healing: 
1.5.5 MMPs in Inflammation and Healing 
MMPs allow the passage of inflammatory cells such as neutrophils by altering the 
basement membrane permeability of both endothelial and epithelial cells. In 
endothelial cells MMP 7 ‘sheds’ VE-cadherin, causing cell junction proteolysis 
(Ichikawa et al., 2006). MMP2 and MMP9 cleave occludin, the endothelial 
component of tight junctions (Reijerkerk et al., 2006). Thus areas that would 
normally be impermeable to plasma proteins and cells, such as the blood brain 
barrier and the blood retinal barrier can become leaky (Figure 1-9). This may be 
important in for example hypoxic brain injury, meningitis or in diabetic eye disease 
(Manicone and McGuire, 2008). Indeed dendritic cells infected with Dengue virus 
over produce MMP9 and MMP2, and are associated with decreased expression of the 
cellular adhesion molecules PECAM1 and VE Cadherin in vitro and in vivo 
(Luplertlop et al., 2006). Therefore MMP expression may contribute to the increased 
vascular permeability and haemorrhagic shock seen in Dengue fever and other 
haemorrhagic fevers, e.g. Ebola virus (Dolnik et al., 2004). 
 
Figure 1-9 Monocyte migration across the blood brain barrier with A adhesion, B local 
redistribution of occludin, C formation of endothelial gap. Adapted from (Reijerkerk et al., 2006). 
MMPs are also involved in proteolysis of epithelial cell junctions. An example is in 
the animal model of autoimmune bullous pemphigoid. MMP 9 contributes to skin 
blisters by cleaving hemidesmosome protein bp 180, through proteolytic inactivation 
of serpin α 1 proteinase inhibitor (Liu et al., 2000).  
 29 
Further knowledge of MMP function comes from studies of cutaneous wounds. In 
intact skin MMP expression is minimal with only MMP-7 and MMP-19 expressed in 
sweat and sebaceous glands (Toriseva and Kähäri, 2009). When there is basement 
membrane disruption, however, there is a sharp rise (within hours) in MMP-1 
expression in migrating epithelial cells. Type 1 collagen appears to be the primary 
stimulus for MMP-1 expression. Furthermore the MMP-1 expression appears to be 
essential for the migration by epithelial cells on collagen. After re-epithelisation the 
epidermal expression of MMP-1 is repressed by contact with basement membrane 
proteins such as laminin-111. The importance of MMP-1 control is illustrated by 
over expressing MMP-1 in mouse epidermis. After wound incision there is markedly 
delayed closure and hyper-proliferation of the epidermis. Its ability to break down 
collagen is also essential for normal function. In mice with collagenase resistant 
collagen, wound closure is impaired with slowed tissue contraction and wound re-
epithelialisation.  
1.5.6 MMPs as Chemoattractants and Modulators of Inflammation 
MMP cleavage of proteins can result in the activation of cytokines or chemokines, or 
the MMP fragments themselves can act as chemoattractants. TNF α is a fundamental 
cytokine in inflammation that is expressed on T cells and macrophages. It exists in 
an inactive form and is switched on by TNF converting enzyme (TACE), a molecule 
identical in structure to ADAM (a disintegrin and metalloproteinase) 17 (Gooz, 
2010). TNF α activation is seen in septic shock, Crohns and rheumatoid arthritis as 
well as many other inflammatory autoimmune diseases. Several other MMPs also 
have TACE activity in vitro including MMPs 1, 2, 3 ,9, 12, 14, 15, 17 (Manicone and 
McGuire, 2008). It is postulated that whilst TACE may be the main converter of pro 
TNF α in systemic disease, local response to wounds may be through MMP 
activation.  
Chemokines are proteins that direct cell migration through concentration gradients. 
They exist in two forms CXC and CC according to the location of cysteine residues. 
The N-terminus end of CXC8 and Lix8 (the mouse model version) are processed by 
MMP 8 and 9, and render more active peptides. Evidence of the role MMP 8 can 
play in the pathogenesis of disease comes from the mouse model lacking MMP 8 
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(Lint et al., 2005). If these mice are made to develop lethal hepatitis, Lix fragment 
release is reduced. Compared to the wild type, the knock out mice had less neutrophil 
migration into the liver and lower mortality. 
MMPs may also affect chemokine influence through chemokine release from tissue 
of cell compartments (Manicone and McGuire, 2008). Ordinarily chemokines are 
bound to the cell surface or ECM. MMPs such as MMP 7 are able to cleave the 
binding proteins, release the chemokine, and thereby set up a concentration gradient. 
MMP 7 ‘sheds’ syndecan 1, an epithelial binding proteoglycan that restricts the 
chemokine CXCL1. MMP7 null mice are unable to release CXCL1 and therefore 
prevent neutrophil migration into the alveolar tissue after lung injury. 
The MMP products themselves can function like chemokines and be involved in the 
pathogenesis of disease, and loss of function can lead to tissue protection. An 
example is illustrated by the activity of MMP 9 in mice after pulmonary infection of 
Francesella tulerinis. MMP 9 null mice have significantly less Pro-Gly-Pro, a 
chemotactic peptide released by that MMPs cleavage of collagen. As a consequence 
there is less neutrophil migration into tissue and less injury. 
1.5.7 MMPs and Granulation Tissue Formation 
During granulation tissue formation fibroblasts express MMP 1 and MMP 2 near the 
wound front. This allows the organisation of the newly synthesised ECM. MMP 1 
may also regulate fibroblast survival by exposing binding sites in collagen for 
fibroblast integrins. MMPs expressed by stromal cells include MMP 1, 2, 3, 9, 11, 
and 12. In the remodelling phase, the stromal cells, including fibroblasts, 
keratinocytes, endothelial and inflammatory cells, populate the granulation tissue and 
are believed to continue their expression of MMP-1,-2,-3,-9,-11,-12 and -14 
(Steffensen et al., 2001).  As a new basal lamina is formed at the wound site, MMP-1 
expression is reduced and the basement membrane-keratinocytes interactions through 
hemidesmosomes are stabilised (Sudbeck et al., 1997). Hemidesmosomes, formed 
within keratinocytes, bind them to anchoring fibrils of the subtending dermis. In 
conclusion, when the cells finish the process of wound healing, there is a decrease in 
MMP expression and MMP levels approach those of normal tissues.  
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1.5.8 MMPs and Remodelling 
There is prolonged expression of MMP2 by fibroblasts in the dermal compartment of 
cutaneous tissue after injury (Karim et al., 2006). MMP 2 is a gelatinase whose 
expression may be important in ECM remodelling. Indeed it is believed that TGF β 
can activate MMP 2 via the NF-κB pathway leading to fibroblast migration and 
collagen remodelling (Wang et al., 2011). 
The process of angiogenesis is also dependent on MMPs. The gelatinases MMP 2 
and MMP 9 cannot only break down the vascular basement membrane (as discussed 
above) but also activate angiogenic cytokines. MMP 9 is upregulated in  stromal 
cancer cells and can release vascular endothelial growth factor (VEGF) from ECM 
(Hawinkels et al., 2008). MMP 9 and MMP 13 have been shown to be more 
upregulated together with VEGF in rheumatoid arthritis (Kim et al., 2011). MT1 
MMP has fibrinolytic and collagenolytic activity that allow vessel invasion through 
tissue stroma (Chun et al., 2004). In vitro MT1 MMP is associated αVβ3 integrins at 
the intercellular contacts in endothelial cells, indicating involvement in endothelial 
cell adhesion and migration (Gálvez et al., 2004).  
1.5.9 MMPs and Conjunctival Injury 
MMPs have been shown to exist in subconjunctival tissue and their expression varies 
with wound healing. Comparison between normal and healing conjunctiva specimens 
showed that MMP-1 and TIMP-1 were located only in the healing subconjunctival 
tissue and not in normal subconjunctival tissue or conjunctival epithelium. MMP-
TIMP expression and activation alterations therefore may play an important role in 
the post-operative cell proliferation and subconjunctival scarring (Kawashima et al., 
1998).  Moreover, expression of other MMPs and TIMPs, including MMP-1, -2, -3, -
9, -14 and TIMP-1 and -2 occur in cultured human Tenon’s fibroblasts (Mietz et al., 
2003). Postmortem examination of patients that had undergone glaucoma filtration 
surgery revealed an increased staining of MMPs near the surgery site. MMPs 1, 2, 
and 3 were found to be expressed in fibroblasts found in the bleb walls around 
Molteno plate implants (McCluskey et al., 2009). A summary illustrating the 
involvement of MMPs in conjunctival wound healing is shown in Figure 1-10. 
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Figure 1-10 MMPs involved in subconjunctival wound healing adapted from (Wong et al., 
2002). 
1.6 MMP inhibition 
As MMPs are key proteins in regulating inflammation and angiogenesis, much 
research has been performed into MMP inhibitors as possible therapeutic agents in 
disease. The greatest area of research and investment has been to use inhibitors as a 
potential treatment for cancer. Evidence for MMP involvement in cancer progression 
comes from work that illustrated that MMP expression was up-regulated in tumours 
at the time of spread and metastasis (Coussens et al., 2002). Furthermore if the 
natural MMP inhibitors such as TIMP 1 were over-expressed, the invasive ability of 
tumours was reduced. Indeed deletion of TIMPs in normal cells can lead to the 
production of cells that are tumourogenic. Although it was not possible to develop 
TIMPs into therapeutic drugs, early artificial smaller MMP inhibitors showed 
promise as therapeutic agents against cancers, for example the treatment of mice that 
human breast cancer xenografts with batimastat (a broad-spectrum hydroxamate 
inhibitor) lead to reduced metastasis and inhibition of local regrowth (Sledge et al., 
1995).  
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That MMPs play a pivotal role not only in wound healing but in also in cancer 
progression is to be expected. Virchow identified chronic inflammation as an 
underlying cause of cancer in 1863. Since then a number of chronic inflammatory 
conditions or chronic inflammatory infectious diseases have been linked to the 
development of cancer: Helicobacter Pylori causes inflammation in the form of 
stomach ulcers and an increased risk of gastric carcinoma (Grivennikov et al., 2010). 
Crohn’s disease causes bowel inflammation and is associated with an increased risk 
of colorectal carcinoma. Hepatitis B and Hepatitis C cause inflammation of the liver 
and are associated with an increased risk of hepatocellular carcinoma. 
What are the mechanisms behind inflammation causing neoplastic change?  
Proliferating cells do not simply result in tumourogenisis. However a sustained 
proliferation of cells in an environment of DNA damaging agents, inflammatory 
mediators and growth factors can potentiate neoplastic change (Grivennikov et al., 
2010). It is hypothesised that the cells damaged or ‘initiated’ by an agent are 
transformed to become somatically different. Promotion by chronic inflammation 
can lead to subversion of cell death and loss of growth control. There is further 
release of inflammatory mediators and angiogenic factors by cells such as tumour 
associated macrophages and in this way this leads to more inflammation.  Therefore 
in effect tumours then become wounds that fail to heal. 
Other directly mutagenic factors are released in chronic inflammation. Peroxynitrite 
is produced by leucocytes and is a highly toxic agent that can interact with the DNA 
of proliferating epithelium. Mutations in p53 are seen at similar rates in rheumatoid 
arthritis as they are in tumours of chronic inflammatory bowel disease. 
The roles that MMPs play in tumour progression continue to be elicited. It is not just 
the cells that are part of the tumour per se that up-regulate their MMP expression, 
enabling the tumour to cause angiogenic stimulation and matrix breakdown. The 
surrounding stromal cells themselves also up-regulate their MMPs. Indeed the 
expression of MMPs can often be up-regulated before the basement membrane 
destruction and tumour metastasis. This suggests that they have more complex 
functions than just causing holes in the basement membrane and allowing malignant 
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cells to escape (Coussens et al., 2002). It also appears that several MMPs have the 
same role and some MMPs have multiple roles. Indeed MMPs are involved in the 
regulation of a number of different events in tumour progression such as cell death, 
cell proliferation, angiogenesis and malignant conversion. 
Early trials involving MMP inhibitors were unsuccessful. The MMPis had poor 
bioavailability and were replaced by other orally active drugs. These second 
generation MMPis, however, had musculoskeletal side effects at high cumulative 
systemic doses that were alleviated with a drug holiday, but this still meant limited 
dosages could be given.  
Later trials using MMPis that had fewer side effects were thwarted by the lack of 
consensus over endpoints for the trials. Previous cancer trials relied upon survival as 
an endpoint. MMPis target cancer cells at the point of spread or metastasis. 
Furthermore they are cytostatic, not cytotoxic. The patients enrolled for trials of 
MMPi mostly had advanced disease. Although tumour marker levels were found to 
decrease with treatment, there were few results where there was an impact on 
survival (Table 1-1)(Coussens et al., 2002). As a consequence there are no MMPi 
treatments that are licensed for use in humans. 
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Table 1-1 Phase III clinical trials with MMPis adapted from (Coussens et al., 2002). 
 
MMP	
inhibitor	
Cancer	 Treatment	 Result	
Marimastat	 Pancreatic	 5,	10,	25	mg	bd	vs	
gemcitabine	1000	mg	/	
m2	
No	significant	difference	
in	overall	survival	
Prinomastat	 Non-small-
cell	lung	
cancer	
Cisplatin	+	gemcitabine	
1250	mg	/	m2	with	
prinomastat	15	mg	bd	
or	placebo	
No	survival	benefit	
Tanomastat	 Small	cell	
lung	
Tanomastat	vs	placebo	 Terminated	prematurely	
because	placebo	patients	
had	better	survival	rates	
BMS-275291	 Non	small	
cell	lung	
cancer	
Carboplatin	+	
paclitaxel	with	BMS	–	
2755291	1200	mg	od	
or	placebo	
Musculoskeletal	toxicity.	
Poor	response	
	
1.7 MMP Inhibition as a Therapeutic Intervention against Scarring  
An exciting potential use for MMPi therapy is the modulation of wound healing after 
surgery to prevent scarring. Most research so far has focused on using MMPis in in 
vitro and in in vivo models. Ilomastat, a broad spectrum potent MMPi was designed 
as an inhibitor of human skin collagenase for the treatment of the invasive phase of 
rheumatoid arthritis (Grobelny et al., 1992). Later studies of this drug showed that it 
had potential to treat corneal ulcers by reducing the infiltration of inflammatory cells 
in alkali burned rabbit corneas (Galardy et al., 1994), however this did not translate 
to humans. Other MMPis, such as marimastat, have also been reported to have a 
reversible inhibitory effect on human dermal fibroblasts (Scott et al., 1998). 
One significant property that ilomastat has, unlike a number of other MMPis, is poor 
solubility in water, yet being very effective at low concentrations (Table 1-2).  This 
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makes ilomastat an attractive prospect as a potential slow release anti-scarring agent 
in an aqueous environment.  
 
 
 
	
Figure 1-11 Ilomastat 
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Table 1-2 The minimal inhibitory concentrations of ilomastat necessary to inhibit enzyme 
activity by half (Ki values for ilomastat) (Galardy et al., 1994) 
 
MMP	 Ilomastat	Ki	Values	
MMP	1	(Fibroblast	collagenase)	 0.4	nM	
MMP2	(Gelatinase)	 0.5	nM	
MMP	3	(Stromelysin)	 27	nM	
MMP	8	(Neutrophil	collagenase)	 0.1	nM	
MMP	9	(Gelatinase)	 0.2	nM	
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1.7.1 In vitro Scarring Model 
One in vitro model of wound healing developed to examine cellular function in the 
scarring process is the gel contraction model using a collagen lattice seeded with 
fibroblasts (Bell et al., 1979). Over time the fibroblasts cause contraction of the gel 
lattice. The effect of different drugs at different concentrations on fibroblastic 
function can be determined.  
Using this model it has been shown that inhibition of MMPs induces inhibition of 
contraction of collagen I lattices populated by human Tenon’s fibroblasts (Daniels et 
al., 2003). Comparison between three MMP inhibitors (MMPis) – Ilomastat, BB-94 
and Cell Tech- revealed inhibition of gel contraction with the application of all the 
three MMPis in a dose-dependent manner, although ilomastat was found to be the 
most effective.  
It also appeared that this inhibition was reversible and non-toxic to the cells. 
Removing ilomastat two days after application on cultured fibroblasts initiated 
further gel contraction. Furthermore there was no inhibitory effect of ilomastat on 
cell proliferation despite being incubated with an ilomastat concentration at a factor 
of 10 higher than that found to inhibit gel contraction. 
 
1.7.2 Animal Model of Glaucoma Surgery 
The use of rabbits as an animal model for glaucoma surgery is well established. The 
earliest experiments with trephination on rabbit eyes date back to 1913. Since the 
trabeculectomy was developed researchers have used the rabbit to characterise the 
healing response post surgery histologically. Initially the experimental technique 
performed on the animals mimicked the procedure performed on humans. However, 
due to the aggressive nature of healing and the anterior position of rabbit ciliary 
processes, conventional trabeculectomy results in bleeding and failure of blebs 
between 10 and 14 days (Skuta and Parrish, 1987). Modification of the technique 
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involving a thermosclerostomy rather than creation of a scleral flap to control 
haemorrhage led to less bleeding, however occlusion with scar tissue still occurred 
by the tenth postoperative day. Even so considerable information has been gained 
such as illustrating how the antimetabolites 5 FU and MMC can prolong bleb 
survival (Khaw et al., 1993; Doyle et al., 1993; Hyung et al., 1994). 
More recently a technique from our group of experimental glaucoma fistulising 
surgery (GFS) in rabbits has been developed that results in longer bleb survival with 
less inter operative variability (Cordeiro et al., 1997). The key changes are: 
1) The sclerostomy is created using an MVR blade (typically used by 
retinal surgeons) instead of a ‘trapdoor’ - the thickness of which can vary and 
considerably affect outcome. 
2)  A 22 gauge cannula is passed into the anterior chamber and sutured 
to the scleral surface.  Iris bleeding is therefore negated by not needing to perform 
an iridectomy. The presence of the tube also prevents the formation of a scar 
tissue plug over the sclerostomy that often caused the failure of blebs in other 
experimental surgeries. 
This method of GFS has conclusively shown how MMC should be applied to a 
greater surface area to promote bleb survival. (Cordeiro et al., 1997) Rabbits were 
assigned to having GFS with MMC application using a larger sponge soaked in 
MMC (8 X 10 mm) or a smaller sponge (4 X 2 mm). Those rabbits that received the 
larger sponge resulted in having blebs that survived longer with a more diffuse 
morphology. 
There was less cellularity in the subconjunctival area over the drainage site in the 
eyes treated with the large sponge as opposed to the smaller sponge or control on 
histological analysis. Furthermore, there appeared to be more extracellular matrix 
deposition and elastic fibres in the eyes treated with the smaller sponge or control. 
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1.7.3 Ilomastat injections promote bleb survival 
Two sequential studies have illustrated how ilomastat injections after GFS on the 
rabbit model can promote bleb survival with minimal scarring. (Wong et al., 2003; 
Wong et al., 2005). The first compared postoperative injections of ilomastat to 
phosphate-buffered saline (PBS). Forty rabbits underwent GFS and then received 
either 10 consecutive days of subconjunctival PBS (0.1 ml), or 10 consecutive days 
of subconjunctival ilomastat (0.1 mls of 100 µM). 
The bleb appearance, height and vascularity were assessed over 30 days. Subsets of 
animals were terminated at weekly time points and their globes enucleated for 
histological analysis.  
The blebs treated with post-operative ilomastat sub conjunctival injections survived 
significantly longer than those treated with the PBS sub conjunctival injections. 
Histological analysis of the blebs found that extracellular matrix was present to a 
greater degree in the PBS treated eyes as opposed to the ilomastat treated eyes. 
Furthermore there was increased cellularity at the surgical site in the PBS treated 
eyes. Indeed the study found that the morphology of the conjunctiva of the operated 
eyes treated with ilomastat closely resembled virgin eyes with no surgical 
intervention or treatment. 
The second study compared the postoperative course of rabbits that had undergone 
GFS treated with subconjunctival injections of ilomastat to those that received 
treatment with MMC at the time of surgery only and PBS subconjunctival injections 
(control). 
The concentration of MMC used was 0.2 mg / ml and applied for 3 minutes at the 
drainage site. Ilomastat injections were applied daily for 10 consecutive days at the 
time of the surgery, and afterwards twice weekly for 2 weeks and weekly for 2 
weeks. The concentration used was 100 µM, as above at a volume of 0.1 ml. The 
PBS injections were of the same volume and applied at the same intervals as 
ilomastat. 
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Overall the MMC and ilomastat treated groups all had blebs that survived compared 
to none of those treated with the PBS injections at day 30.  
Histological examination of the ilomastat and PBS treated eyes revealed similar 
findings to the first study, namely that there was less scar tissue formation in the 
ilomastat treated blebs. The conjunctival tissue in the ilomastat treated eye more 
closely resembled unoperated eyes than either the MMC or control eyes. Ilomastat 
also reduced the population of cells expressing α-smooth muscle actin indicating 
fewer myofibroblasts. The MMC treated eyes, however, had conjunctiva with 
thickened disrupted epithelium with cells sloughing from the surface.  
1.8 The Ilomastat “tablet” implant   
Multiple postoperative injections of ilomastat inhibit scarring after GFS in the rabbit 
animal model, however to translate this to the clinical setting a slow release 
preparation would be desirable. Patients are unlikely to tolerate multiple ocular 
injections due to the discomfort and inconvenience caused. Furthermore, injections 
also result in ‘spikes’ of drug delivery with rapid clearance.  
Georgoulas et al developed an implant consisting of pure ilomastat known as the 
“ilomastat tablet”, which could be applied at the time of surgery resulting in drug 
release over the following weeks (Georgoulas, 2010). By using a drug where the 
solubility (Cmax) in aqueous fluid was similar to its therapeutic level the release is 
“set” or limited to this range. Ilomastat’s low solubility should also mean that the 
drug persists in the subconjunctival space for a significant duration, and could be 
adjusted according to implant size. Furthermore, by only using pure drug without 
excipient to bind the drug together or enhance dissolution there should be no ‘by 
product’ remaining that might cause toxic or inflammatory side effects.   In an in 
vivo experiment with 24 rabbits it was claimed that the ilomastat “tablet” implant 
prolonged bleb survival significantly longer than MMC with significantly less 
collagen deposition than either MMC or negative control (application of water in the 
same way as MMC at the time of surgery) (Georgoulas et al. 2010).  
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1.9 Aim and summary of experiments 
Given the promise of this anti-scarring therapy the aim of this PhD was to investigate 
further its potential as a treatment for patients undergoing glaucoma surgery. The 
hypothesis was that MMPi therapy could inhibit fibrosis to the same extent as current 
treatments for glaucoma filtration surgery, but with fewer side effects than those seen 
with the antimetabolites 5-FU and MMC. By prolonging the antiscarring 
pharmacokinetic profile fewer postoperative interventions might be required than 
seen with Kirwan et al., 2013.   
The research was funded by the Medical Research Council as part of a project whose 
aim was to develop the antiscarring MMPi tablet implant for clinical trials. The 
unique selling point of this implant and the basis of its international patent was that it 
was constructed without any excipient.  
Because the experiments by Georgoulas et al., 2010 showed complete success in 
vivo with implants of 3 mm diameter the first experiments aimed to investigate the 
pharmacokinetic profile of different smaller sized implants in vitro and efficacy in 
vivo.  
Implants were fabricated using a cylindrical punch and die apparatus that pressed 
crystalline drug into a compacted implant. Cylinders of different diameters produced 
drug implants of different sizes. In in vitro flow release studies these implants were 
placed in chambers with fluid flow passing over them designed to mimic the aqueous 
flow in a bleb environment. High performance liquid chromatography analysed the 
concentration of drug in solution sampled at different times, thus determining the 
dissolution behaviour of the implant. 
Ilomastat implants of 1 mm, 2 mm, and 3 mm diameter released drug at a 
concentration of more than 10 µM (the concentration reported to inhibit fibroblast 
contraction (Daniels et al., 2003)) for between 12 and 26 days. Because theoretical 
therapeutic levels were attained with even the smallest implants the 1st in vivo 
experiment investigated the anti-scarring efficacy of implants of a smaller size than 
previously examined by Georgoulas et al., 2010. Twenty-eight New Zealand White 
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Rabbits were divided into 4 different perioperative antiscarring treatments for 
modified glaucoma filtration surgery:  1 mm ilomastat implant, 2 mm ilomastat 
implant, MMC (0.2 mg / ml applied for 3 minutes), and 2 mm ethylcellulose implant 
(an implant with similar dimensions to the 2 mm ilomastat implant but with no 
presumed active anti-scarring component). 
Contrary to expectation although the ilomastat implants appeared to prolong the bleb 
survival of glaucoma surgery in rabbits, a significant foreign body reaction was seen 
at a histological level conflicting with the findings of the previous in vivo data and 
raising questions about therapeutic efficacy. The 2nd in vivo experiment therefore 
aimed to confirm whether ilomastat implants of the same diameter as the original 
pilot studies (3 mm) had a similar response, and the same foreign body reaction was 
seen. The effect of increasing drug dissolution on surgical survival was investigated 
by using ilomastat implants combined with hyaluronic acid, excess aqueous fluid at 
the time of implant placement, and using more water soluble MMPi implants 
(AZ8955 and AZ 6731). The implants that dissolved faster had less scar tissue, but 
failed earlier. 
Implants of the highly water soluble broad spectrum MMPi marimastat were found 
to dissolve completely within 48 hours and showed little foreign body reaction in a 
pilot 3rd in vivo study. In a 4 arm efficacy in vivo experiment (4th in vivo experiment) 
the anti-scarring efficacy of marimastat implants were compared to a combination 
implant made of the dexamethasone and ilomastat. The positive control was MMC 
sponge application (0.2 mg / ml applied perioperatively for 3 minutes) and negative 
control water applied in the same way as MMC. The hypothesis for using 
dexamethasone was that a potent steroid anti-inflammatory would dampen the 
foreign body response, leading to less foreign body encapsulation, greater MMPi 
dissolution and enhanced anti-scarring efficacy.  
The combined implant of the steroid dexamethasone and ilomastat appeared to 
prolong survival with a less, but still significant tissue reaction but those blebs 
treated with marimastat failed shortly after the negative control. It was therefore 
postulated that reducing the dose size of the combined implant might tip the balance 
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in favour of the active soluble moiety away from the aggravating antagonistic effect 
of the non-solubilised drug. Combination implants of a smaller size were not 
physically possible to create due to incomplete mixing and fragmentation, and 
therefore individual 1 mm dexamethasone and ilomastat implants were fabricated 
and applied together. These were investigated in a pilot 5th in vivo together with 
polymers to create a less abrasive tissue implant interface. Different types of 
hyaluronic acid polymer were examined. The aim was either to dissolve the drug or 
shield the drug in a hyaluronic acid / drug / hyaluronic acid “sandwich” implant. 
Another hydrophobic polymer (used by Alex Sefalian’s group for the development 
of artificial tracheas) was also piloted to see whether these could coat pure drug 
implants. 
The hyaluronic acid ilomastat implants and individual dexamethasone / ilomastat 
implants still had considerable tissue reaction, but the polymer coated pure drugs had 
less. Pockets of inflammation were seen instead, associated with presumed defects in 
the implants. Further work with the hydrophobic polymer however found that the 
challenge of coating pure drug uniformly without defects, and allowing drug elution 
was too great. 
A more hydrophilic polymer was insvestigated in the 6th in vivo efficacy experiment 
compared to MMC positive control and sterile water negative control. Here too there 
was less reaction than seen with naked implants, though with significant macrophage 
infiltration. 
From all of the experiments involving space occupying implants it was apparent that 
bleb appearance did not necessarily correlate with histological scarring. Thus the 
notion of ‘bleb survival’ as an outcome was questioned and other outcomes tested. 
Indocyanine Green dye to trace aqueous movement by injection into the anterior 
chamber after glaucoma filtration surgery was too slow, and fluorescence from the 
dye was found in the blood vessels within the bleb tissue, shortly after application, 
suggestive of egress into the systemic circulation via traditional aqueous outflow 
mechanisms.  
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Induction of ocular hypertension was examined as a potential means to using IOP as 
an alternative outcome of success for experimental glaucoma surgery.  Injection of 
magnetic beads or cross linked hyaluronic acid into the rabbit anterior chamber to 
block aqueous outflow caused only a temporary, unpredictable pressure rise, and 
buphthalmos. Pooling IOP data from larger numbers after standard surgery appeared 
to be a more accurate method. 
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Chapter 2 Materials and Methods 
2.1 Implant formulation 
The implants were formulated without excipient using custom-made punch and die 
sets (Holland, Nottingham, UK). Three different punch and dies created implants of 
of 1 mm, 2 mm and 3 mm in diameter. A diagram illustrating the apparatus for a 1 
mm punch and die set is in Figure 2-1. To lubricate the parts, micrograde Poloxamer 
188 (Lutrol F68, BASF, Germany) 0.1% in acetone was applied and solvent allowed 
to evaporate before tablet compression. The FDA has approved the use of Poloxamer 
188 in ophthalmic drops.  
The implants were pressed using a Specac IR press. Powdered drug was poured into 
the die. The punch was placed with the pin inside the die and compression applied. 
Various compression forces were used according to the tablet size and drug pressed. 
The implant heights were measured with a micrometer screw gauge. 
 
Figure 2-1 The different components of the punch and die set. To fabricate an implant the lower 
punch was inserted into the die of corresponding size and pre-weighed drug poured into the die 
funnel. The upper punch was then placed on top of the die and alignment spacer used to keep the 
apparatus stable during pressing. The implant was ejected with a punch and then reweighed. 
2.2 Flow Release Studies using an in vitro model of a bleb 
Artificial ‘blebs’ or ‘flow rigs’ were constructed to allow examination of drug release 
from the implant (Figure 2-2). These consisted of watertight containers of 200 µl 
volume that have an inflow and outflow. Tubes were connected to a peristaltic pump 
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(ISMATEC, Switzerland) and allowed media to pass into the rig at a constant rate. 
By being placed in a heated oil bath (Grant) the rigs were maintained at a constant 
temperature. For the purpose of these studies the temperature was maintained at 35.5 
°C, an estimate of the sub-conjunctival temperature (Kawasaki et al., 2009). The 
effluent was collected at time points and High Pressure Liquid Chromotography 
(HPLC) used to analyse drug concentrations. Using the flow rate, quantity of drug 
release was determined. 
Initial experiments examined the drug release profile from implants at a flow rate of 
2 µl / minute, a putative rate of aqueous production in the normal eye (McLaren, 
2009). PBS at pH 6.5 was used as the solvent to mimic the aqueous. A slower flow 
rate was also used, a setting that might occur after surgery when the eye is 
recovering.  The flow rig apparatus was calibrated and checked using by collecting 
and weighing effluent over a set period of time. Calibration took place at the start 
and the end of the experiment. A temperature of 35.5 °C (estimated temperature of 
conjunctiva (Kawasaki et al., 2009)) was maintained for the duration of the 
experiments. An attempt was made to use sterilised ‘balanced salt solution’, a 
solution that is used to irrigate the eye during ocular surgery and whose constituents 
closely resemble those of the aqueous humour, however this led to microbial 
overgrowth that thwarted HPLC analysis.  
The media used for the majority of flow rig experiments was phosphate buffer saline 
(PBS). The pH of the media was maintained at 7.4. HPLC analysis took place 
according to the methods below: 
2.2.1 HPLC method for Ilomastat 
The detection of ilomastat in the first set of drug release experiments was through the 
use of an isocratic HPLC with a reverse phase C18 Superlco Discovery column 
88913-05. The detection wavelength was 280 nM. The following settings were used: 
flow rate 1 ml / min, running time 12 minutes and injection volume of 10 µl. The 
mobile phase consisted of 25% acetonitrile and 75% buffer (0.0135 M ammonium 
acetate, 0.6% triethylamine adjusted to pH 5.0 ± 0.1 with acetic acid). An integrated 
HP 1050 series HPLC system comprising an HP1050 autosampler, HP 1050 pump 
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and HP 1050 multiple wavelength UV-vis spectrophotometric detector was 
employed. The detector was interfaced with a pc with PC/Crhom + Software (H & A 
Scientific Inc., Greenville, NC). 
2.2.2 HPLC method for Marimastat and Ilomastat / Dexamethasone  
The detection of marimastat, ilomastat and dexamethasone in later experiments used 
a gradient HPLC method with a reverse phase Synergi Polar-RP Phenomenex 4 µm, 
15 cm column. The detection wavelengths for marimastat, ilomastat and 
dexamethasone were 210 nm, 280 nm and 241 nm respectively. There was a flow 
rate of 1 ml/min, a running time of 24 minutes and an injection volume of 10 µl. The 
mobile phases 0.1 % Trifluoroacetic acid (TFA) in water and acetonitrile were used 
in a gradient where TFA:acetonitrile started at 4:1 and ended at 3:7. The time 
between start and end point was 17 minutes. The Agilent 1200 series HPLC system 
(Agilent, USA) was employed with Chemstation software (Agilent, USA). 
2.2.3 Sterilisation of implants 
The implants were sterilised using gamma irradiation at a level of 25 KGy (Isotron, 
Swindon, U.K.). USP regulations stipulate a 25 KGy dose and 5 KGy has been 
proven to achieve a sterility assurance level of SAL=10-6. Irradiation has been shown 
in previous work not to affect the ability of ilomastat to inhibit HTF gel contraction 
(Georgoulas, 2010).  
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Figure 2-2 Flow rig chamber illustrating inflow and outflow tubes, 'O' ring seal and implant 
within the chamber. 
2.3 First in vivo experiment implant fabrication 
All rabbits were acclimatised for 5 days in the Biological Research unit (BRU) of the 
UCL Institute of Ophthalmology before the start of the experiments. The 
experiments conformed to the ARVO statement for the Use of Animals in 
Ophthalmic and Vision Research as well as the Animal Scientific Procedures Act 
(1986). The Animals were observed for a period of 30 days. The experiments were 
performed as a randomised, controlled study with an observer who was as masked as 
possible (the MMC treated arm had no implant and therefore an implant’s absence at 
follow up may indicate this treatment). This observer assessed the clinical data from 
28 males New Zealand White Rabbits (Harlan LK Ltd. C. 2.0-2.5 kg, 12-14 weeks 
old) 
2.3.1 Modified glaucoma filtration surgery 
Rabbits were anaesthetised with Ketamine (50 mg / kg) and Xylazine (10 mg / kg). 
All rabbits underwent surgery to the left eye only.  Povidone iodine 5 % was instilled 
into the left eye. The nictitating membrane was excised. A partial thickness 8-O silk 
corneal traction suture (Ethicon) was placed superiorly and the eye infraducted. A 
fornix-based conjunctival flap was then raised and blunt dissection exposed sclera to 
approximately 15 mm behind the limbus. An MVR blade was passed through the 
sclera at a shallow angle to enter the anterior chamber tangentally to the iris and then 
withdrawn. A 22 gauge / 25 mm cannula was then passed along the tract created by 
the blade and sutured to the scleral surface with a single 10-O nylon suture. The 
cannula was trimmed and beveled so that it would extend 1 mm above the scleral 
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surface. The conjunctival incision was closed laterally with two purse string sutures. 
Chloramphenicol ointment was instilled at the end of surgery. The surgical steps are 
illustrated in Figure 2-3. 
 
A           B 
 
    
C   D 
          
          E 
Figure 2-3 Surgical steps. [A] conjunctival flap, [B] cannula insertion, [C] implant placement if 
applicable, [D] conjunctival closure, [E] bleb filled at the end of surgery. 
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2.3.2 Treatment Regimen 
The 28 Rabbits were randomly assigned into 4 groups (7 rabbits in each group) with 
a Latin square crossover design (Table 2-1). Ethylcellulose, an excipient that does 
not swell, is poorly soluble in water, is not pharmacologically active, and was 
therefore used as a negative control. Mitomycin C was applied prior to cannula 
insertion using PVA sponges, and washed off with sterile water.  
 
Table 2-1 Treatment arms for 1st in vivo experiment. (For left eyes, during GFS; Right eyes are 
untreated and unoperated) 
 
 
 
 
 
 
 
2.3.3 Clinical Assessment 
Clinical examinations by a masked observer were performed preoperatively and at 
set time points after surgery. The following parameters were recorded using a 
portable slit lamp (Keeler SL-14 Portable Slit Lamp)(         Figure 2-4): 
Treatment 
Group 
Pharmaceutical Treatment 
A 
 
Ethylcellulose implant (2 mm, 1 mg)  (Negative 
Control) 
 
B 
 
One ilomastat implant (1mm, 0.5 mg) 
C 
 
One ilomastat implant (2 mm 1 mg) 
D 
 
Mitomycin  C  (0.2mg/ml) 
3 minute application 
(positive control) 
 52 
 
         Figure 2-4 Use portable slit lamp. 
 
• Intraocular pressure. Measurement of both eyes was performed using a 
‘Tonovet’. Readings were taken until 3 consecutive readings were within 2 
mm Hg of each other and the mean calculated. 
• Bleb surface area. Length and width measurements with calipers enabled 
surface area calculation. 
• Bleb height. Height was graded semi-quantitatively by slit lamp examination 
(0, flat; 1, shallow/formed < 1 mm; 2, elevated < 2 mm; 3, high > 2 mm) 
• AC depth (determined as flat, shallow or deep) 
• Bleb vascularity (graded as: 0 = vascular, 1 = normal, 2 = hyperaemic, 3 = 
very hyperaemic) 
• Anterior chamber inflammation (graded as: 0 = no inflammation, 1 = cells 
present, 2 = fibrin, 3 = hypopyon).  
 
 
2.3.4 Termination of the study 
 All animals were terminated after experiment completion with a lethal injection of 
intravenous pentobarbitone (4 mls) according to schedule 1. After termination eyes 
were enucleated and placed in formaldehyde. 
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2.3.5 Histology 
Eyes were fixed in 10% neutral buffered formalin. In the first study the globe was 
divided into two: a transverse anterior to posterior section was made to divide the 
globe into superior and inferior halves. The filtration tube was not removed from the 
operated rabbit eyes. The section was placed in a cassette and loaded into the tissue 
processor for 48 hours. To dehydrate the eyes, they were immersed in gradually 
increasing alcohol concentration (70 % methyl alcohol, 80 % methyl alcohol, 95 % 
methyl alcohol, 100 % methyl alcohol) and finally washed with xylene.  
The specimens were then embedded in molten paraffin wax in a mold of 
approximately 4 cm x 2 cm x 3 cm. Orientation was such that the eyes were lying on 
their sides with cornea and posterior pole at the front and rear of the cassette 
respectively. The molds were kept in the cold storage area until they became solid. 
The paraffin blocks were then secured to a microtome and sagittal sections were cut 
with a blade at 15°. Ribbons of tissue embedded in wax 5 µm thick were obtained 
and placed on the surface of warm distilled water to allow the ribbons to straighten. 
The paraffin sections were collected on microscope slides and briefly exposed to 
temperatures of 65oC, the melting point of paraffin wax, to encourage adhesion.  
Prior to staining the specimens were dewaxed and rehydrated with immersion in 
xylene for 5 minutes, followed by two further xylene washes for three minutes each. 
They were then washed with descending concentrations of methylated spirit, and 
finally with water. Histological stains used for the purposes of this experiment 
include haematoxylin and eosin (to assess the inflammatory reaction and cellularity 
of the bleb), and Picrosirius red (to evaluate collagen deposition). 
2.3.6 Haematoxylin and Eosin staining 
The sections were hydrated incrementally. Immersion began with xylene and then 
decreasing concentrations of methyl alcohol: 100 %, 90 %, 80 %, and 70 %. 
After rinsing they were then stained with Harris’s haematoxylin for 3 minutes, and 
rinsed again. For differentiation purposes, the slides were placed in 1% acid alcohol 
(1%HCl and 70% alcohol) for 5-10 seconds. They were then washed with tap water 
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for 5 minutes or until sections were blue. The sections were then stained with 1% 
Eosin Y for 10 minutes, and washed in tap water for 1-5 minutes. The specimens 
were dehydrated with ascending concentrations of methylated spirit and finally 
xylene. A drop of Digital Picture Exchange mounting media was placed in the centre 
of a coverslip, which was pressed gently onto each slide and left to dry. 
Using this method, nuclei are stained blue or black, cytoplasm is presented as 
varying shades of pink, muscle fibres show as dark pink-red, red blood cells are 
orange or red in colour, and fibrin are deep pink. 
 
Figure 2-5 Orientation of globe for histology. Thin red line indicates sagittal plane of sections 
through the drainage tube. 
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Figure 2-6 Sagittal section through a globe in a plane similar to that of the drainage tube 
illustrating anatomy. Blue circle indicates bleb area. 
 
2.3.7 Picrosirius Red staining 
The Picrosirius Red staining was done with 100ml of a saturated picric acid solution 
mixed with 0.1 g Sirius red powder.  
The sections were hydrated incrementally. Immersion began with xylene and then 
decreasing concentrations of methyl alcohol:100 %, 90 %, 80 %, and 70 %. Once 
hydrated, the sections were placed in distilled water for 10 minutes, then dehydrated 
as before with ascending concentrations of methylated spirit and finally xylene. For 
each slide, a drop of Digital Picture Exchange was placed in the centre of a coverslip 
and pressed gently to the slide, then left to dry. 
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Using polarizing microscopy, collagen type I is stained yellow, orange or red, 
collagen type II is stained blue or pale yellow depending upon orientation, and 
collagen III is stained green (Junqueira et al., 1979). 
2.4 Second in vivo experiment implant fabrication 
Excipientless ilomastat and AstraZeneca 8955 and 6357 implants were formulated as 
above in the first experiment using a punch and die set. Unfortunately there was error 
in calculating the mass of the some of the implants. Preparation was rushed. The 
overall dimensions of diameter were the same, however weights of the pre-pressed 
drug were confused with implant weights, furthermore weighing took place on scales 
that were less accurate (+/- 0.5 mg error) and therefore it was not possible to be sure 
of the masses of 5 of the implants. 
Those implants where there was doubt over the accuracy have been labelled as 
unknown in the table below (Table 2-2) 
Ilomastat / hyaluronic acid (Visiol) implants were produced by dissolving 2.5 mg of 
ilomastat in 1.5 ml of ethanol 96% (v/v) and 2 ml of demineralised water. Visiol (1.5 
ml) was added to this solution. The mixture was then freeze-dried. The homogenate 
weighed 45 mg after freeze-drying and was compressed into five tablets of 
approximately 9 mg each (diameter 3 mm, height 1 mm).  A compression of 0.4 bar 
for 10 seconds was used. The compaction was kept constant during the preparation 
of all tablets. The drug was assumed to be dispersed evenly thoughout the 
homogenate and therefore each tablet to contain approximately 0.5 mg of ilomastat. 
The tablets were stored at 4°C in an eppendorf tube (1.5 ml). Four tablets were 
placed in one eppendorf tube (1.5 ml) and transported at room temperature to 
Moorfields Eye Hospital for beta-irradiation using Strontium 90 (215 Gy) for 6 h. 
Sterilisation was not confirmed. The weights at the time of surgery were determined 
by subtracting the weight after each tablet removal. 
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2.4.1 Treatment regimen  
Eighteen rabbits were assigned into 7 groups. Three rabbits were assigned to each of 
groups A, B, C, D and 2 rabbits to each of groups E, F, and G (Table 2-1). The 
rabbits were randomised in a Latin square crossover design.  
 
Table 2-2 Treatment regimen 2nd in vivo. Treatment groups A and B aimed to determine whether 
excess aqueous fluid (phosphate buffer solution) applied perioperatively enhanced dissolution. The 
implants in arms A and B were supposed to be approximately 2 mg, however due to errors in 
fabrication were variable. Where denoted unknown* there was doubt over the exact mass of the 
implant (Right eyes are untreated and unoperated). 
 
 
 
 
Treatment 
Group 
Pharmaceutical Treatment 
A 
n=3 
 
 3 mm (2.1mg, 3.5 mg and one unknown* mg) 
ilomastat implant dry  
B 
n=3 
 
 
3 mm (3.4 mg, 3.4 mg and 3.6 mg) ilomastat implant 
hydrated.  
C 
n=3 
 
 
1 mm (0.4 mg and two unknown* mg) ilomastat 
implant hydrated 
D 
n=2 
 
 
1 mm (0.4 mg and two unknown* mg) ilomastat 
implant surrounded by Healon 5 
E 
n=2 
 
 
Hyaluronic acid (Visiol) / ilomastat tablet freeze dried 
3 mm; weight of the tablets 9.3 mg and 8.3 mg (0.52 
and 0.46 mg Ilomastat); 
        F 
n=2 
 
 
1 mm (0.4 mg and 0.2 mg) AZ 6357 tablet hydrated 
G 
n=2 
 
1 mm (0.5 mg and 0.4 mg) AZ 8955 tablet hydrated 
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2.4.2 Additional Surgical Technique 
Modified glaucoma filtration surgery was performed as in the first in vivo 
experiment. For each arm where applicable the additional surgical techniques were 
followed: 
 
2.4.2.1 Hydration of the 3 mm and 1 mm excipient free implants 
The conjunctiva and Tenon’s tissue were hydrated with sterile Phosphate Buffer 
Saline solution (PBS) using a syringe and a pressure similar to that used for 
hydrodissection in cataract surgery. The implant was placed behind the tube and then 
further saline droplets applied to ensure complete wetting. The conjunctiva was then 
sutured and then further hydrated underneath to facilitate bleb formation. 
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Figure 2-7 Implant hydration and conjunctival inflation at the time of surgery. 
 
2.4.2.2 Implant surrounded by hyaluronic acid gel cushion 
A small drop of Healon 5, approximately 0.1 ml was applied to the sclera behind the 
tube and an implant placed on top. A drop of phosphate buffered saline solution was 
then applied, followed by further Healon 5 to completely surround the implant. 
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Figure 2-8 Healon V application to sclera before implant placement. 
 
2.4.3 Outcomes 
Clinical evaluation and termination were performed in a similar manner to the first in 
vivo experiment. All operated eyes and one unoperated eye from each treatment 
group (26 eyes total) were used for histology. The whole globe was used for 
processing and analysis. This enabled conjunctiva and sclera on the operated side of 
the eye to be examined and compared to the unoperated side on the same slide. From 
the first experiment it became clear that anatomical localisation of the bleb area 
within a millimetre or two was of crucial importance. To enable more accurate 
location of the surgical site during microtoming, a marker 7-0 silk suture was used, 
placed 2 mm adjacent to the drainage tube.  
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Figure 2-9 Suture position 2 mm adjacent to the drainage tube. Visualising suture through the 
opaque paraffin wax enables the location of sectioning to be determined. 
2.5 Third in vivo experiment implant fabrication 
Excipient free marimastat tablets were fabricated using a punch and die set; a 
lubricant (0.1 % polaxamer 188 in acetone) was applied to the punch and die after 
each tablet fabrication. Marimastat powder was weighed out, and poured through a 
hopper into the 2 mm punch and die, and compressed at 4.5 bars for 10 seconds. The 
tablets were weighed and placed individually into tared eppendorf tubes (1.5 ml), and 
stored at 4°C. For the in vivo experiment they were then transported at room 
temperature to Isotron and sterilised by exposure to gamma irradiation (~25 kGy). 
To confirm the final weight of the tablets used, individual eppendorfs with individual 
tablets are weighed pre and post surgery. 
2.5.1 Treatment regimen  
Four rabbits each received a 2 mm marimastat implant (2.2 – 2.4 mg). Application of 
the implant and modified glaucoma surgery was performed was as per the 1st 
experiment. 
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2.5.2 Termination 
Animals were terminated as in the previous in vivo experiments. The termination day 
for 2 rabbits was day 7 and for the other 2 rabbits was day 14. All operated eyes and 
1 unoperated eye for each time point were harvested for histology. 
2.6 Fourth in vivo experiment implant fabrication 
Marimastat implants were fabricated as in the last in vivo experiment. To create 
dexamethasone / ilomastat implants twenty percent of the end implant weight was 
assumed to be lost during fabrication: for dexamethasone 1mg / ilomastat 1 mg 
implants approximately 1.2 mg of dexamethasone and 1.2 mg of ilomastat were 
weighed out and placed in an eppendorf lid and mixed using a spatula. Once fully 
mixed the mixture was poured using a hopper into the 2 mm punch and die, and 
compressed at 2 bars for 10 seconds. The implants were weighed and placed 
individually into tared eppendorf tubes (1.5 ml) and stored at 4°C. They were then 
transported at room temperature to Isotron and sterilised by exposure to gamma 
irradiation (~25 kGy). To confirm the final weight of the implants used, individual 
eppendorfs with individual tablets are weighed pre and post surgery 
2.6.1 Treatment regimen  
Twenty-four rabbits received treatments (Table 2-1) following a Latin Square design. 
Modified glaucoma surgery was performed on the rabbits as per the 1st experiment. 
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Table 2-3. Treatment arms. (For left eyes, during GFS; Right eyes are untreated and 
unoperated). The marimastat implants dimensions and weight were chosen because these were the 
most stable and least likely to fragment. Two implants were used to maximise dose within the 
physical limitations of the surgical site. 
 
 
 
2.6.2 Examinations  
Examinations were performed as in the previous experiments, however the additional 
procedures were performed: 
• Photographs of the bleb were taken with a Canon EOS 7D SLR at each time 
point looking down on the bleb from above and a view anterior to posterior to 
gauge bleb height. A macro lens was used. The settings were AV mode for 
the camera and flash with diffusers applied. The focus was set as close as 
possible to enhance detail and consistency. Multiple photographs were taken 
at each time point to enable selection of similar views at the various time 
points for comparison. 
• Anterior segment optical coherence tomography (SL-OCT, Heidelberg 
Engineering, Berlin, Germany) was used as an adjunct to visualise the 
implants. The OCT consists of a 1310 nm Superluminescent Diode to 
produce cans of 15 mm in width and 7 mm in depth. Rabbits were restrained 
by an assistant and encouraged to look down. 
Treatment 
Group 
Pharmaceutical Treatment 
A 
 
 Two 2 mm marimastat implants (2.9 – 3.1 mg) 
Overall drug mass 6 mg. 
B 
 
2 mm ilomastat / dexamethasone tablet  (total drug 2 
mg made up of 1 mg ilomastat and 1 mg 
dexamethasone ) 
C 
 
Mitomycin C (0.2 mg/ml) 
3 minute application 
(positive control) 
D 
 Sterile water group (negative control) 
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2.6.3 Histology 
Twenty-six eyes (22 operated and 4 unoperated controls) were harvested and fixed 
with 10% neutral formaldehyde buffer for approximately one week. The whole of the 
eye was used without removing the filtration tube. A 6 ‘O’ suture was used to mark 
the position 2 mm lateral from the tube. The tissue was processed and embedded as 
before. Sections were cut from the globe with a microtome (in a sagittal plane) so the 
bleb area is at the top of the ribbon. Five µm cut sections are placed in warm distilled 
water and then collected on a microscope slide. The slides were subsequently stained 
with haematoxylin and eosin. 
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2.7 Fifth in vivo experiment implant fabrication 
2.7.1.1 Ilomastat and dexamethasone implants  
The excipient-free ilomastat and dexamethasone implants were fabricated using a 
1mm punch and die set. Approximately 0.6 mg of ilomastat powder was weighed 
out, and poured into the 1 mm punch and die, and compressed at 0.4 bars for 10 
seconds. The implants were weighed and placed individually into tared eppendorf 
tubes (1.5 ml) and stored at 4°C. They were then transported at ambient temperature 
to Isotron and sterilised by exposure to gamma irradiation (~25 kGy). To confirm the 
final weight of the implants and the amount of ilomastat and dexamethasone used, 
individual eppendorfs with individual implants were weighed pre- and post-surgery. 
2.7.1.2 Polymer coated ilomastat implants 
Excipient-free ilomastat tablets were fabricated using a 2 mm punch and die. 
Approximately 1.2 mg of ilomastat powder was weighed out, and poured into the 2 
mm punch and die, and compressed at 2 bars for 10 seconds. The implants were 
weighed and placed individually into tared eppendorf tubes (2 ml) and stored at 4°C. 
They were then transported at room temperature to UCL Business (contact Jaspal 
Kaur-Griffin) for coating with polymer in the laboratory of Alex Seifalian 
(UCL/Royal Free Hospital). The coating process involved spraying a 
dimethylacetamide solution of the polymer onto the tablet; other details are not 
known due to the Seifalian group wishing to keep this knowledge to themselves.  
The coated implants were then reweighed in individual eppendorfs before being 
transferred to Isotron and sterilised by exposure to gamma irradiation (~25 kGy). To 
confirm the final weight of the tablets used, individual eppendorfs with individual 
tablets are weighed pre- and post-surgery. The proportion of polymer to ilomastat 
was not accurately known. 
2.7.1.3 Ilomastat-Hyaluronic acid implants 
The following mixing processes were conducted in a biological flow hood to 
maintain aseptic conditions. Ilomastat powder (32.0 mg) was dissolved in tert-
butanol (40% aqueous solution) (32.0 ml), then sterilised by filtration using a syringe 
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filter (0.22 µm). Healon GV® (14.0 mg/ml) or Healaflow® (22.5 mg/ml) was 
transferred into a 1.0 ml syringe slowly to avoid entrapment of air bubbles inside the 
syringe. An amount of Healon® or Healaflow® equivalent to 3.0 mg hyaluronic acid 
(133.3 µl of Healon or 214.3 µl of Healaflow) was aliquoted into a glass vial (14.0 
ml). The polymer solution was diluted by addition of sterile water (1.0 ml) then 
vortexed to produce a homogenous solution. The ilomastat solution (1.0 mg/ml) (1.0 
ml) was added into the polymer solution in the glass vial and vortexed to produce a 
homogenous solution. The mixture was then frozen quickly using dry ice. An empty 
syringe (50.0 ml) was capped with a sterile filter (0.22 µm).  Air was removed from 
the filter by pulling the syringe plunger slowly. The glass vial containing the frozen 
mixture of ilomastat and the polymer was sprayed with ethanol (70% in water) and 
then placed inside the syringe (50.0 ml). The syringe (50 ml) was then placed into 
dry ice and transferred quickly into the freeze drier after being sprayed with aqueous 
ethanol (70%). The formulation was freeze-dried for 4 days. The freeze-dried 
powder was pressed using a clean tablet press (3 mm punch and die), which had been 
placed in an aseptic flow hood. The punch and die were sterilised by dry autoclave 
and the tablet press machine was sterilised by spraying with aqueous ethanol (70 %). 
Empty eppendorf tubes (1.5 ml) were weighed and then sterilised by autoclaving.  
The fabricated tablets were then transferred under sterile conditions into the 
autoclaved eppendorf and then weighed.  The implants were stored at 4°C under 
argon to eliminate moisture.  
2.7.1.4 Sandwich implant  
These tablets involved prefabrication and sterilisation of an excipient-less ilomastat 
implant as was done in arm A. The ilomastat tablet was then pressed with solid 
hyaluronic acid as a process to coat the ilomastat with hyaluronic acid. This process 
can be termed “a solid tablet coating process.”  Since these tablets are fabricated by a 
process involving the pressing of a tablet within solid hyaluronic acid, these implants 
are named sandwich implants to distinguish them from traditionally coated implants 
(i.e. tablets coated for arm B).   
i. Preparation of ilomastat implants 
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The excipient-less ilomastat implants were fabricated using a punch and die (2 mm 
diameter) with no lubricant being used. Ilomastat (1.2 mg) was weighed and placed 
into the die and compressed (2 bar) for 10 seconds. The implant was ejected from the 
die and its weight was recorded. The ilomastat implant was placed individually into 
tared eppendorf tubes (1.5 ml) and stored at 4°C. They were transported at ambient 
temperature to Isotron and sterilized by exposure to gamma irradiation (~25 kGy).  
ii. Preparation freeze-dried hyaluronic acid using Healon GV : Revanesse Ultra 
(cross-linked hyaluronic acid) (1:3 by weight)  
A total of approximately 3.0 mg of solid hyaluronic acid was used to press around 
each ilomastat implant. To prepare the hyaluronic acid for freeze-drying, Healon GV 
(30 µl; 14 mg/ml) and Revanesse Ultra (50 µl; 25 mg/ml) were transferred to an 
autoclaved 7 ml glass vial in an aseptic hood. Sterile water (1.0 ml) was added to the 
hyaluronic acid solution in the glass vial and this solution was then vortexed till a 
homogeneous mixture was obtained. After freezing the hyaluronic acid mixture in 
the vial with dry ice, the vial was transferred to a 50 ml syringe that was capped with 
a sterile filter (0.22 µm) and the solid mixture in the vial was freeze-dried for a 
period of 3 days following the same procedures as described for arms C and D. 
 
iii.     Preparation of sandwich implants  
The following mixing and pressing processes were conducted in a biological flow 
hood to maintain aseptic conditions. The freeze-dried hyaluronic acid powder and 
pre-formed ilomastat implant was pressed using a clean and sterilised press (3 mm 
punch and die) as described in arms C/D. The punch and die were sterilised by dry 
autoclave and the press was sterilised by spraying with aqueous ethanol (70 %). The 
freeze-dried hyaluronic acid contents from a vial (1.5 mg) were emptied into the 3 
mm die. The ilomastat implant was carefully centred in the middle of the 3 mm die 
on top of the freeze-dried hyaluronic acid.  To this was added freeze-dried hyaluronic 
acid from a second vial (1.5 mg). Fitting the punch into the die, this combination of 
solids was compressed (2 bars) for 15 seconds to yield a hyaluronic acid coated 
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ilomastat tablet that was ejected from the punch. The implants were then transferred 
under sterile conditions to empty eppendorf tubes (1.5 ml) that had been tared and 
previously sterilised (autoclaved). The tablets were stored at 4°C under argon to 
eliminate moisture.  
2.7.2 Treatment Regimen 5th in vivo 
Twenty-four New Zealand White rabbits underwent modified glaucoma filtration 
surgery (as per 1st in vivo experiment) with six groups of four animals each receiving 
treatments according to Table 2-4 and following a Latin Square randomisation.  
Table 2-4. Treatment Groups. For left eyes, during GFS; Right eyes are untreated and 
unoperated. 
 
Treatment 
Group 
Pharmaceutical Treatment 
A 
One ilomastat implant (1 mm, 0.5 mg) and one 
dexamethasone implant (1 mm, 0.5 mg) 
B 
One ilomastat implant (2 mm, 1 mg) coated with polymer 
provided by Alex Seifalian, UCL/Royal Free Hospital. 
C 
Ilomastat (1 mg) / hyaluronic acid (3 mg) (Healon GV) 
combination freeze dried and fabricated into a 3 mm 
implant.  
D 
Ilomastat (1 mg) cross-linked hyaluronic acid (3 mg) 
(Healaflow) combination freeze-dried and fabricated into a 
3 mm implant.  
E 
Healon GV: Cross linked HA (1:3) (3mg) combination 
freeze dried and fabricated as base and top (3 mm) for 
ilomastat implant 2 mm (1 mg).  
F Sterile water treated group (negative control) 
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2.7.3 Examinations  
A single masked observer undertook examinations pre-operatively, and on days 3, 7, 
10 and 14. Each examination is within 24 hours of the time point. Both eyes were 
examined in every rabbit with a portable slit lamp. Evaluations were performed as in 
the previous in vivo experiments. 
2.7.4 ICG dye evaluation of bleb functionality 
One rabbit from each treatment arm of the 5th in vivo experiment was chosen at 
random and prior to termination on day 14 before terminal anaesthesia. This 
particular in vivo was chosen for this type of test following extensive discussions 
regarding whether clinical observation of a bleb indicated functionality. Furthermore 
due to it being only 14 days long dye flow would be more likely to be seen. It was 
also a pilot study and not an efficacy study when intervention should be kept to a 
minimum. The animal was positioned in front of the Heidelberg Retinogram digital 
camera. A butterfly needle (27Fr) connected to a transducer to measure intracameral 
IOP was inserted into the anterior chamber. The IOP was measured every 2 minutes. 
Using an insulin needle inserted inferiorly at an angle parallel to the iris into the 
anterior chamber, 0.1 mls of aqueous was drawn off and 0.1 mls of 0.5 % ICG 
injected. Using a digital camera several sequenced images were recorded. 
2.7.5 Termination 
All animals are killed under Schedule 1 with a lethal injection of intravenous 
pentobarbitone (1ml/kg) via ear marginal vein. The termination was at day 14. All of 
the eyes were exenterated for histology and placed in formalin. 
2.7.6 Histology 
All eyes were harvested and fixed with 10% neutral formaldehyde buffer for 
approximately 2 weeks. The whole of the eye was processed without removing the 
filtration tube and stained as in the previous experiment. 
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2.8 Sixth in vivo experiment implant fabrication 
Excipient-free ilomastat implants were fabricated using a 2 mm punch and die set. 
Approximately 1.2 mg of powder was weighed out, and poured into the 2 mm punch 
and die, and compressed at 2 bars for 10 seconds. The tablets were weighed and 
placed individually into tared eppendorf tubes (2 ml) and stored at 4°C. They were 
then transported at room temperature to Vertellus (Basingstoke) for coating with 
polymer in the laboratory of Mike Driver (Vertellus).  If being used for the in vivo 
experiment the coated tablets were then reweighed in individual eppendorfs before 
being transferred to Isotron and sterilised by exposure to gamma irradiation (~25 
kGy). To confirm the final weight of the tablets used, individual eppendorfs with 
individual tablets are weighed pre- and post-surgery.  
The design of experiment was chosen after considering the advantages / 
disadvantages of possible treatment arms (Table 2-5) 
Tissue sampling 
Blood was sampled at two time points: days 3 and 30 for systemic levels. 
Six globes treated with polymer coated ilomastat tablets were used to determine 
tissue drug levels. The globes were dissected to yield tissue from the bleb 
conjunctiva, remaining implant, cornea, aqueous and vitreous. The concentrations of 
drug were analysed by Dr Ahmed using liquid chromatography mass spectrometry. 
The unoperated eyes from the sterile water group were used as controls.
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Table 2-5 Advantages and disadvantages of different in vivo designs. 
Experimental design For Against 
MMC, Ethylcellulose spacer, drug, sterile water, 30 day 
outcome.  
Sterile water provides baseline 
Ethylcellulose qualifies spacer effect / isolates drug effect 
MMC gold standard 
Earlier time points missing, which may miss changes in the inflammatory process, 
i.e. sterile water may show greater inflammation at an earlier time point, and tissue 
remodeling likely to be significant by day 30. Conversely, if implant disappears 
before day 30 any particulate effect may be missed  
MMC, Ethylcellulose spacer, drug, sterile water, histology 
at multiple time points 
Sterile water provides baseline 
Ethylcellulose qualifies spacer effect / isolates drug effect 
MMC gold standard 
Multiple time points evaluates wound healing process and 
effect on the wound healing process comprehensively. Less 
likely to miss earlier peaks in inflammatory activity.   
Numbers of animals required significant. Harvesting at multiple time points requires 
minimum of n of 3 at each time point. If 6 in each arm, only 2 time points allowed! 
 
 
MMC, drug, sterile water, 30 day outcome Sterile water provides baseline 
MMC gold standard 
More n numbers 
 
Earlier time points missing, which may miss changes in the inflammatory process. 
i.e. sterile water may show greater inflammation at an earlier time point, as tissue 
remodeling likely to be significant by day 30. Conversely if implant disappears 
before day 30 any particulate effect may be missed. 
Remodeling in the sterile water group will most likely result in significantly less 
inflammation than around implant at 30 day time point. Difficult to make 
comparison therefore. 
Bleb survival interpretation affected by spacer. 
MMC, drug, sterile water, histology at multiple time points More n numbers 
Sterile water a useful gauge for the effect of surgery 
No spacer comparison for bleb survival or to show anti-scarring effect of drug 
compared to spacer. 
MMC, Ethylcellulose spacer, drug, 30 day outcome More n numbers particulate effect of ethylcellulose useful 
comparison for histology 
No baseline comparison – therefore any early scarring in the wound healing process 
related purely to surgical intervention missed 
MMC, Ethylcellulose spacer, drug, multiple time points More n numbers particulate effect of ethylcellulose useful 
comparison for histology 
No baseline comparison – therefore any early scarring in the wound healing process 
related purely to surgical intervention missed 
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Table 2-6 Treatment groups (for left eyes, during glaucoma filtration surgery; right eyes are 
untreated and unoperated) 
Treatment 
Group 
Pharmaceutical Treatment 
 
A 
n = 16 
One 2 mm (1 mg presumed) pure ilomastat tablet 
coated with polymer provided by Mike Driver 
(Vertellus) 
B 
n = 10  
MMC (0.2 mg / mL) applied perioperatively for 3 
minutes 
C 
n = 10 
Water sponge (sterile water applied in the same way 
as MMC in ‘C’) 
 
2.8.1 Histology 6th in vivo 
Thirty-six eyes (30 operated and 6 un-operated controls) were harvested and fixed 
with 10% neutral formaldehyde. The whole of the eye was processed without 
removing the filtration tube. The processing and embedding were planned to be the 
same as in previous experiments, however due to breakdown of the processor this 
was not possible (please see start of 6th in vivo results section). 
2.9 Investigation into inducing raised intraocular pressure to be used a 
measure of success in vivo 
Six rabbits were used (n = 3) in each arm to investigate the potential to induce ocular 
hypertension (Table 2-7). All treatments were applied to the left eye. The right eye 
did not receive any treatment during the study and serves as the un-operated control.  
 73 
Magnetic beads, approximately 100 mcg (Bangs laboratories) were washed in 70% 
ethanol and resuspended in 0.5 mls sterile PBS, then aliquoted into an eppendorf. 
 
Table 2-7 Experimental arms to investigate induction of ocular hypertension.  
A 
Magnetic bead injection into the anterior chamber 
(sterilisation prior to injection by washing in 50% aqueous 
ethanol and rinsing with sterile PBS) 
B 
Cross linked hyaluronic acid injection into the anterior 
chamber 
 
2.9.1 Surgical technique 
An MVR blade was used to create a paracentesis and an insulin needle (30 gauge) 
attached to an empty 1 ml syringe advanced into the anterior chamber. 
Approximately 100 ul of aqueous was drawn off. A second syringe and needle 
containing either suspended beads or Healaflow® was advanced into the anterior 
chamber and 100 ul of contents injected into the angle. If magnetic beads were 
injected a ring magnet of 16 mm diameter (Supermagnete, Germany) was used to 
pull the beads into the angle. Chloramphenicol ointment was instilled at the end of 
surgery. 
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2.10 Appendix 
2.10.1 Equipment and Materials 
2.10.2 Tablet fabrication 
- Punch and die set designed and supplied by Holland Ltd, Nottingham, UK. 
- Ilomastat obtained from Ryss Inc, Union City, California,  
- Dexamethasone obtained from Sigma, UK,  
- Healaflow purchased from Vision Matrix, Harrogate, UK. 
- Revanesse Ultra, source of cross-linked hyaluronic acid was purchased from 
Boston Medical Group Limited, London, UK. 
- Polymer from Alex Seifalian (UCL/Royal Free), London, UK. 
- Sterilization of tablets by Isotron UK, 25 KGY, Swindon, UK. 
- Micrometer screw gauge produced by Mituoto, Japan. 
Medication 
- Ketamine (Ketaset) 35mg/kg 
- EMLA Cream 
- Xylazine (Rompun) 5mg/kg 
- Povidone iodine  
- Chloramphenicol 
- Viscotears 
- Sterile water  
Surgical Instruments  
- 7-0 silk corneal traction suture (Johnson and Johnson Ethicon W817)  
- Microvitreoretinal Blade (20 Gauge) (Beckton Dickinson, Oxford, UK) 
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- 22-gauge, 25-mm IV cannula (Venflon 2: Beckton Dickinson, Oxford, UK)
  
- 10-O Nylon suture attached to needle (B/V 100-4; ethicon) Alcon 8065 
198001, Camberley, Surrey. 
- Orange needles (25 gauge)  
- Syringes (5ml) 
- PVA surgical Spears (Altomed Spears)   
- Needle holder  
- Heavy scissors 
- Speculum  
- Toothed forceps  
- Artery forceps  
- Non- toothed forceps  
- Spring scissors/Wescotts  
- Vannas scissors  
- Suture tiers  
- Corneal light shield      
- Tonovet, Finland  
 
Termination Medication (Schedule 1) 
- Thiopenthal Sodium (pentothal) 
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Histology 
- 4% Formaldehyde  
- Insulin 1ml syringes  
- Vials 2ml 
- Histology Slides 
Beads 
-magnetic polymer coated beads 8 um COMPEL™ Magnetic COOH modified 
(Bang’s laboratory, Indiana)   
 Randomisation – using random number generator (http://www.randomizer.org) 
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Chapter 3 Results 
3.1 Excipientless pure ilomastat tissue-tablet implant studies 
3.1.1 Ilomastat implant in vitro experiments 
Cells that are instrumental in the process of scarring can be inhibited reversibly by 
using the MMPi ilomastat. As ilomastat has a low aqueous solubility (Parkinson et 
al., 2012) and a low concentration of therapeutic efficacy (Daniels et al., 2003) it 
was hypothesised that an excipientless implant of appropriate size and mass would 
release drug at a therapeutic concentration over the wound-healing period after 
glaucoma surgery. The aim of these experiments was to see whether it was possible 
to formulate and determine release kinetics from 1, 2 and 3 mm implants in vitro and 
the duration a therapeutic concentration that could be maintained. The range of sizes 
was chosen according to what seemed reasonable to insert into the sub conjunctival 
space. Investigations also examined the pharmacokinetics of two implants together 
to see if the therapeutic concentration could be prolonged. Furthermore the rate of 
dissolution was looked at to discover whether drug concentration in the surrounding 
fluid was sufficient to limit the rate of release of drug from the implant. The 
compression pressure for implant formulation needed to be great enough to create a 
stable implant that would not fragment, but not so high as to impair release 
significantly (as found in pressure experiments performed by S Georgoulas). 
3.1.1.1 Implant fabrication 
Compression forces of 0.4, 2 and 4 bars were required for stable implants of 1, 2 and 
3 mm diameter respectively. The source of ilomastat used (Ryss) consisted of 
particles that poured easily into the press and resulted in less than 10% loss between 
weighing the powder and the resulting implant. After fabrication, a number of 
implants were then re-weighed and those that were greater than 10% either side of 
the target weight were discarded. The approximate yield was 60%. To ensure 
fabrication was as consistent as possible one supplier was chosen. Batch numbers 
were recorded and tried to be kept as constant as feasible.  
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Figure 3-1 A 2 mm ilomastat implant after fabrication of 2 mg mass 
 
Table 3-1 Ilomastat tissue-tablet implant dimensions. A range of 10% either side of the target was 
chosen as acceptable 
Implant	
diameter	
(mm) 
Implant	
height	(mm) 
Implant	mass	
(mg) 
Tablet	surface	
area	(mm2) 
Tablet	volume	
(mm3) 
1 0.55 0.5 3.3 0.43 
2 0.35 1 8.5 1.09 
3 0.35 2 17.4 2.47 
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3.1.1.2 Release profile of implants 
3.1.1.2.1 Release from a 3 mm implant 
Single 3 mm implants released ilomastat at concentration above 10 µM (14.3+/- 25 
µM to 170 +/- 44 µM) for 23 days (Figure 3-2 and Figure 3-3). The mean maximum 
concentration (Cmax) released was 170 µM with a cumulative release of 81%. 
 
Figure 3-2 Ilomastat concentration of elutent from single 3 mm ilomastat implants over time. A 
concentration of ilomastat of  > 10 µM was maintained for 23 days. Number of implants n = 3. 
Implant masses were 1.7, 1.4, and 1.9 mg (mean 1.7 mg). PBS flow rate was 2 µl / minute. The data 
displays mean +/- standard deviation. 
 
Figure 3-3 Cumulative mean percentage release of the 3 mm implant. The release was determined 
by calculating the quantity of drug present in the elutent at each time point.  The data displays mean 
+/- standard deviation. 
 
 
0 200 400 600
0
50
100
150
200
250
Time (hours)
C
on
ce
nt
ra
tio
n 
(µ
M
)
0 200 400 600
0
20
40
60
80
100
Time (hours)
%
 D
ru
g 
re
le
as
e
 80 
3.1.1.2.2 Release from a 2 mm implant 
Single 2 mm implants of ilomastat released drug at a concentration that was 
maintained above 10 µM for 12 days (Figure 3-4 Figure 3-5). The mean Cmax 
released was found to be 100 µM.  
 
Figure 3-4. Ilomastat concentration of elutent from single 2 mm ilomastat implants with time. A 
mean concentration of ilomastat of  > 10 µM was maintained for over 12 days. Number of implants n 
= 3. Implant masses were 1.1, 1.1 and 1.29 mg (mean 1.16 mg). Error bars indicate standard 
deviation. 
 
Figure 3-5 Cumulative mean percentage release of the 2 mm ilomastat implants with time. The 
release was determined by calculating the quantity of drug present in the elutent at each time point. 
Error bars indicate standard deviation. 
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3.1.1.2.3 Release from a 1 mm implant 
The release of ilomastat from 1 mm implants maintained a drug concentration of  > 
10 µM for 19 days. The mean Cmax of drug released was 68 µM. One rig released a 
much higher concentration of drug for the time-points between 22 and 43 hours.
 
Figure 3-6 . Ilomastat concentration of elutent from single 1 mm ilomastat implants with time. 
A concentration of ilomastat of  > 10 µM was maintained for over 19 days. Number of implants n = 3. 
Implant masses were 0.45, 0.65 and 0.50 mg (mean 0.53 mg). Error bars indicate standard deviation. 
 
 
Figure 3-7 Cumulative mean percentage release of the 1 mm ilomastat implants with time. The 
release was determined by calculating the quantity of drug present in the elutent at each time point. 
The rate of release was slower than the larger implants. 
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3.1.1.3 Two 2 mm implant release 
A concentration of > 10 µM was maintained for 11 days when the rigs contained 2 implants 
implants (Figure 3-8 and 
 
Figure 3-9). The total masses of implants in each rig were 1.52 mg, 1.5 mg and 1.53 
mg. The Cmax was 288 µM.  
 
Figure 3-8 Ilomastat concentration of elutent from two 2 mm ilomastat implants with time. A 
concentration of ilomastat of  > 10 µM was maintained for over 12 days. Number of implants n = 6. 
Implant masses in each rig were: 0.76 and 0.77 mg, 0.73 and 0.77 mg, 0.7 and 0.82 mg (mean total 
1.52 mg). Error bars indicate standard deviation. 
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Figure 3-9 Cumulative mean percentage release of two 2 mm ilomastat implants with time. Rig 
n = 3. The release was determined by calculating the quantity of drug present in the elutent at each 
time point. Approximately 80% of calculated drug was released, attributable to loss during handling 
and systematic error in weighing. 
 
 
 
3.1.1.4 Determining release of drug from at a slower flow rate 
Aqueous production can be impaired after ocular surgery or in certain pathological 
states, and therefore the kinetics of release at a lower flow rate was investigated. 
Implants of 2 mm diameter were exposed to PBS flow rates of 1 µl / minute (Figure 
3-10 and Figure 3-11). The mean maximum concentration reached was 206 µM. A 
concentration of > 10 µM was maintained for 22 days. All implants had dissolved by 
40 days at the 1µl / minute flow rate.  
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Figure 3-10 Concentration of ilomastat released over time with a flow rate of 1 µ l / minute.  
Single 2 mm implants of 1.1 mg, 1.15 mg and 1.3 mg (mean 1.18 mg) were exposed to a flow rate of 
1 µl / minute PBS.  
 
 
Figure 3-11 Mean cumulative percentage release profile of 2 mm ilomastat implants exposed to 
a flow rate of 1 µ l / minute PBS. Drug loss during handling may be the cause of release not reaching 
100%. Alternatively the speed of flow at lower flow rates may be less accurately controlled. 
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3.1.1.5 Discussion 
Single implants in this in vitro rig model exposed to a fluid flow rate similar to 
aqueous production have the potential to maintain a therapeutic concentration of 
ilomastat (> 10 µM) for a range of between 12 to 26 days. The low solubility of the 
drug means that toxicity is unlikely. At lower flow rates the duration of drug release 
is extended and the concentration of drug increased. This in theory would be of 
benefit, as reduced aqueous production and flow occurs commonly in situations 
where there is heightened inflammation.  
The results can be related to the Noyes Whitney equation (1897), which determines 
the factors involved in the drug dissolution from a single spherical drug particle: 
dm/dt = k-1A*(Cs-Ct)/h 
where the mass transfer (dm/dt) of a substance is a function of the surface area (A) 
available for dissolution, the diffusion coefficient of the compound in the dissolution 
media (k1), the boundary layer thickness of surrounding fluid (h), and the difference 
between the concentration of the drug’s saturated solubility, (Cs) and its 
concentration in the bulk of the dissolution media at time t (Ct).  
It is therefore unsurprising that in the single implant experiments the larger the 
individual implant surface area, the greater the mass transfer and the greater the peak 
concentration seen in solution. That two 2 mm implants increased the mass transfer 
by two fold and did not increase the duration of the drug release indicates that Ct is 
not increasing significantly to affect release for the 2 mm implant, and that 
dissolution is operating in “sink” conditions. Conversely at the lower flow rate the 
duration of drug release is extended approximately two fold indicating “non-sink” 
conditions are occurring and the presence of drug in solution is limiting release. In 
this situation the surrounding solubilised drug has a greater effect on the mass 
transfer of the drug into solution than the solubility. This effect may be illustrated by 
using a dialysis membrane to determine drug release from colloidal formulations 
(Washington, 2009). 
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The kinetics of drug release for the 1 mm implants are of interest. According to the 
above equation, as the surface area is less, the mass transfer should be 
correspondingly less than the larger implants. This is presuming that the implant is a 
solid piece of drug and does not fragment into particulates. For example, the 1 mm 
implant has a surface area that is 0.39 of the 2 mm implant (if the surface area of the 
implant bases are excluded, as these are in contact with the rig surface, the factor 
then is 0.47). The peak concentration seen with the 1 mm implant was 69 µM, 
whereas with the 2 mm implant it was 100 µM. However if the time-points between 
minutes 22 and 43 are excluded due to the spurious results from one rig – which may 
have been caused by an air bubble in the apparatus affecting flow or particulate 
release from the implant - the concentration released for the 1 mm implant is 
between 30 and 40 µM, which correlates well with what is expected from the 
equation. 
That the release duration for the 1 mm implant is at least 1.6 times than that of the 2 
mm is contrary to initial expectations; the release duration of the 2 mm implant was 
less than the 3 mm. However the surface area to mass ratio for the 1 mm implant is 
less (6.6 mm2 / mg) than the surface area to mass ratio of the 2 mm implant (8.5 mm2 
/ mg) or the 3 mm implant (8.5 mm2 / mg). It is likely that this ratio will also change 
as the implants dissolve with time, and that the disparity between ratios will increase 
as more dissolution occurs from the superior surface of the larger diameter discs. 
Furthermore, the larger discs are more fragile and over time were more likely to 
develop cracks, which would also contribute to an increased surface area.  
The boundary layer is another factor in the equation that is difficult to determine in 
this model. Velocity of fluid flow will affect the pattern of flow as will the diameter 
of the implant (Sumer and Fredsøe, 2006). These variables combined with the 
kinematic viscosity of water (viscosity / density) enable a ‘Reynolds’ number to be 
determined. At the slow flow rate in this experiment it is unlikely that eddies will 
form, however to be sure a detailed examination using dye and flow in a more easily 
visualised environment, is required.  
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𝑅𝑒 = 𝐷𝑈/𝑣 
 
Figure 3-12 The Reynolds number for fluid flow behaviour around a cylinder. This factor is 
determined by the diameter of the cylinder (D), flow velocity (U), and kinematic viscosity (v). For a 
cylinder of diameter 3 mm (3 x 10-3 m) and a chamber where the fluid flow is presumed to be 2 ul 
min-1 through a cross sectional area of approximately 25 mm2 gives 0.8 mmmin-1 (1.3 x 10-5 m/s) 
Presuming water has a kinematic viscosity of 0.7 x 10-6 m2/s at 35 0C, the Reynolds number is 3.9 x 
10-2.  
 
 
 
Figure 3-13. The pattern of fluid flow for different Reynolds numbers.  Adapted from (Sumer and 
Fredsøe, 2006). With a Reynolds number of 3.9 x 10-2 turbulent flow is unlikely.  
Intrinsic and proportional to the size of the implants are the systematic errors in their 
formulation and measurement of release. The mass balance used, although one of the 
most accurate in the School of Pharmacy, still has an error of +/- 0.25 mg (personal 
communication Dr Simon Gaisford). Thus smaller implants have a greater error in 
measurement than larger ones. This is not just related to the capability of the balance 
itself, but also to the effect of air currents – just having the air-conditioning on can 
increase the mass of an implant by 0.2 mg! (Shown by repeating measurements in 
different environments) Efforts were made to limit airflow and even perform the 
measurements in a closed environment. Nonetheless this error and loss of drug in 
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handling is the most likely reason for the release not reaching 100%. Further repeat 
experiments would be able to determine the variability of error, but some idea of the 
variability is indicated by the error bars. That residual drug did not remain in the rig 
at the end of experiments was shown by opening the chambers and finding no visible 
pellets. 
The measurement of low concentrations of drug using HPLC is also susceptible to 
increased error. As measurements approach the baseline the variability increases. 
This is reflected in the graphs of concentration vs time for the implant release, and is 
one reason for the error bars increasing as the drug concentration falls. 
The rig provides valuable information regarding drug dissolution in an open flow 
system. It shows that theoretically an implant could release drug at a therapeutic 
concentration in a sustained manner, without the spikes and troughs that might be 
seen with an injection. It does, however have limitations as a model of the bleb. The 
chamber is 200 mm3 whereas a functioning bleb has been estimated to have a fluid 
volume as small as 6.3 mm3 using optical coherence tomography (Kawana et al., 
2009). The aqueous fluid drains through one exit point as opposed to diffusely 
through episcleral veins. However key factors involved in the pharmacokinetics of 
release are the interplay of cells and tissue around the implant, and to be able to test 
this an experimental animal model is required.  
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3.1.2 In vivo results of pure ilomastat 2 mm and 1 mm implants 
As the results of the previous drug release experiments found that therapeutic 
concentrations of ilomastat could be maintained for 12 to 23 days, it was postulated 
that 1 mm and 2 mm implants would prolong the success of glaucoma filtration 
surgery in the in vivo model, and that the lower dose implant might be sufficient. 
The details of the procedure are outlined in the methods. In brief however, a fornix 
based conjunctival flap is raised and a 23 gauge cannula (blue) is inserted into the 
anterior chamber. The tube is trimmed and fixed with nylon, an implant placed if 
appropriate for the treatment arm, and the conjunctiva replaced and sutured with 
nylon. The visible presence of a bleb is taken as the main observational outcome 
measure of success, because unlike patients with glaucoma, rabbits have a low 
intraocular pressure before surgery.  
The four treatment arms in a 28 rabbit experiment (n = 7 in each arm) were: 
1) Ilomastat implant1 mm (0.5 mg) 
2) Ilomastat implant 2 mm (1 mg) 
3) Mitomycin C 0.2 mg/ml for 3 minutes perioperatively 
4) Ethylcellulose implant 2 mm (1 mg) negative control 
The rabbits treated with ilomastat 1 mm (0.5 mg) tablets all had blebs that survived 
to day 30. The ilomastat 2 mm (1 mg) tablet group all survived until day 27, and 6 
(86%) survived to day 30. Of the MMC treated group, 2 (29%) had successful blebs 
at day 30. Three (43%) of the ethylcellulose tablet treated group had successful blebs 
at day 30. The differences in bleb survival between the ilomastat 1mm and 
ethylcellulose groups, and the ilomastat 1 mm and MMC groups, were statistically 
significant (log rank P = 0.0221 and 0.0078 respectively). Representative images at 
different time points are shown in Figure 3-12 and Figure 3-13. The Kaplan Meier 
curve in Figure 3-14 illustrates bleb survival. 
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Figure 3-14 Representative photos of blebs at day 15 for each of the treatments: ilomastat 1 mm 
(A), ilomastat 2 mm (B), ethylcellulose 2 mm (C), and mitomycin C (D). All eyes have the 
appearance of a functional bleb at this stage. Blue line indicates bleb margins. 
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Figure 3-15 Representative photos of blebs at day 30 for each of the treatments: ilomastat 1 mm 
(A), ilomastat 2 mm (B), ethylcellulose 2 mm (C), and mitomycin C (D). The appearance of blebs A 
and B indicate functionality and those of C and D as failures. Blue line indicates bleb margins.  
 
 
Figure 3-16 Bleb survival of the four groups. The ilomastat 1 mm and ilomastat 2 mm implants 
survived significantly longer than the ethylcellulose and MMC groups (log rank P = 0.0221 and 
0.0078 respectively). 
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The bleb surface area of all four groups decreased with time (Figure 3-17). Those 
blebs with the ilomastat 1 mm and ilomastat 2 mm implants maintained blebs of 
greater surface area than those of either MMC or ethylcellulose after day 9 to day 30.  
A Kruskal-Wallis test showed that there was a significant difference between bleb 
surface areas at day 30  (H (3) = 10.2, P = 0.017). Compared to ethylcellulose using 
Dunn’s multiple comparison test there was no significant difference for individual 
treatments.  
 
Figure 3-17  Mean bleb surface area over time for the four groups. The ilomastat 1 mm and 2 mm 
maintained a greater mean bleb surface area than MMC and ethylcellulose from day 12. Error bars 
indicate standard error.  
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A Kruskal-Wallis test revealed that there was a significant difference between bleb 
heights at day 30  (H (3) = 10.2, P = 0.017). Inspection of the group means using 
Dunn’s multiple comparison test showed no significant difference, however, 
compared to the ethylcellulose treated group.  
 
 
Figure 3-18 Mean bleb height of the 4 groups over time. Bleb height was graded as 0, flat; 1, 
shallow/formed; 2, elevated < 2 mm and 3, high > 2 mm. From day 12 the ilomastat 1 mm and 
ilomastat 2 mm treated animals maintained higher blebs than the ethylcellulose or MMC treated 
animals. Error bars indicate standard error. 
 
There was a fall in mean IOP early after surgery. This was followed by a post-
operative return to base line for all groups (Figure 3-19). There was no significant 
difference between treatment groups. An attempt was made to reduce variability in 
IOP between rabbits that might be unrelated to the surgery by subtracting the IOP of 
the operated eye from the IOP of the unoperated eye. No increased discernible 
difference was found. n 
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Figure 3-19 Mean IOP of operated eye with time. There was an initial fall in IOP followed by a 
return to baseline for all groups. Error bars indicate standard error. 
The vascularity of the blebs in the initial stages of the experiment showed no 
difference between the four groups. After 15 days the ilomastat 1 mm and 2 mm 
blebs appeared to have comparatively greater vascularity than the ethylcellulose or 
MMC blebs (Figure 3-20). A Kruskal-Wallis test showed that there was a significant 
difference between vascularity at day 30  (H (3) = 9.1, P = 0.028). Compared to 
ethylcellulose using Dunn’s multiple comparison test there was no significant 
difference for other treatment arms. 
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Figure 3-20 Bleb vascularity post surgery.  The vascularity was graded as  0 = avascular, 1 = 
normal, 2 = hyperaemic, 3 = very hyperaemic. Data displays blebs at each time point as mean and 
standard error of the mean. 
 
 
There was no significant inflammation in any of the four treatment groups. 
3.1.2.1 Bleb dissection 
After termination 3 blebs from each group (chosen at random) were dissected to 
investigate implant presence and obtain a macroscopic view. Implants were found in 
all ethylcellulose, ilomastat 1mm and ilomastat 2 mm treated blebs. The surrounding 
tissue was found to have bands of adhesions to the implants, and dissection led to 
their fragmentation. 
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Figure 3-21 Bleb dissection of an ilomastat 1 mm treated bleb. Adhesive bands can be seen 
between the implant and the reflected conjunctiva. 
 
3.1.2.2 Histology 
Ethylcellulose treated blebs showed some thickening of the conjunctiva with a mild 
increase in cellularity in comparison to the unoperated conjunctiva (Figure 3-20, 
Figure 3-21). Posterior to the tube site revealed implant remnants in three of four 
blebs. Infiltrating the remnants was a network of inflammatory cells, and 
surrounding the remnants were closely compacted fibroblasts. 
The MMC blebs showed some evidence of increased cellularity and conjunctival 
thickening with some epithelial disruption (Figure 3-24). Increased inflammation 
was seen associated with the tube site and suture material in a similar way to the 
other three experimental arms. 
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Figure 3-22 Haematoxylin and Eosin of an Unoperated eye. Legends: Co: cornea, T: drainage 
tube, S: sclera. Scale bar 1 mm. A loosely packed conjunctiva was seen. 
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Figure 3-23 Ethylcellulose treated bleb. Legends: C: conjunctiva, T: drainage tube, S: sclera, I: 
implant remnants. Scale bar 1 mm.  A mildly thickened conjunctiva with increased cellularity was 
seen with Haematoxylin and Eosin stain. Where implant remnants were seen they were interlaced 
with inflammatory cells. Surrounding the remnants were fibroblasts. 
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Figure 3-24 MMC treated bleb. Legends: C; Conjunctiva, T: drainage tube, S: sclera. Scale bar 1 
mm. Increased cellularity and thickening of the conjunctiva was seen with Haematoxylin and Eosin 
staining. Increased inflammation was seen associated with the tube location.  
 
The ilomastat 1 mm and 2 mm blebs showed evidence of immune cell infiltration 
and greater conjunctival thickening around the surgical site with more protein 
deposition. In the 2 mm treatment arm refractile pink implant remnants were seen in 
two of the four blebs and the edge of an inflammatory capsule in the remaining 2 
blebs. In the 1 mm treatment arm an implant remnant was seen in one of four blebs 
and the edge of an inflammatory capsule in one other bleb. Where implant remnants 
were seen there was an associated dense halo of surrounding inflammatory cells 
(Figure 3-25, Figure 3-26). Adjacent to the remnant were seen neutrophils, and 
macrophages with eosinophilic granular cytoplasm. More peripherally the 
predominant cells appeared to be smaller, with densely staining nuclei and little 
cytoplasm, consistent with lymphocytes. More peripheral still were closely 
compacted fibroblasts. 
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Figure 3-25 Ilomastat 2 mm treated bleb. Legends: C: conjunctiva, T: drainage tube, S: sclera, I: 
implant remnants. Scale bar 1 mm. A purple halo of immune cells was seen surrounding the implant 
with Haematoxylin and Eosin staining. Amongst those cells seen were neutrophils, macrophages and 
a smaller number of eosinophils  
 101 
 
Figure 3-26 Ilomastat 1 mm treated bleb. Legends: C: conjunctiva, S: sclera, I: implant remnants. 
Scale bar 1 mm. A purple halo of immune cells was seen surrounding the implant with Haematoxylin 
and Eosin staining. 
Picrosirius red staining for collagen revealed increased collagen deposition in the 
ilomastat 2 mm, ilomastat 1 mm, and ethylcellulose arms associated with the implant 
remnants (Figure 3-27). 
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Figure 3-27 Picrosirius red staining of the four treatment arms: ilomastat 1 mm (A), ilomastat 2 
mm (B), ethylcellulose (C) and MMC (D).  Legends: S: sclera, C: conjunctiva. Scale bar 1 mm. A 
greater density of staining in the conjunctiva was seen associated with the ilomastat 1 mm and 
ilomastat 2 mm treatment arms with most concentration associated with implant remnants. 
 
3.1.3 Discussion 
The results of this in vivo study lead to conflicting conclusions. Both the ilomastat 1 
mm and 2 mm implants appear to prolong the clinical observational parameter of 
bleb survival, a parameter used in other studies (Cordeiro et al., 1997; Wong et al., 
2003; Wong et al., 2005), compared to either ethylcellulose or MMC. However there 
was a relative increase in inflammation and scarring seen in the ilomastat implant 
treated blebs. Indeed the ilomastat implants themselves were associated with the 
greatest amount of inflammatory infiltrate, with many macrophages, lymphocytes 
and eosinophils. 
Ilomastat has been proven to inhibit fibroblast mediated contraction in collagen gels 
(Daniels et al., 2003). Multiple postoperative injections have promoted bleb survival 
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in the same animal model as used in this experiment accompanied by a significant 
reduction in scarring and inflammation (Wong et al., 2003; Wong et al., 2005). 
Ilomastat also showed promise as an anti-inflammatory drug for corneal ulcers 
following experiments that proved that it would inhibit inflammatory cell infiltration 
in rabbit corneas after alkali exposure (Galardy et al., 1994). 
A drug is only active, however, if it is in solution form. In solution it is able to 
occupy the binding sites of its target enzyme or other molecule, and exert its effect. 
The above examples used ilomastat in solution form either as an injection using the 
solvent dimethyl sulphoxide (DMSO) (Wong et al., 2003; Wong et al., 2005) or as a 
topical droplet (Galardy et al., 1994).  
Two deductions can be made from this experiment’s histological observations: 
1) The inactive solid state ilomastat is stimulatory to the immune system. 
2) Any active solubilised ilomastat is insufficient to dampen this immune response. 
Solid particulate matter is well known to cause an immune response. In the acute 
inflammation stages this response consists predominantly of neutrophil recruitment 
and infiltration. These cells are limited in their ability to reconstitute the proteases 
needed to eliminate pathogens, and if a foreign material persists, recruitment of 
macrophages in great numbers occurs during the stages of chronic inflammation. 
Although the macrophage has a much greater appetite for ingestion – it is capable of 
ingesting particles of more than its own size (Cannon and Swanson, 1992) – larger 
particles cause the macrophages to “wall off” the stimulus and contain it in a foreign 
body granuloma. For example, fragments of cotton retained from gauze used in 
surgery can cause a significant foreign body reaction, similar to seen in this 
experiment (Parmar and Sharr, 1999). In the conjunctiva this has been explicitly 
demonstrated by the retention of particles of methylcellulose sponge, and is the 
reason why most surgeons now use polyvinyl alcohol sponges (Al-Shahwan and 
Edward, 2005). 
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It may not simply be the presence of a solid that excites a foreign body reaction.  
Examining crystalline ilomastat under the scanning electron microscope also reveals 
a spiky appearance with multiple rods of up to 200 µM long and compression into an 
implant does not eliminate this appearance. It is possible that micro movements of 
the implant could lead to adjacent tissue trauma stimulating the immune response. It 
is believed that failure of glaucoma drainage devices due to scarring is enhanced by 
micromovements (Jacob et al., 1998). How smooth or how rough a surface is will 
also determine the overall surface area, fluid flow behaviour and drug dissolution 
(Jimenez, 2004). A completely smooth surface will not necessarily yield the least 
friction for fluid passing over it however, as demonstrated by the America’s cup 
yacht ‘Stars and Stripes’, whose hull was coated in fine grooves to ease passage of 
water. In 1987 she beat Kookaburra III to regain the America’s cup (Demeis, 1988).  
 
Figure 3-28 Scanning electron micrograph of crystalline ilomastat and ilomastat implant. The 
crystals in the compressed drug are shorter, but the surface remains irregular. Magnifications left to 
right 500 x, 100 x, 1000 x. 
An example of where spiky material causes “frustrated phagocytosis” is seen in 
asbestosis (Kamp and Weitzman, 1999; Shin and Firminger, 1973). Particles of 
insoluble crystalline hydrated silicates, particularly if in an amphibole form (straight, 
brittle fibres), are able to penetrate deep into the lungs. Too small to be impacted in 
the upper airways and removed by the mucociliary elevator, the fibres enter and 
lodge themselves in the alveoli. Macrophages fail to ingest the fibres and cause 
continuing inflammation through the release of reactive oxygen species.  
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Figure 3-29 Macrophage attempting to ingest an asbestos fibre. Adapted from (Environmental, 
2011) 
Tackling host tissue response is a major challenge in the development of implantable 
drug delivery devices throughout the body (Zhang et al., 2013). Inevitably cell – 
implant surface interaction results in the adhesion of non-specific proteins that coat 
the implant. These too could encourage macrophage activation (Ratner, 2002). The 
same frustrated phagocytosis then occurs and a key result is the sealing off of the 
implant in a collagenous bag preventing drug release (Figure 3-30), destroying any 
correlation seen with the in vitro results.  
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Figure 3-30 Foreign body encapsulation of an implant.  Adapted from (Ratner, 2002). 
Evidence for a collagenous capsule surrounding the ilomastat implants not only 
comes from the histology but also from the macroscopic appearance of the dissected 
blebs. If the ilomastat implants had been walled off effectively, so no drug was 
available to diffuse out, this would explain the second deduction: that “there was 
insufficient free ilomastat to provide an anti-inflammatory or anti-scarring effect.” 
Removing samples of bleb fluid throughout the experiment would have provided an 
indication of the free ilomastat concentration, but would have necessitated a surgical 
intervention and possible interference in the wound healing response. 
Bleb survival was found not only to be greater in the ilomastat treatment arms than 
the MMC arm but also in the ethylcellulose arm. Although there was no significant 
difference between them, that both the positive and negative control achieved a 
similar success rate is of interest. Bleb survival is an outcome based on the 
observation of the “presence” of a bleb. Ethylcellulose implants were chosen as a 
negative control: the implants were of a similar dimension to the ilomastat 2 mm arm 
and had supposedly no biological activity, thereby attempting to account for a 
“spacer” effect that the physical presence of an implant might have. Assuming that 
ethylcellulose does indeed have no biological activity, this leads to the conclusion 
that this spacer effect can promote bleb survival in this model to the same degree as 
MMC. A further negative control to examine the spacer effect would be to use water 
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instead of MMC. When the experiment was designed however it was believed that 
there would be little implant at the end, that the ilomastat implant was efficacious 
and that the question to be asked was whether size was important. 
These findings therefore also raise the question of how much bleb survival reflects 
drug efficacy as an anti-scarring treatment. The surface area and bleb height 
followed the pattern of bleb survival, however there was almost an exponential 
decay. This would suggest that there is more than just the physical presence of an 
implant playing a role in outcome, or else one would see more of an initial fall in 
bleb surface area and height, followed by a plateau.  
Three factors would each seem to be able to play an independent role in contributing 
to the appearance of a bleb in this rabbit model: 1) the presence of aqueous, 2) the 
spacer effect of the implant, 3) the conjunctival thickening associated with 
inflammation and scarring, i.e. a more fibrotic response to the implant could increase 
“bleb size” and prolong “bleb survival”. It is not possible to quantify the contribution 
of each in this experiment, but in the MMC treatment arm one can be sure that there 
is no contribution from a spacer effect. In the ilomastat arms there is clearly a 
contribution from the spacer effect and from conjunctival thickening from fibrosis – 
seen in histology, the macroscopic appearance of bleb dissection, and the level of 
vascularity.  
 Is there another possible end point that could be used? In clinical trials of patients 
with glaucoma, the endpoint most commonly used for evaluating surgical or medical 
efficacy is intraocular pressure. With humans it is a measurement that is easy to 
perform, is reproducible and takes minimal time, as compared to visual field testing 
which is frequently unreliable, and optic nerve head appearance, which is dependant 
on subjective interpretation. The rabbits in this experiment however do not have 
glaucoma, and their baseline intraocular pressure is low. There is considerable 
variability not only between animals, but also between measurements taken at 
different times in the same animal. Easily startled, a tense rabbit was found to 
increase its IOP. The exact mechanism is not known, however an analogy is that of a 
patient squeezing in anticipation of having tonometry performed or a weight lifter 
who increases his IOP through a valsalva manoeuvre (Vieira et al., 2006). Previous 
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studies have found difficulty in using IOP as an outcome measure in rabbits (Miller 
et al., 1989).  
These results show that the ilomastat implants are able to promote the longevity of 
the appearance of a bleb, but encapsulation with a foreign body reaction occurs 
around the implants that will distort the interpretation of a functional bleb. This is the 
first time to our knowledge that encapsulation with a foreign body reaction around a 
pure drug anti-inflammatory / anti-scarring implant has been described at a 
histological level. Other reports of implants are also not without a foreign body 
reaction, however they use carriers such as the Ozurdex implant (SooHoo et al., 
2012). It is likely that in the blebs where implant remnants were not seen, this was 
due to the section being in a different plane, rather than complete dissolution in that 
bleb due to the strength of foreign body response in those blebs where remnants 
were seen. 
If the foreign body reaction we are seeing is associated with negligible drug release 
after surgery, would enhanced dissolution with drug in solution negate this effect? 
From the Noyes Whitney equation and the previous in vitro experiment this might be 
achieved by increasing the implant surface area. Using a 3 mm diameter implant 
would increase the surface area by more than two times that of the 2 mm implant. 
Another method of increasing drug release would be to expose the implant to more 
aqueous fluid at the time of surgery. By ensuring adequate hydration there would be 
a greater solvent volume, and in theory more active drug in solution.  A third way to 
increase MMPi in solution would be to use a more soluble MMPi. Perhaps by 
making the implant less abrasive there would be less physical stimulation of 
surrounding tissue. This might be achieved by surrounding the implant in a cushion 
of polymer such as hyaluronic acid, or indeed combining the drug with hyaluronic 
acid to create a rapidly hydrating gel: this would also have the added bonus of 
enhancing surface area and drug release.  
In the next experiment these hypotheses were tested. An excipient would enable the 
drug material to be more easily distributed, and alter its dissolution characteristics. It 
also allows the implant to have a greater cohesiveness. Unfortunately, however this 
project had a patent attached that stipulated that the implant should be excipientless. 
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The lines of investigation UCL partners who were directing this MRC funded project 
were keen to retain this “intellectual property”. Therefore lines of investigation that 
satisfied this were the avenues of first choice.  
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3.2 Optimisation of MMPi release to reduce inflammatory response: a second 
in vivo study 
As pure 1 mm and 2 mm ilomastat implants resulted in a significant foreign body 
reaction to the undissolved material and questionable drug release, it was postulated 
that increasing dissolution or altering implant tissue surface interaction might reduce 
this significantly.  
A pilot in vivo study of 7 arms was constructed to examine the effect on histology 
after GFS of increasing the amount of active drug in solution, whilst reducing the 
antagonistic particulate effect: 
1) The effect of increasing the surface area for dissolution was examined using a 
larger 3 mm ilomastat implant (n = 3). This diameter was chosen because it was the 
same as the diameter of implants in the pilot study (Georgoulas, 2010).  
2) In the second arm 3 mm implants were used as in ‘1’ but excess PBS was also 
applied to irrigate the implant at the time of surgery to see whether hyper-hydration 
would encourage dissolution and reduce the foreign body response (n = 3). 
3) Smaller (1 mm) implants with excess PBS applied at the time of surgery were 
used in the 3rd treatment arm (n = 3). The hypothesis was that reducing the 
aggravating particulate might, with hyper-hydration, result in less foreign body 
reaction. 
4) It was postulated that cushioning the implant might reduce tissue abrasion and 
inflammation: The ilomastat implant (1 mm) was placed within a soft cushion of 
high molecular weight gel hyaluronic acid (Healon 5)(n = 2). Healon 5 is a high 
molecular weight hyaluronic acid gel suspension commonly used for providing 
temporary structural support to the globe during ocular surgery. The advantage of 
this approach is that in theory there would be less abrasion from the implant sides to 
the surrounding conjunctival tissues, however the duration of this effect is unknown 
and the Healon 5 may dissipate relatively quickly. 
 111 
5) An ilomastat hyaluronic acid combination implant was also created. Although 
outside the patent, this line of investigation combined both a method of increasing 
dissolution (in vitro release see below), and potentially reducing the abrasiveness of 
the implant. Visiol was selected for the in vivo, as it appeared easy to combine with 
an aqueous ethanol (10%) solution of ilomastat (n = 2). 
6) MMPis that have a similar inhibitory profile as ilomastat but were more soluble 
were also investigated. Two compounds (AZ 8955 and AZ 6357) in previous in vitro 
studies had shown potential to be developed into effective anti-scarring slow-release 
implants (PhD thesis S. Dhingra). The compound AZ 8955 had a water solubility of 
more than 3 fold that of ilomastat (140 µg ml-1) and was formulated into 1 mm 
implants (n = 2) 
7) AZ 6357 has a water solubility of more than 16 fold that of ilomastat                
(624 µg ml-1). Implants (1 mm) were formulated for the in vivo (n = 2). 
3.2.1 In vitro release of ilomastat hyaluronic acid (visiol) implants 
Combination implants of ilomastat and hyaluronic acid (visiol) (0.75 mg ilomastat 
overall mass 8.0 mg) released ilomastat over the period of 8 days (Figure 3-32). 
They were created by mixing a solution of aqueous ethanol containing ilomastat,  
and then freeze dried (see methods). The mean maximum concentration was found to 
be 146 µM. A sustained early release of ilomastat maintained a mean concentration 
≥ 10 µM for 4 days. 
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Figure 3-31 Ilomastat released from combination implants of hyaluronic acid (visiol) and 
ilomastat over time. A concentration of ilomastat of  > 10 µM was maintained for 4 days in one rig 
and 7 days in the other rig.  
 
Figure 3-32 Cumulative mean percentage release of ilomastat combined with hyaluronic acid 
over time. The release was determined by calculating the quantity of drug present in the elutent at 
each time point. Again there was approximately 80% of calculated drug released, attributable to loss 
of drug during handling. 
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3.2.2 Experiment to optimise MMPi release in vivo results 
The seven arms for the in vivo pilot study are summarised in the table below. During 
the formulation of the implants in this second in vivo study error occurred in the 
measurement of the implant masses. The overall dimensions of diameter were the 
same, however weights of the pre-pressed drug were confused with implant weights, 
and therefore it was not possible to be sure of the masses of 5 of the implants. The 
range of masses was between 2.1 to 3.6 mg for 3 mm implants and 0.5 to 1 mg for 1 
mm implants  (see methods). 
Table 3-2 Treatment regimen 2nd in vivo.  Where denoted unknown* there was doubt over the 
exact mass of the implant (range 2.1 – 3.6 mg for 3 mm implants and 0.5 to 1 mg for 1 mm implants). 
 
 
 
 
Treatment 
Group 
Pharmaceutical Treatment 
A 
 
 3 mm (2.1mg, 3.5 mg and one unknown* mg) 
ilomastat implant dry  
B 
 
3 mm (3.4 mg, 3.4 mg and 3.6 mg) ilomastat implant 
hydrated.  
C 
 
1 mm (0.4 mg and two unknown* mg) ilomastat 
implant hydrated 
D 
 
1 mm (0.4 mg and two unknown* mg) ilomastat 
implant surrounded by approximately 0.1 mL Healon 5 
E 
 
Hyaluronic acid (Visiol) / ilomastat tablet freeze dried 
3 mm; weight of the tablets 9.3 mg and 8.3 mg (0.52 
and 0.46 mg Ilomastat); 
        F 
 
1 mm (0.4 mg and 0.2 mg) AZ 6357 tablet hydrated 
G 
 
1 mm (0.5 mg and 0.4 mg) AZ 8955 tablet hydrated 
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3.2.2.1 Survival and bleb surface area 
All blebs treated with pure ilomastat implants appeared to be raised until day 30 
(Figure 3-33, Figure 3-34). The group of animals with 3 mm ilomastat implants that 
received hydration (n = 3) had a greater bleb surface area than those that received 
dry 3 mm implants in the initial stages of the experiment, though after day 12 there 
was minimal difference between the two. The animals treated with 1 mm hydrated 
ilomastat and 1 mm Healon 5 cushion implants retained similar surface area blebs 
throughout the experiment. Both of the blebs treated with an AZ 8955 implants 
failed at day 27. One of the blebs treated with AZ 6357 failed at day 21 and the other 
failed at day 27. Both of the blebs treated with the combination implant of ilomastat 
and Visiol failed at day 24. The surface area of the blebs treated with the AZ 8955 
were consistently greater than those treated with AZ 6357 or ilomastat / Visiol. A 
Kruskal-Wallis test showed that there was a significant difference between bleb 
surface areas at day 30  (H (6) = 16.34, P = 0.012). There was no significant 
difference between the individual means, however, using Dunn’s multiple 
comparison test.  
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Figure 3-33 Representative photos of blebs at day 15 for each of the treatments: ilomastat 3 mm 
dry (A); ilomastat 3 mm hydrated (B); ilomastat 1 mm hydrated (C); ilomastat 1 mm enveloped in 
hyaluronic acid gel (Healon 5) (D); ilomastat in combination with hyaluronic acid (Visiol) formulated 
as a freeze dried implant 3 mm (E); AZ 6357 1 mm hydrated (F); AZ 8955 1 mm hydrated (G). All 
blebs were classed as surviving at this stage. Blue dotted line indicates bleb margins. 
 
Figure 3-34 Representative photos of blebs at day 30 for each of the treatments: ilomastat 3 mm 
dry (A); ilomastat 3 mm hydrated (B); ilomastat 1 mm hydrated (C); ilomastat 1 mm enveloped in 
hyaluronic acid gel (Healon 5) (D); ilomastat in combination with hyaluronic acid (Visiol) formulated 
as a freeze dried implant 3 mm (E); AZ 6357 1 mm hydrated (F); AZ 8955 1 mm hydrated (G). The 
pure ilomastat implant treated blebs (A, B, C, D) were classed as surviving (blue dotted line indicates 
bleb margins) and the remainder had failed.  
 
A B C` D
E F G
A B C` D
E F G
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Figure 3-35 Bleb survival of the 7 different groups: ilomastat 3 mm hydrated (n = 3); ilomastat 3 
mm dry (n = 3); ilomastat 1 mm hydrated (n = 3); ilomastat 1 mm enveloped in hyaluronic acid gel 
(Healon 5) (n = 2); ilomastat in combination with hyaluronic acid (Visiol) formulated as a freeze 
dried implant 3 mm (n = 2); AZ 6357 1 mm hydrated (n = 2); AZ 8955 1 mm hydrated (n = 2).  
 
 
Figure 3-36 Bleb surface area for the 7 groups over time. After day 12 similar bleb surface areas 
were seen for rabbits treated with the hydrated 3 mm and non hydrated 3 mm pure ilomastat implants, 
and the hydrated 1 mm ilomastat and 1 mm ilomastat enveloped in hyaluronic acid gel (Healon 5). 
Error bars indicate standard error.  
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3.2.2.2 Bleb height 
The results of the bleb height correlated with those of the surface area (Figure 3-37). 
 
Figure 3-37 Bleb height for the 7 groups over time. Bleb height was graded as 0, flat; 1, 
shallow/formed; 2, elevated < 2 mm and 3, high > 2 mm. Error bars indicate standard error. 
 
3.2.2.3 Intraocular pressure 2nd in vivo 
Little difference was seen between the seven treatment arms with the exception of 
the ilomastat 3 mm non-hydrated arm. These rabbits maintained a lower IOP for 
days 12 and 15 (Figure 3-38). 
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Figure 3-38 IOP for all 7 groups over time. The eyes that received the non-hydrated 3 mm 
ilomastat implant maintained a lower IOP for day 12 and 15 though no significant trend could be seen 
otherwise. Error bars indicate standard error. 
 
3.2.2.4 Bleb vascularity 
The larger implants showed greater vascularity than the smaller implants. Little 
difference could be distinguished between the 1 mm implant treatment arms (Figure 
3-39). 
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Figure 3-39 Bleb vascularity. The vascularity was graded as  0 = avascular, 1 = normal, 2 = 
hyperaemic, 3 = very hyperaemic. Data displays functional blebs at each time point as mean and 
standard error of the mean. 
 
3.2.2.5 Other events 
One of the 3 mm implants was found to extrude during the 30 day period. It is not 
clear exactly when this took place, however it became apparent that the leading edge 
of the conjunctiva retracted after day 18 with the implant migrating towards the 
limbal edge. 
3.2.2.6 Histology 
A cuff of inflammatory cells was seen surrounding the 3 mm ilomastat implants. 
Amongst those cells seen were neutrophils, macrophages and Langhans’ giant cells. 
There was no appreciable difference in immune cell infiltration between the hydrated 
and non-hydrated implants. There was also no appreciable difference between the 
immune reaction around the hydrated ilomastat 1 mm implants and the hydrated AZ 
8955 1 mm implants (Figure 3-40). 
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Figure 3-40 Hamatoxylin and Eosin staining of pure ilomastat implants. Legends: C: conjunctiva, 
T: drainage tube, S: sclera, I: implant remnants. Scale bars 1 mm. No appreciable difference was seen 
in quantity of immune cell infiltration or conjunctival thickening between the hydrated (A) and non-
hydrated (B) 3 mm implants. There was also no appreciable difference in the quantity of immune cell 
infiltration between the 1 mm hydrated ilomastat implant (C) and the 1 mm hydrated AZ 8955 
implant (D). 
There appeared to be less immune reaction around the ilomastat implants enveloped 
in Healon 5 although the morphology of the conjunctiva was similar to the previous 
arms discussed, namely that there was thickening with closely packed fibroblasts 
(Figure 3-41). 
There was no evidence seen of any refractile substance consistent with drug remnant 
seen in the blebs that received the 3 mm ilomastat / Visiol combination or the 
hydrated 1 mm AZ 6357 implant. The subconjunctival area had some inflammatory 
cells, but these were not distributed in a structured manner (Figure 3-41).   
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Figure 3-41 Haematoxylin and Eosin stain of blebs treated with ilomastat 1 mm enveloped in 
Healon 5 (E), AZ 6357 1 mm hydrated (F), ilomastat / Visiol 3 mm (G). Legends: C: conjunctiva, 
T: drainage tube, S: sclera, I: implant remnants. Scale bars 1 mm. Remnants were not detected in the 
blebs that received either AZ 6357 1 mm or the ilomastat / Visiol 3 mm implants. 
3.2.3 Discussion 
Increasing the amount of active drug available will increase the effect that it has, 
providing that this increase occurs within the therapeutic range, and that the counter 
stimulatory factors of foreign body reaction are minimised or at least maintained as 
constant. The results presented here demonstrate that hydration has no effect on the 
foreign body reaction and increasing the surface area of implants appears to increase 
it. Conversely, combining the ilomastat with Visiol, and using the much more 
soluble MMPi AZ 6357, did lead to significantly less foreign body response than 
previously seen at day 30.   
It was hypothesised that hydration of the implant prior to implantation would 
encourage dissolution by reducing Ct – the concentration of fluid surrounding the 
implant and may create a boundary dissolution layer. The hydrated blebs certainly 
retained more fluid, signified by the greater bleb surface area in the initial stages of 
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the experiment. As the stimulatory effect of insoluble drug remained constant it 
would seem that any increased amount of free drug had no extra potency as an anti-
inflammatory or anti scarring agent, reflected in the correlation of bleb surface area 
later in the experiment as well as the histology. This is most likely due to the 
quantity of extra free drug being negligible (due to the poor solubility of the 
compound). However, it could also be that the drug has already reached its 
maximum therapeutic effect: ilomastat has an inhibitory constant (Ki) of 0.4 nM for 
MMP1 in fibroblasts (Grobelny et al., 1992).  
That the 3 mm implants caused no less (and possibly more) inflammation than the 
smaller 1 mm implants, supports the principle that the antagonistic effect caused by 
the insoluble drug was greater than the increased available free drug. Indeed if the 
concentration in the bleb was approaching Cs for the 1 mm implant, the only factor 
playing a role would be the antagonistic undissolved drug. The vascularity in this 
experiment again concurred with the foreign body response. In humans severe 
vascularity has been shown to represent risk of bleb failure (CATT study Group, 
2007). 
The inconsistencies between the results of the first in vivo and those of Geourgolas 
et al 2010 led to this second in vivo. It is clear that the application of an ilomastat 
implant perioperatively for experimental GFS resulting in a reduction of conjunctival 
scarring cannot be repeated. What is not clear is why this should be. The results of 
those experiments showed the presence of implants in photos at day 30. One 
explanation put forward for the lack of implant seen was that it dissolved between 
harvesting of the eyes, and histological processing. Pure implants inserted into 
formaldehyde fluid did not dissolve however after two months. In other in vivo 
experiments, despite globes having too much exposure or too little exposure to 
processing fluids than planned, if an implant was seen with the naked eye at the end 
of an experiment there was an implant found in histology. This was true for the 1 
mm implants as well as 2 or 3 mm implants. 
There was concern that the ilomastat being used for these experiments did not have 
the same structural properties as the ilomastat used for previous experiments by 
Georgoulas et al 2010. This might account for the foreign body reaction. We (Dr H 
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Fadda, Dr A Vetter and myself) performed pharmaceutical analysis including HPLC, 
mass spectrometry and found minimal differences for results in characterisation 
between different batches however (Parkinson et al., 2012). That the AZ 8955 
implants gave a similar reaction to the ilomastat implants provides evidence that the 
response was due to particulate material or solid MMPi in general, and not just to the 
ilomastat per se.  
It appeared that there were fewer inflammatory cells seen in the blebs that were 
treated with the ilomastat implants surrounded with Healon 5. However, with an n of 
2 it is not possible to be sure that this appearance is significant, and more evaluation 
would be required. Apart from the ability of a gel to provide some reduction in the 
abrasiveness of the implant, the hyaluronic acid in the gel may also have an anti-
inflammatory effect. Hyaluronic acid has been shown to reduce binding by 
macrophages to surfaces, believed to be due in part to its negative charge, and 
therefore may reduce inflammation (Tsai et al., 2011). 
The AZ 6357 1 mm implants are the first excipientless implants in this project to 
show no evidence of a foreign body reaction at day 30. AZ 6357 has a similar 
inhibitory profile to ilomastat but is somewhat less potent, particularly with respect 
to MMP1 (Table 3-3). At 16 times the solubility of ilomastat though, far greater drug 
will be in solution, and the duration of antagonistic effect of insoluble drug will be 
far less: AZ 6357 2 mm implants took eight days to achieve complete dissolution 
(thesis S. Dhingra). That the blebs for the rabbits treated with AZ 6357 maintained 
‘normal’ vascularity for the duration of the experiment after day 9 indicates that 
inflammation during this time is less. 
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Table 3-3. The inhibitory profile of the ilomastat as compared to AZ 6367 or AZ 8955. The 
values given indicate Ki for ilomastat and IC50 for AZ 6357 and AZ 8955. 
 
MMP	inhibited	 Ilomastat	 AZ	6357	 AZ	8955	
MMP	1	 0.4	 6858	 378	
MMP	2	 0.57	 0.3	 0.1	
MMP	3	 27	 19	 26	
MMP	7	 	 >10000	 966	
MMP	8	 0.18	 5	 0.8	
MMP	9	 0.2	 1	 1	
MMP	12	 	 4	 1	
MMP	13	 	 0.6	 0.8	
MMP	14	 	 1533	 28	
There are a number of reasons why the combination ilomastat / Visiol implant also 
resulted in no evidence of a foreign body reaction at day 30. Hyaluronic acid is one 
of the most hygroscopic polymers, and by having drug dispersed evenly throughout a 
combination implant, with exposure to aqueous fluid there would be enhanced 
dissolution through the greatly increased surface area. As a consequence there would 
also be reduced duration of exposure to undissolved particulate material as well as a 
maintenance of maximal solubilised drug.  Other factors that could contribute to the 
dampening of inflammation are the less abrasive preparation, and the direct 
inhibitory effect of hyaluronic acid (Tsai et al., 2011). Challenges that arise when 
developing this as an implant include optimisation of the preparation, and 
characterisation. Visiol was chosen because, while it appeared to mix easily with 
aqueous ilomastat, it is a pre-prepared substance made up of a multitude of buffers 
and salts as well as the hyaluronic acid. 
Another challenge raised by the use of implants constructed with hyaluronic acid is 
sterilisation. The most convenient and effective method of sterilisation is √ 
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irradiation. Due to the constraints of time it was not possible to sterilise these 
implants in the conventional way, and instead β irradiation from a Strontium 90 
probe was used (itself an antiscarring device used in the ophthalmological theatres). 
That no endophthalmitis was seen in this treatment arm supports the concept that 
some sterilisation has taken place, but sterilisation by this method has not been 
confirmed and would not be accepted for translation into man without further 
optimisation and validation. Indeed when samples of hyaluronic acid gel were sent 
for irradiation sterilisation there was considerable denaturation consistent with the 
literature (Srinivas and Ramamurthi, 2007). Other methods such as micro filtration 
would need to be investigated.  
That the least soluble implants with the most foreign body reaction had the greatest 
bleb survival again shows how little bleb survival reflects the anti-scarring effect of 
the drug. It is not possible to determine the quantity of each of the possible 
contributory factors: presence of aqueous, physical implant and inflammatory 
response leading to conjunctival thickening.  
One 3 mm implant that extruded during the experimental process could be due to 
surgical error in the closure of the conjunctiva at the leading edge, although no 
wound leak was detected. An alternative possibility is that contraction of the 
conjunctival tissue posterior to the implant pulled the conjunctiva at the leading edge 
away.  
It is important to remember that this study is a pilot and consisted of 7 treatment 
arms, of which there were 4 groups of 3 animals, and 3 groups of 2 animals, with no 
positive or negative controls. Furthermore there was error in the formulation of the 
implants and therefore conclusions should be drawn with these factors in mind. It 
would appear, however, that a more soluble MMPi showed promise as a potential 
anti-scarring agent implant. Research in the following experiments was focussed on 
examining the efficacy of a more soluble MMPi formulated as a pure implant. By 
remaining pure the intellectual property for an excipientless implant was satisfied. 
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3.3 Investigation into the anti-scarring efficacy of a more water soluble MMPi  
The pilot in vivo study just described found that an implant formulated from either 
an MMPi with a greater water solubility than ilomastat, for example AZ 6357 or 
ilomastat combined with hyaluronic acid thereby enhancing dissolution, might 
increase success whilst avoiding a foreign body response. As implants formulated 
from AZ 6357 remained within the intellectual property and did not require the 
characterisation of the ilomastat / hyaluronic combination, further investigation was 
performed by S. Dhingra. Although in another study no foreign body response was 
seen at day 30, harvesting eyes at days 7 and 14 revealed significant inflammation 
around the implants (thesis S. Dhingra). Research was then focussed on MMPis with 
the same spectrum of activity but with an even greater water solubility.  
Marimastat was identified as a possible candidate. It is a broad spectrum MMPi that 
has been taken to human trials as an oral anti cancer chemotherapeutic (Wojtowicz-
Praga et al., 1998; Bramhall et al., 2001). It too has a similarly broad inhibitory 
spectrum of MMPs to ilomastat but is over 100 times as soluble in water (aqueous 
solubility of 3.38 mg / ml). Marimastat has also been shown to inhibit the gel 
mediated contraction of dermal fibroblasts. In the presence of marimastat (10 µM) 
dermal fibroblast contraction was completely inhibited (Scott et al., 1998). 
It was hypothesised that marimastat might be able to be formulated into an 
excipientless implant and used as an anti scarring treatment. 
3.3.1 Fabrication of marimastat implants 
The fabrication of marimastat implants was more technically difficult than either the 
ilomastat or AZ implants, as the powder was far less cohesive. Only 2 mm implants 
of more than 1 mg could be produced because upon removal the tablets frequently 
broke on punch and dye pressing. Even coating the die using the lubricant 
(polaxamer) between each implant fabrication, approximately 60 % of implants 
disintegrated. Using a 2 mm punch and die implants of 1 to 3 mg could be pressed. . 
The sterilisation process was by gamma irradiation, and approximately half of the 
implants fractured on passage to and from the site of sterilisation. Analysis of the 
drug post irradiation by mass spectrometry and HPLC showed no change, however. 
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3.3.2 In vitro release of marimastat implants 
Marimastat implants of a mean of 1.56 mg completely dissolved in the rig by day 2 
(46 hours)(Figure 3-42 and Figure 3-43). The mean maximum concentration in the 
elutent was 2.5 mM. 
 
Figure 3-42 The concentration of marimastat released over time in the rig from 2 mm implants 
(mean 1.56 mg).  At 46 hours there was no drug detectable in the elutent. Implants n = 3 (1.18 mg, 
1.9 mg, 1.6 mg). The flow rate was 2 µl minute-1.  Error bars indicate SD. 
 
Figure 3-43 Cumulative release of the 2 mm marimastat implants (n = 3). Error bars indicate SD. 
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3.3.3 Pilot study using pure marimastat implants harvesting eyes at 14 days 
To determine whether there would be implant remnant remaining at day 7 or day 14 
and gain a better understanding of the wound healing process at an earlier time point, 
a pilot in vivo of 4 rabbits was performed. Each rabbit received a 2 mm marimastat 
implant (2.2 – 2.4 mg). Unfortunately one rabbit died under anaesthesia and a second 
developed endophthalmitis a few days after surgery. It was decided to terminate and 
harvest the eyes of the remaining two animals at day 14, and discard the day 7 time 
point (Figure 3-44). Histological analysis of the drainage area revealed a collection 
of inflammatory cells at the site of tablet placement but no implant remnant (Figure 
3-44). As no remnants were seen it was concluded that marimastat might be a 
potential candidate as an antiscarring implant. An efficacy study was planned to 
compare marimastat with positive and negative controls. The discussion of 
marimastat results is incorporated into the discussion after this study. 
 
Figure 3-44 Haematoxylin and Eosin staining of the two rabbits treated with marimastat 2 mm 
implants. Legends: C: conjunctiva, T: drainage tube, S: sclera. Scale bars 1 mm. No implant 
remnants were seen at the site of implant placement (X), only collections of inflammatory cells.  
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3.4 Investigation into the efficacy of dexamethasone in combination with 
ilomastat as a slow release antiscarring agent 
An additional line of investigation to develop an effective anti scarring MMP 
implant was to consider another class of anti-inflammatory in combination with an 
MMPi. Dexamethasone is one of the most potent of steroids. Dexamethasone is also 
poorly soluble (physicochemical attributes). It is routinely used after almost every 
surgical ocular procedure to reduce inflammation, therefore if a combination were to 
be successful this preparation would be comparatively easy to translate into the 
clinic. Fixed dose combinations are frequently used to treat infectious diseases such 
as TB and HIV, or chemotherapeutic cancer regimens. 
It was hypothesised that an implant consisting of both dexamethasone and ilomastat 
in combination might provide the inhibition of inflammation necessary in the early 
postoperative period to prevent foreign body encapsulation, whilst allowing the 
MMPi to be freely available in solution. 
In order to figure out the dose for the formulation vitro experimentation investigation 
determined the feasibility of formulating combination implants, and determining the 
release profile.  
3.4.1 Fabrication of dexamethasone / ilomastat implants 
The fabrication of implants using crystalline solid dexamethasone and ilomastat was 
achieved through mixing powder in eppendorf lids for each individual implant. 
Poorly soluble in water (Galardy et al., 1994), attempts were made to improve 
uniformity by dissolving the mixture in a solution of tert-butanol 40 % and then 
freeze drying, however the amorphous product had minimal cohesiveness and 
fragmented constantly. Amorphous material also crystallizes with moisture 
exposure, making physicochemical analysis more challenging. Due to time 
constraints it was not possible to pursue this further. 
Investigations were performed into the optimum size of implant and ratio of 
dexamethasone to ilomastat. Two mm diameter combination implants were found to 
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be the optimum size to press without fragmentation however the crystalline 
dexamethasone had far less cohesiveness than the ilomastat. The minimum 
proportion of ilomastat in an ilomastat / dexamethasone combination that could be 
pressed without fragmentation was 0.5:1.  
3.4.2 In vitro release data from Dexamethasone ilomastat implants 
The concentration and release profiles over time for different combinations of 
ilomastat / dexamethasone are illustrated in Figure 3-45 to Figure 3-50. The length 
of time a drug concentration of > 10 µM was maintained is shown in Table 3-4. 
Sustained release of dexamethasone and ilomastat was achieved with all 
combinations of implants. The decay was not smooth however, which may be related 
to the implant developing fracture lines that abruptly increased implant surface area. 
An alternative explanation might be temperature change in the laboratory, although 
efforts were made to maintain this as constant. The level of 10 µM for 
dexamethasone was taken as previously found to be inhibitory for inflammation, in 
particular macrophage activation by lipopolysaccharide (Jarvis and Qureshi, 1997). 
Table 3-4 Duration of release where > 10 µM was maintained for the combination implants. 
Ilomastat : 
Dexamethasone 
Duration > 10 µM 
ilomastat maintained 
Duration > 10 µM 
dexamethasone 
maintained 
1 mg : 1 mg 25 days 29 days 
1 mg : 0.5 mg 22 days 16 days 
0.5 mg : 1 mg 15 days 29 days 
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Figure 3-45 Mean concentration released from ilomastat and dexamethasone (1 mg : 1 mg) 
implants over time. Ilomastat was released at a concentration of > 10 µM for 25 days. 
Dexamethasone was released at a concentration of  > 10 µM for 29 days. 
 
Figure 3-46 Cumulative release of ilomastat and dexamethasone (1 mg : 1 mg ) implants over 
time. Error bars indicate SD. 
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Figure 3-47 Mean concentration released from ilomastat and dexamethasone (1 mg : 0.5 mg) 
implants over time. A concentration of > 10 µM ilomastat was maintained for 22 days and a 
concentration of  > 10 µM dexamethasone was maintained for 16 days. 
 
 
Figure 3-48 Cumulative release of ilomastat and dexamethasone (1 mg : 0.5 mg) implants over 
time.  Error bars indicate SD. 
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Figure 3-49 Mean concentration released from ilomastat and dexamethasone (0.5 mg : 1 mg) 
implants over time. A concentration of > 10 µM ilomastat was maintained for 15 days and a 
concentration of > 10 µM dexamethasone was maintained for 29 days. 
 
 
Figure 3-50 Cumulative release of ilomastat and dexamethasone (1 mg : 0.5 mg) implants over 
time. Error bars indicate SD. 
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3.4.3 In vivo results of dexamethasone / ilomastat combination implants and 
pure marimastat implants as anti-scarring agents 
An in vivo experiment to test the anti-scarring efficacy of marimastat and 
dexamethasone / ilomastat combinations was designed.  
As the greatest release for both of the drugs ilomastat and dexamethasone were with 
the 1 mg : 1 mg implants, it was decided that this ratio should be tested in the animal 
model of aggressive scarring. To achieve the greatest likelihood of success the 
greatest dose of marimastat that could be made into an implant without 
fragmentation was chosen. 
The four experimental treatment arms investigated on 6 rabbits each were: 
1) Ilomastat / dexamethasone 2 mm implant (1 mg : 1 mg) (height 0.6 mm) 
2) Marimastat 6 mg (two 2 mm 3 mg implants) (height 0.8 mm) 
3) Mitomycin C applied at a concentration of 0.2 mg/ml for 3 minutes 
perioperatively (positive control) 
4)  Sterile water applied in the same way as MMC (negative control) 
Four of the six rabbits treated with ilomastat / dexamethasone combination 
maintained the appearance of a functional bleb until day 30. Of those that did not, 
one developed an endophthalmitis in the first week post surgery and the other failed 
on day 27. If the animal with endophthalmitis is excluded then 80% (4/5) had the 
appearance of a functional bleb at day 30. The marimastat treated rabbits had blebs 
that failed at a median of 24 days (range 21 - 24). The sterile water treated group 
failed at a median of 18 days (range 12 -21). Of the MMC treated group one animal 
had a bleb that failed at day 27 and the other 5 survived until day 30 (Figure 3-51).  
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Figure 3-51 Bleb survival of the four groups. The MMC and ilomastat / dexamethasone groups 
survived significantly longer than the marimastat and the sterile water groups (log rank P < 0.005). 
The marimastat group survived significantly longer than the sterile water group (long rank P < 0.01).  
 
3.4.3.1 Bleb Surface area 
The bleb surface areas of the MMC and the ilomastat group were greater than the 
marimastat or sterile water groups from day 6 (Figure 3-52).  A Kruskal-Wallis test 
revealed that there was a significant difference between bleb heights at day 30  (H 
(3) = 14.37, P = 0.024). Inspection of the group means using Dunn’s multiple 
comparison test showed that there was a significant difference between ilomastat 
dexamethasone group and sterile water group, and sterile water group and MMC 
group 
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Figure 3-52 Mean bleb surface area over time for the four groups. The ilomastat / dexamethasone 
implants consistently maintained a greater mean bleb surface area than marimastat and the sterile 
water group from day 9. Error bars indicate standard error. 
 
3.4.3.2 Bleb Height 
The bleb heights of the MMC and ilomastat / dexamethasone groups were constantly 
greater than marimastat or sterile water group. Initially the bleb height of the 
ilomastat dexamethasone group was greater than the MMC group however the two 
maintained similar heights after day 15 (Figure 3-53). A Kruskal-Wallis test revealed 
that there was a significant difference between bleb heights at day 30  (H (3) = 
15.44, P = 0.015). Inspection of the group means using Dunn’s multiple comparison 
test showed that there was a significant difference between ilomastat dexamethasone 
group and sterile water group, and sterile water group and MMC group. 
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Figure 3-53 Bleb height of the 4 groups over time. Bleb height was graded as 0, flat; 1, 
shallow/formed; 2, elevated < 2 mm and 3, high > 2 mm. From day 6 the ilomastat / dexamethasone 
and MMC groups maintained higher blebs than the marimastat or sterile water groups. Error bars 
indicate standard error. 
3.4.3.3 Intraocular pressure 
There was an initial fall in IOP for all four groups, as expected. This was followed 
by a return to baseline, of which the sterile water and marimastat groups returned 
most quickly, followed by the ilomastat / dexamethasone group, and then the MMC 
group. After day 18 the IOP of the ilomastat / dexamethasone group became 
consistently greater than the other three groups and the initial baseline pressure. 
Although not significant at day 30, on day 27 there was a significant difference 
between the groups (Kruskall-Wallis: (H (3) = 12.2, P = 0.067). Between day 18 and 
the end of the experiment the MMC group maintained a lower IOP than the other 3 
groups, however this was not less than the baseline preoperative IOP (Figure 3-54). 
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Figure 3-54 Mean IOP of operated eye with time. There was an initial fall in IOP. Between days 6 
and 18 the ilomastat / dexamethasone and MMC treated animals maintained a lower IOP than the 
other groups. Between day 18 and day 30 the ilomastat / dexamethasone group maintained a higher 
IOP than preoperative baseline. Error bars indicate standard error. 
3.4.3.4 Bleb Vascularity 
There was similar bleb vascularity for all groups from day 9 until day 30 (Figure 
3-55). 
 
Figure 3-55  Bleb vascularity post surgery.  The vascularity was graded as  0 = avascular, 1 = 
normal, 2 = hyperaemic, 3 = very hyperaemic. Data displays blebs at each time point as mean and 
standard error of the mean. 
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3.4.4 Bleb morphology 
High resolution photographs revealed detailed morphology of the blebs at different 
time points. Information about the contours of the blebs was obtained by high 
magnification from the side.  
Photographs of examples of blebs at day 15 are illustrated below (Figure 3-56). At 
this stage three of the sterile water group had failed (the example illustrated failed at 
day 21). 
 
Figure 3-56 Representative photos of blebs at day 15 for each of treatments ilomastat / 
dexamethasone 2 mm (A), marimastat 2 mm (B), sterile water (C), and mitomycin C (D). Blue 
dashed line indicates location of bleb edge. The blebs illustrated have the appearance of functionality 
at this stage. 
Implants in the dexamethasone / ilomastat treatment arm became clearly visible in 
four of the blebs from day 12. Once visible they remained so until termination 
(Figure 3-57). The one implant that was not visible was discovered to have migrated 
posteriorly out of the bleb area on histology. It was this bleb in the dexamethasone / 
ilomastat treatment arm that failed on day 27. None of the marimastat implants were 
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visible during the observational period. The contours of three of the blebs of the 
dexamethasone / ilomastat implants outlined the shape of the implant from day 18. 
The bleb morphology of the fourth visible dexamethasone / ilomastat implant 
(number 14) became temporarily conical, and the implant inside became smaller 
with time. The bleb morphology of this particular rabbit also became conical in 
appearance when viewed from the side (Figure 3-59). Optical coherence tomography 
(OCT) revealed evidence of implant fragmentation. Later in the experiment the 
conical shape diminished with the implant appearing to become smaller on OCT 
examination and visually. One of the MMC blebs became cystic in appearance. 
 
 
 
Figure 3-57 Sequential photos of dexamethasone / ilomastat treated blebs where the implants 
were seen using the extension tube. The implant within the bleb of rabbit no 14 appeared to be 
diminishing in size with time. Vascularity is also increased. Photos courtesy of A. Khalili. 
 
     Day 16                      Day 21                        Day 27 
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Figure 3-58 Outlines of three blebs of the ilomastat / dexamethasone implant rabbits at day 18. 
The bleb morphology follows the contours of the implant. Photos display rabbits 12 (A), 20 (B) and 
21 (C). Here the conjunctiva appears to be closely apposed to the implant. The mean intraocular 
pressure at this time-point was raised in comparison to baseline. 
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Figure 3-59 Sequential images of the bleb of R14 dexamethasone / ilomastat. The OCT views the 
bleb in a sagittal section with cornea to the right of the picture. Implant fragmentation can be seen at 
day 23. 
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3.4.5 Histology 
There was a paucity of nuclear staining of cells posterior to the drainage site in the 
MMC treated group using the Haematoxylin and Eosin stain (Figure 3-60). This was 
seen in the section bisecting the drainage tube and at parallel sections 1 mm and 2 
mm away. Extra sections were taken to ensure that the histological response was the 
similar throughout the bleb. Lining the inside of the cystic bleb of number 1 (MMC) 
was evidence of necrotic and apoptotic tissue.  
The marimastat treated blebs revealed no evidence of encapsulated drug material, 
however there were considerable numbers of inflammatory cells localised around 
where the implant had been placed. On higher magnification refractile deposits were 
seen amongst the inflammatory cells. Overlying this area and more posterior there 
was evidence of eosinophilic staining of collagen deposition. 
Blebs of the dexamethasone / ilomastat combinations revealed refractile drug 
material located in close proximity to the tube in four of the five blebs (Figure 3-61). 
If not found in the tube section evidence of the implant was seen in the 1 mm or 2 
mm parallel sections away from the tube. Associated with the implants were a 
number of inflammatory cells in the conjunctiva, though far fewer than seen 
associated with ilomastat implants in the previous experiments. There were a number 
of inflammatory cells also seen in the sclera. The conjunctiva overlying the implants 
showed denser eosinophilic staining consistent with collagen deposition. There were 
a number of large blood vessels found in this tissue that were sectioned. 
The sections of the sterile water treated group revealed an infiltration of 
inflammatory cells around the tube implant, however posterior to this and in parallel 
sections not including the tube the numbers were fewer and distributed more evenly. 
The morphology of the conjunctiva had the appearance of being loosely packed with 
less eosinophilic staining, similar to an unoperated eye.  
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Figure 3-60 Sections of representative blebs of the MMC and sterile water groups. Scale bar 1 
mm. The planes of section were: sagittal, bisecting the tube, 1 mm parallel and 2 mm parallel. The 
sections of blebs treated with MMC showed cellular paucity in the region of the bleb. Sterile water 
treated group had a diffuse inflammatory infiltrate that was less than either marimastat implant treated 
blebs or dexamethasone treated blebs (see below). 
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Figure 3-61 Sections of representative blebs of the marimastat and ilomastat / dexamethasone 
groups.  Scale bar 1 mm. The planes of section were sagittal: bisecting the tube, 1 mm parallel and 2 
mm parallel. The blebs treated with implants of ilomastat / dexamethasone exhibited significant 
inflammatory infiltrate and fibrosis, although less than the pure ilomastat implants in the first in vivo 
experiment. 
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3.4.6 Discussion 
This in vivo experiment revealed results that require careful consideration. On the 
face of it the ilomastat / dexamethasone implants appeared to prolong the survival of 
the bleb. However, again there was more collagen deposition in the overlying 
conjunctiva in the implant treated groups than in the controls. It was increasingly 
clear from halfway through the experiment that the physical presence of an implant 
was contributing to the bleb outline (Figure 3-59). Furthermore from day 18 the 
intraocular pressure became greater than the baseline, and than in the other treatment 
groups; something that is counter intuitive to what would be expected in a 
functioning bleb, with dexamethasone believed to induce ocular hypertension due 
changes in the cytoskeletal structure of the trabecular meshwork. The marimastat 
treated group had the greatest MMPi dose with the greatest amount of MMPi in 
solution in the first 48 hours (assuming correlation with the in vitro data), yet 
although there was a significant difference in survival between the two groups, a 
third of the blebs failed on the same day as half of the sterile water treated group, 
and the remainder failed at the next time point suggesting little difference in 
efficacy. In the sterile water treated group (the negative control where no 
antiscarring treatment was given other than the standard postoperative 
dexamethasone injection), there was the least amount of eosinophilic staining 
consistent with collagen deposition.  
Steroids are commonly used as therapy to reduce inflammation and prevent 
pathological consequences in disease processes. They are the mainstay of treatment 
in acute asthma, reducing the inflammation and oedema in the walls of bronchi 
(Dziedziczko and Banach-Wawrzeńczyk, 1997). In rheumatoid arthritis, an 
autoimmune disease where the immune system targets connective tissue resulting in 
joint destruction, steroids can reduce inflammation and symptoms (Bijlsma, 1999). 
In Crohn’s disease, a chronic inflammatory disease of the gastrointestinal tract where 
scar formation can result in obstruction of the tract, steroids are often the first line of 
treatment in an exacerbation (Cottone et al., 2011). They are also the first line of 
treatment for a multitude of ocular inflammatory diseases including uveitis and 
thyroid eye disease (Saraiya and Goldstein, 2011) (Meyer, 2006). 
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Steroids are believed to interact directly with immune cells and have a myriad of 
effects (Weller et al., 1998). There is a reduction in circulating monocytes with 
steroid therapy: if humans are given a dose of 40 mg / kg of glucocorticoid the 
number of circulating lymphocytes drops from 2000 mm-3 to 500 mm-3 6 hours after 
administration.  IL1 production by monocytes in general is inhibited, which then 
results in an inhibition of T cell activation and less IL2 production. Indeed there is a 
generalised inhibition of the synthesis of inflammatory cytokines Il1, Il2, Il4, Il6, 
Il10 and TNFα. The mechanisms involved include the acceleration of IL1 mRNA 
breakdown and direct inhibition of the promoter regions for IL4, IL6 and Il10. 
In comparison to the ilomastat implants in previous in vivo experiments, there was 
far less of an immune cell infiltrate around the dexamethasone / ilomastat 
combination implants on staining with haematoxylin and eosin. No dense “halo” was 
seen. This would indicate that having the addition of the steroid does reduce the 
inflammation, whether or not there was a significant contribution from the 
postoperative injection of dexamethasone (the only other difference in surgical 
technique for this in vivo compared to previous experiments).  
Why then did the dexamethasone / ilomastat combination not lead to less collagen 
deposition than either the negative or positive control? Why too were the blebs not 
enlarged, diffuse and full of aqueous fluid? Basal cortisol levels in the blood in 
humans have been recorded as 351 nM and can increase by 300 nM (Zarković et al., 
2008). Dexamethasone has a potency that is 25 to 30 times that of hydrocortisone 
(Cantrill et al., 1975). A study on the binding of dexamethasone to intact fibroblasts 
found a dissociation constant (KD) of 3.47 ± 0.38 nM (Nakada et al., 1987), and can 
cause an inhibition of TNFα induced VEGF expression by 30 % at levels of 10-12 M 
(Raidl et al., 2007). The concentration of dexamethasone in this experiment should 
therefore have been at least at a therapeutic level even if the rig data was a gross 
overestimate of bleb dexamethasone concentration (Figure 3-45). Less foreign body 
encapsulation should also have readily allowed more MMPi dissolution. Again it 
would appear that the antagonistic effect of inactive solid drug is playing a 
significant role. Despite the presence of a highly potent, slowly dissolving steroid 
and a highly potent MMPi, the particulate effect is overriding. Interestingly the 
vascularity of all of the blebs throughout the experiment was relatively similar. It 
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may be that the injection of dexamethasone at the end of surgery was sufficient to 
cause this similarity. 
Other possible mechanisms at play that may impair antiscarring efficacy are 
redundancy and resistance. MMPs can perform a number of functions and a 
particular function can be performed by a number of different MMPs (Hu et al., 
2007). If the immune system is activated yet enzymes or other signalling molecules 
are inhibited, other ones can be upregulated to compensate (Nish and Medzhitov, 
2011). Steroid resistance is well documented (Sibley and Tomkins, 1974) and may 
develop directly through glucocorticoid mediated inhibition of glucocorticoid 
receptor mRNA transcription. The half-life for this down regulation in human 
lymphocytes can be as fast as 120 minutes (Rosewicz et al., 1988). Inflammatory 
cytokines may also contribute to resistance. In asthma, a disease where the 
mechanism of steroid resistance is one of the most studied, IL1β and IL6 can form 
protein complexes with the glucocorticoid receptor preventing activation (Barnes 
and Adcock, 1995).  
The mean bleb heights for the ilomastat / dexamethasone arms in this experiment 
were less than the recordings for the 2 mm ilomastat implants in the first in vivo 
experiment at comparable time points, particularly after day 15, even though the 
initial heights of the implants were greater. This is most likely due to the difference 
in inflammation between the two groups. A caveat must be made when comparing 
the experiments, for example the two groups of animals are different; the first 
experiment used males whilst the others used females. Little is known about the 
differences in scarring between rabbits, however in humans women are believed to 
scar less following myocardial infarction, and therefore may benefit from cardiac 
resynchronisation therapy more than men (Kwon et al., 2014). 
Bleb height estimation is difficult and highly subjective. On the whole lower blebs 
led to clearer outlines of implants within the conjunctiva, and it could be determined 
that the spacer effect was contributing to the appearance of a bleb from day 18. As in 
the previous experiment it is not clear how much the spacer effect contributes to 
functionality. Furthermore if the bleb were not functional in the presence of an 
implant, would the appearance of the bleb be any different? The area of conjunctival 
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elevation would be significant. The conjunctiva has a thickness of approximately 0.4 
mm judged on OCT. Even discounting any extra elevation caused by inflammation, 
an implant of 2 mm diameter and 0.6 mm height could raise the conjunctiva an area 
whose diameter is almost 1.5 x the implant diameter (2 + 0.4 + 0.4), and therefore 
mislead the observer into thinking a bleb was present (Figure 3-62).  
 
 
Figure 3-62 Diagram illustrating conjunctival elevation caused by an implant and 
representative photograph of dexamethasone / ilomastat implant at day 30. Legends: Implant (I); 
conjunctiva (C), length of conjunctival elevation (A). 
The spacer effect may be in itself an advantage in developing an antiscarring agent. 
A number of studies have reported on their use in trabeculectomy surgery with 
variable success (Takeuchi et al., 2009). Where the principal of a spacer is most 
commonly used, however, is by glaucoma drainage devices such as the Ahmed, the 
Baerveldt and Molteno tubes. They structurally consist of a flexible plate attached to 
a tube, and rely on foreign body encapsulation around the plate to create a lake of 
aqueous in a Tenon’s cyst (Rao et al., 2009; Filho and Sit, 2009). A randomised trial 
performed in the USA indicated that a device might even have a better success rate 
A
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than augmented trabeculectomy for patients that required repeat glaucoma surgery 
(Gedde et al., 2007a; Gedde et al., 2007b; Gedde et al., 2009). Little is understood 
about the foreign body reaction around implants, although some data from rabbits 
suggests that there are relatively few giant cells (Jung et al., 2013). Globes with 
Molteno implants have been studied histologically after patients’ death (Molteno et 
al., 2009) The time an implant had been present varied widely (2 months to 20 years) 
but older capsules appeared to have newer cells with fibroblasts and other 
inflammatory cell types on the periphery and degenerate cells on the inside, 
suggestive of a continuous cell turnover. 
The bleb of rabbit 14 (dexamethasone / ilomastat) had an unusual morphology of 
almost conical shape at day 15 that is not solely explained by the spacer effect. OCT 
revealed some fluid located around the implant at 14 days (Figure 3-59). However 
the edges of the base of this conjunctival cone appeared to be contracting in a similar 
way to the ‘ring of steel’ that is most often seen in the scarring process of limbal 
based trabeculectomies (Wells et al., 2003). Towards the end of the experiment this 
conical shape resolved. Histological analysis did not reveal any gross differences 
between this bleb and others of the same group other than the presence of less 
implant remnant. The changes in morphology of this bleb over time indicate how 
dynamic the process of wound healing is, and histological analysis at an earlier time 
point may have yielded differences between these blebs. 
The rise in IOP in the ilomastat / dexamethasone treated group after day 18 indicates 
that drainage of aqueous is impaired. A rise in IOP in patients treated with topical 
steroids is not uncommon and can occur in up to 90% of primary open angle 
glaucoma patients due to changes in the trabecular meshwork. Mechanisms believed 
to be in play are the increased expression of glycosaminoglycans and the altered 
phagocytic activity of trabecular meshwork endothelial cells (Jones and Rhee, 2006). 
Topical dexamethasone can also cause a significant rise in the IOP of rabbits, 
particularly if they are young (Qin et al., 2010). The Ozurdex implant was found to 
cause a rise of more than 10 mm Hg in 17% of patients (Lobo et al., 2010). The 
findings raise the question as to whether there was drainage of aqueous into the blebs 
at this stage, i.e. that they were functional or whether the drainage of aqueous from 
the blebs is being impaired.  
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The blebs treated with marimastat failed to survive beyond day 24, although this 
treatment group had the highest dose of solubilised MMPi. It was hoped that the 
high dose of MMPi in solution would tip the balance in favour of dampening of 
inflammation and scarring away from the undissolved aggravating solid drug. 
However, MMPis are cytostatic and not cytotoxic, and it is likely that there was 
rapid clearance of the drug and the process of healing continued undeterred. As 
MMPs have wide reaching effects during the wound healing process, it is likely that 
an MMPi presence is required for the duration of increased activity of the cells 
involved. 
A paradoxical finding in this experiment was that the negative control (sterile water 
treated group) exhibited minimal evidence of scarring, for example compared to the 
negative (ethylcellulose) control in the first experiment. This may have been due in 
part to the postoperative dexamethasone injection, but may also have been due to the 
remodelling behaviour of the animal. The rabbit is an aggressive model of scarring, 
however it is likely to be able to remodel extremely efficiently as well. Furthermore 
the animals are young, and younger animals heal more quickly. If histology is 
examined at day 30 only, a considerable proportion of the wound healing response 
may be missed (Bruno et al., 2007). In a diagram adapted from an analysis of 
cutaneous wound healing in humans it can be seen that sectioning at day 30 would 
be in the middle of the remodelling phase (Figure 3-63). In rabbits the wound 
healing process will be more rapid, and sectioning at day 30 may be after resolution 
of tissue architecture as found with the AZ 6357 implants. Of pivotal importance 
therefore in the evaluation of an antiscarring therapy is histological examination at 
multiple time points post surgery. Interestingly the MMC bleb of number 1 showed 
signs of toxicity, with tissue necrosis in the conjunctiva. The surgery for this animal 
was planned to be no different, however may represent a longer operation, this being 
the first rabbit to undergo the procedure. Similar blebs were seen in earlier and later 
studies
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Figure 3-63 The stages of cutaneous wound healing in humans.
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The dose of 1 mg dexamethasone was chosen for the in vivo study; the implants 
constituted with this dose released the greatest amount of drug and were therefore 
likely to be the most efficacious. High dose dexamethasone can cause toxicity 
however, and this also needed to be taken into account when considering the dose. 
Most ocular data is related to intravitreal injection (Nabih et al., 1991). One study 
found that up to 4.8 mg could be injected intravitreally without deleterious effect 
(Nabih et al., 1991). Kwak et al injected dexamethasone phosphate, in Dutch 
pigmented rabbits. Eyes enucleated after injection found that there were minimal 
changes at 800 mcg, but there was distinct vacuolation in between the outer 
plexiform layers and outer nuclear layers of the retina and photoreceptor 
degeneration at 1.2 mg dose (Kwak and D'Amico, 1992). They suggest that 
vacuolation might be related to impaired glucose transport. A number of studies have 
reported on the use of intravitreal sustained release devices that release 
dexamethasone (Chang-Lin et al., 2011; Cheng et al., 1995; Hainsworth et al., 1996; 
London et al., 2011). Ozurdex has recently been licenced for use in humans in the 
treatment of non-infectious uveitis and macular oedema associated with retinal vein 
occlusion (London et al., 2011). The dose of dexamethasone used is 0.7 mg. 
Minimal evidence of toxicity was seen in monkeys treated Ozurdex implants over 
the period of nine months (Chang-Lin et al., 2011). In this experiment there appeared 
to be some vacuolation of the goblet cells in the conjunctiva overlying the implants, 
and possibly some scattering of inflammatory cells in the sclera. It is not possible to 
be sure of whether the vacuolation of the goblet cells is related to that seen in the 
Muller cells of the retina after high dose dexamethasone exposure (Kwak and 
D'Amico, 1992). 
 Unlike pure ilomastat implants the dexamethasone / ilomastat combination implants 
were more fragile due to the less cohesive nature of dexamethasone. This is likely to 
have contributed to the variable release seen in the in vitro experiments and also to 
the fragmentation seen in rabbit number 14. In the formulation process one of the 
key challenges identified was to establish a method of mixing that resulted in the 
implants having consistent quantities of each drug, and for that ratio to be evenly 
dispersed throughout the implant. Freeze-drying a solution of ilomastat and 
dexamethasone using 40 % tert butanol was attempted: this would provide an 
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amorphous uniform mixture. However pressing the product was analogous to 
pressing powder snow and no implants could be formulated. Furthermore this state 
quickly changes with exposure to water, with crystallisation. Adding an excipient 
would have been necessary as a binding material, however this would have been 
outside our patent and the grant funding this research (for legal purposes 
dexamethasone was considered an active and not an excipient). Another method 
attempted was to use a fine sieve however this led to increased drug loss. It is not 
possible to be sure from these experiments of the uniformity of the implants and 
whether the powdered drug lost during pressing was consistently of the same 
proportions of drug. Further work would be required if this line of preparation was 
developed.  
In the release experiments there was considerable variability in release not just 
between implants (as shown by the considerable size of the error bars) but also with 
time, with not just a steady decay. It is likely that the implants were not uniformly 
mixed with islands of pure ilomastat and dexamethasone, fracture lines could open 
up within the implant which would lead to greater surface area exposed to fluid, and 
greater drug dissolution dissolution. Although attempts were made to maintain the 
temperature of the rigs at a constant level there was still variability with the 
thermostatically controlled oil bath that may have affected drug release (temperature 
varied +/ 5 degrees in this experiment). Dexamethasone solubility is particularly 
affected by temperature and varies by a factor of 10 between 20 and 37 degrees 
centigrade (Yalkowsky and He, 2003). 
The findings of these experiments indicate the challenges faced in developing a solid 
form of antiscarring agent, not only in terms of tissue response to the particulate 
microstructure of the tablet surface, but also in being able to determine what defines 
success in the in vivo model. Further work is required to determine functionality of 
the bleb, either through following a tracer injected into the anterior chamber or by 
modifying the model to make it hypertensive as has been done in the mouse in 
models to test treatments of optic nerve regeneration (Sappington et al., 2010). In an 
ocular hypertensive model IOP could then be used as an outcome measure. For a 
sustainable release antiscarring agent to be developed further work is required to 
make it non-particulate, either encased in a device or in liquid form. 
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3.5 Investigation into the release and efficacy of ilomastat in conjunction with 
dexamethasone, ilomastat / hyaluronic acid combinations and polymer 
coated ilomastat implants 
In the previous experiment it was shown that using dexamethasone in combination 
with ilomastat the inflammatory response surrounding the implant was considerably 
less than ilomastat alone, however there was still the significant aggravating 
antagonistic effect of the non solubilised drug. It was postulated that reducing the 
dose size might tip the balance in favour of the active soluble moiety so long as a 
therapeutic level could be maintained. Mixing smaller drug doses to produce 
implants that were consistent in mass, uniform and unlikely to fragment was too 
great a challenge. It was possible, however, to formulate ilomastat and 
dexamethasone as individual 0.5 mg implants, which could be inserted together.  
The combination of ilomastat with hyaluronic acid in an implant had shown potential 
as a candidate for formulation as an antiscarring implant in the 2nd in vivo 
experiment, with minimal evidence of foreign body reaction at day 30 and promotion 
of bleb survival. It was hypothesised that dissolving ilomastat in solution and 
combining with hyaluronic acid (HA) would enable the drug to be dispersed evenly 
throughout an implant. This approach is common in pharmaceutical science (Aulton 
and Taylor, 2013). After freeze drying and pressing, exposure to aqueous fluid 
would lead to rapid hydration and the implant becoming a gel. There would been less 
abrasion between implant and surrounding tissues, and enhanced drug dispersion. 
Both linear and cross-linked HA were investigated that might release drug at 
different rates. Cross-linked HA will become hydrated in the same way as non-cross-
linked HA, but due to it being cross-linked, its dissolution from the subconjunctival 
space would, in theory, take more time. 
Surrounding the pure ilomastat implant in the second in vivo study possibly showed 
less inflammation than the implant alone. It was postulated that surrounding a pure 
ilomastat implant with a freeze dried hyaluronic acid preparation would enable a 
reduction in inflammation, and this effect might be prolonged by using a preparation 
of hyaluronic acid that would be more likely to persist in the bleb. Based on previous 
experiments dried hyaluronic acid appeared to remain present for longer. 
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Masking the non-solubilised drug from cells that trigger an immune response whilst 
allowing drug dissolution may also reduce a foreign body reaction. A polymer 
known as POSS PCU developed by Alex Seifalian (UCL/Royal Free Hospital) has 
shown promise in humans when used as a cardiovascular stent (Tan et al., 2013). 
Other work has shown that it may also be used to make an artificial trachea as a 
replacement for one invaded by tumour that is able to integrate well into host tissue 
(Jungebluth et al., 2011)(Crowley et al., 2014). The polymer may also be coated in a 
substance such as an antibody to allow for enhanced efficacy after implantation (Tan 
et al., 2013). It was postulated that an ilomastat implant, coated in this low 
immunogenic polymer might allow drug dissolution, but without dendritic or 
immune cell access. As a drug-eluting device ideally the polymer would be 
degradable and resorb following dissolution. The Seifailian group were in the 
process of developing a biodegradable version, however this was at a concept stage. 
Non-degradable material is not necessarily contraindicated in the sub conjunctival 
space, as shown by the use of glaucoma drainage devices such as the Ahmed or 
Baerveldt tubes. 
The outcome of “success” when expressed as Kaplan Meier curve or “bleb survival” 
in previous in vivo experiments is ambiguous. Treatment arms with a persisting 
implant have shown promotion of bleb survival where the interpretation of “bleb 
survival” may have been significantly affected by the implant’s physical presence: 
this spacer effect will contribute to bleb appearance and may contribute to bleb 
functionality. Furthermore it was apparent that the deposition of scar tissue or 
inflammation did not correlate with bleb survival in the implant treatment arms. 
Considerable conjunctival re modelling may have occurred in the negative control 
that resulted in the little collagen deposition seen. A shorter study was therefore 
planned examining the blebs at the earlier time point of 14 days.  
To attempt to determine a method of testing bleb functionality that did not rely 
simply on the appearance of a bleb the use of a tracer was investigated. Indocyanine 
green (ICG)(Cardiogreen) is a negatively charged polymethine dye that forms 
noncovalent fluorescent complexes with proteins. This fluorescent dye is commonly 
used in the clinic to image the choroidal vasculature, and delineate structures during 
ocular surgery such as the inner limiting membrane in macular hole repair, corneal 
 157 
tissue in keratoplasty, and the lens capsule during cataract extraction (Rodrigues et 
al., 2009). It was hypothesised that an injection of ICG into the anterior chamber 
under terminal anaesthetic would result in ICG being carried through the drainage 
tube, and diffuse throughout the bleb. This would enable the dimensions to be 
determined, and bleb volume.  
3.5.1 Scanning electron microscope analysis 
Coating the implants was not trivial. The polymer is only soluble in 
dimethylacetamide (DMAC), which has the potential to be significantly hepatotoxic 
(Kennedy and Sherman, 1986). The implants were spray coated using an applicator. 
The implants were then washed three times in water to remove the DMAC after they 
had been spray coated (Seifailian group personal communication). The polymer 
coated implant exhibited a smooth surface covering the crystalline drug beneath 
(Figure 3-64). There were a number of holes / pits however up to 20 micrometres in 
diameter (Figure 3-65).  
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Figure 3-64 Scanning electron micrograph of polymer coated implant. A cut edge revealed 
smooth coating (P) over the crystalline drug (D). The pictures show a polymer spray-coated 2 mm 
implant. The cut edge shows how the polymer might be able to mask the particulate crystalline nature 
of the drug. 
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Figure 3-65 Images of increasing magnification of the implant surface clockwise from left, 
illustrating pits and crystalline drug beneath. Defects although useful to allow drug dissolution, if 
as large as shown (20 µm) would allow immune cell access. 
 
3.5.2 In vitro release 
3.5.2.1 Release from ilomastat 1 mm and dexamethasone 1 mm implants 
The release of ilomastat from the rigs containing individual 1 mm ilomastat and 
1mm dexamethasone implants side by side resulted in the maintenance of a drug 
concentration of > 10 mM for 15 days for ilomastat and 16 days for dexamethasone 
(Figure 3-62). The peaks concentration of ilomastat and dexamethasone were 49 mM 
and 34 mM respectively. The appearance of the cumulative release for the ilomastat 
appeared similar to that of the 1 mm implants examined without the dexamethasone 
in previous experiments (Figure 3-66). 
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Figure 3-66 Ilomastat and dexamethasone released from implants of ilomastat (1 mm, 0.46 mg) 
and dexamethasone (1 mm, 0.5 mg) over time (n = 3). A mean concentration of ilomastat of  > 10 
µM was maintained for 15 days and a mean concentration of dexamethasone of > 10 µM was 
maintained for 16 days. Flow rate 2 ul/min. 
 
 
Figure 3-67 Cumulative mean percentage release of ilomastat 1 mm and dexamethasone 1 mm 
implants over time. 
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3.5.2.2 Ilomastat release from polymer coated 2 mm implants 
Ilomastat release from the POSS PCU polymer coated implants was at a slower rate 
than for previous experiments using 2 mm implants. It was not possible to determine 
the exact quantity of drug present after coating by the polymer, however given that 
overall mass of the implants was similar it is likely that some of the drug dissolved 
in the solvent (DMAC) used in the coating process. Further drug will have dissolved 
in the washing process. A concentration of  > 10 µM was maintained for over 34 
days (Figure 3-68, Figure 3-69). The peak concentration of ilomastat was 38 µM. At 
this point a small shell of polymer could be seen on the base of the rig chamber 
(Figure 3-70). No defects were seen macroscopically, however any manipulation 
caused damage to the thin and fragile shell.  
 
 
Figure 3-68 Mean concentration of ilomastat released from polymer coated 2 mm ilomastat 
implants (n = 3). Presumed mean mass of drug = 1 mg rigs (n = 3) with time. A concentration of  > 
10 µM was maintained for 34 days. 
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Figure 3-69 Cumulative release of ilomastat over time from polymer coated implants. 
 
 
Figure 3-70 Polymer shell around implant remnant after 34 days of release experiment. Distance 
between lines is 2 mm. Macroscopically no defects could be seen before removal, however the casing 
was delicate and any manipulation resulted in the casing crumpling.  
 
3.5.2.3 Ilomastat release from Healon GV / ilomastat combination 
The release of ilomastat from combination implants of Healon GV (3 mg) and 
ilomastat (1 mg) took a little over 10 days (Figure 3-71, Figure 3-72). A 
concentration of  > 10 µM was maintained for 9 days. The maximum concentration 
achieved was 210 µM. 
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Figure 3-71 Ilomastat release from the combination implants ilomastat / Healon GV.  
Combination implants consisted of 1 mg ilomastat and 3 mg of hyaluronic acid (Healon GV), mixed 
as a solution, freeze dried and pressed into an implant (n = 3). A concentration of > 10 µM was 
maintained for 9 days. 
 
 
Figure 3-72 Cumulative release of ilomastat from Healon GV / ilomastat combination implants. 
 
3.5.2.4 Ilomastat release from Healaflow / ilomastat combination implants 
The release of ilomastat from combination implants of Healaflow (3 mg) and 
ilomastat (1 mg) lasted 32 days (Figure -3-73, Figure 3-74). A concentration of  > 10 
µM was maintained for 27 days. The maximum concentration reached was 212 µM. 
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Figure -3-73. Ilomastat release from the combination implants Healaflow / ilomastat. 
Combination implants consisted of 1 mg ilomastat and 3 mg of cross-linked hyaluronic acid 
(Healaflow), mixed as a solution, freeze dried and pressed into an implant (n = 3). A concentration of 
> 10 µM was maintained for 27 days. 
 
 
Figure 3-74 Cumulative release of ilomastat from Healaflow / ilomastat combination implants. 
Error bars indicate SD. 
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that had a mixture of freeze-dried hyaluronic acid pressed on either side, so called 
0 200 400 600 800 1000
0
100
200
300
C
on
ce
nt
ra
tio
n 
(µ
M
)
ilo / healaflow
0 200 400 600 800 1000
0
50
100
Time (hours)
%
 D
ru
g 
re
le
as
e
ilo / healaflow
 165 
‘sandwich implants’ are illustrated in Figure 3-75. Fabrication and collection of 
samples for in vitro analysis were performed by S Awwad and G Sharma.  An 
ilomastat concentration of   > 10 µM was maintained for 14 days. The mean 
maximum concentration achieved was 97 µM. 
 
Figure 3-75 Scanning electron micrograph of a sandwich implant. Picture displays implants cut in 
half with 2 mm diameter drug implant (D) and 3 mm diameter freeze dried cross-linked / non cross-
linked hyaluronic acid mixture (1:3 Revanesse: Healon GV) on either side (HA). Mean mass of drug 
= 1 mg. Mean mass of hyaluronic acid = 3 mg. 
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Figure 3-76 Concentration of ilomastat released with time from sandwich implants (n=3). 
Sandwich implants consisted of 2 mm 1 mg pure ilomastat  implants (D) with 3 mm diameter freeze 
dried cross-linked / non cross-linked hyaluronic acid mixture (1:3 Revanesse: Healon GV) pressed on 
either side (HA).  A concentration of   > 10 mM was maintained for at least 13 days.  
 
Figure 3-77 Mean cumulative ilomastat release from the sandwich implants     (n = 3). Error bars 
indicate SD. 
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3.5.3 In vivo experiment 
The six arms that were investigated in a 24 rabbit experiment (n = 4 each arm) for a 
15 day study (as this was a pilot a time point was chosen that would hope to achieve 
significant differences in histology and reduce expense and time): 
1) An ilomastat 1 mm 0.5 mg implant and a dexamethasone 1 mm 0.5 mg implant  
2) An ilomastat 2 mm 1mg (presumed) implant coated with POSS PCU polymer 
provided by Alex Seifalian, UCL/Royal Free Hospital. 
3) A combination of ilomastat 1 mg and hyaluronic acid 3 mg (Healon GV), which 
was freeze dried and pressed into a 3 mm implant. 
4) A combination of ilomastat 1 mg and cross-linked hyaluronic acid 3 mg 
(Healaflow), which was freeze dried and pressed into a 3 mm implant. 
5) An ilomastat 2 mm 1 mg implant with freeze dried hyaluronic acid mixture - 
hyaluronic acid / cross linked hyaluronic acid ratio 1:3 (Healon GV /  Revanesse) – 
pressed on either side of the implant in a 3 mm punch and die. This arm would be 
referred to as the sandwich implant arm. The ratio of hyaluronic acids and their ratio 
were chosen according to most uniform appearing implants with the most consistent 
release characteristics (performed and communicated by S. Awwad). 
6) Sterile water group (negative control). 
3.5.3.1 Survival and bleb surface area 
All blebs survived until day 14 with the exception of one bleb in the sterile water 
group, which failed at that time point. One animal in the ilomastat / Healon GV 
group developed an endophthalmitis at day 3 and was terminated. The mean bleb 
surface area was greater for the sandwich implants than the other groups from day 10 
(Figure 3-78).  
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Figure 3-78 Bleb surface area of the six groups. Legends: ilo / dexa, individual implants of 
ilomastat 1 mm 0.5 mg and dexamethasone 1 mm 0.5 mg; ilo / GV, ilomastat 1 mg combined with 
Healon GV 3 mg (3 mm); ilo / Heal, ilomastat 1 mg combined with Healaflow 3 mg (3 mm); 
polymer, ilomastat 2 mm 1mg coated in polymer provided by Alex Seifalian; SW, sandwich implant 
consisting of ilomastat 2 mm 1 mg with hyaluronic acid combination (3 mg) pressed on either side (3 
mm); Water, sterile water applied in the same way as MMC (negative control). The sandwich (SW) 
implants maintained a greater mean bleb surface area than the other groups from day 10. Error bars 
indicate standard error. Total number of rabbits = 24, n = 4 each arm. 
 
 
 
 
3.5.3.2 Bleb Height 
The heights of the blebs in the ilomastat / Healaflow arms and sandwich implants 
were consistently greater than the other arms for the duration of the second half of 
the experiment (Figure 3-79). 
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Figure 3-79 Bleb height of the six groups over time. Bleb height was graded as 0, flat; 1, 
shallow/formed; 2, elevated < 2 mm and 3, high > 2 mm. From day 7 the sandwich and ilomastat / 
Healaflow groups maintained higher blebs. Error bars indicate standard error. 
 
3.5.3.3 Intraocular pressure 
There was an initial fall in IOP in all groups and a return to baseline in five of the 
groups. The IOP of the sandwich implant group appeared to be consistently lower 
(Figure 3-80). 
 
Figure 3-80 Intraocular pressure for all six groups.  The sandwich implants appeared to maintain a 
lower IOP after day 7 of the experiment compared to the other treatment arms. 
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3.5.4 Bleb vascularity 
There was considerable variation in vascularity across the six arms. Those blebs of 
the sandwich implant treated arm were the most hyperaemic and those of the sterile 
water treated group the least hyperaemic (Figure 3-81). 
 
Figure 3-81 Bleb vascularity for the six groups. The vascularity was graded as  0 = avascular, 1 = 
normal, 2 = hyperaemic, 3 = very hyperaemic. The blebs with the greatest hyperaemia were those of 
the sandwich treated group and those with the least hyperaemia were those of the sterile water treated 
group.  
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3.5.5 Bleb morphology 
The ilomastat / dexamethasone treated blebs had conspicuous implants in three of 
four animals at day 10. At this stage the contours of the bleb surface outlined the 
shape of the implants, indicating little adjacent tissue or fluid. In a similar way the 
polymer coated implants were conspicuous from day 10 in all four animals, and their 
physical presence appeared to contribute to the bleb shape from this point (Figure 
3-82). The bleb morphology in the sandwich, Healaflow / ilomastat, and Healon GV 
/ ilomastat treatment arms also appeared to be affected by the compounds within, 
with the surface contours of some blebs resembling more of a “bell shape.” 
Furthermore some of the contents appeared to precipitate down the tube into the 
anterior chamber (Figure 3-84). Those of the Healon GV / ilomastat implant treated 
blebs had the least disturbance (Figure 3-83). 
 
Figure 3-82 Representative photographs of blebs of the dexamethasone / ilomastat and polymer 
coated implants. Both the dexamethasone and ilomastat blebs were conspicuous by day 10. (A). A 
side view illustrates how both implants affect the surface bleb contour (C). The polymer coated 
implants were conspicuous at day 10 (B) and affected the bleb surface contour in a similar way (D). 
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Figure 3-83 Photographs of the bleb morphology of the hyaluronic acid / ilomastat 
combinations and the sterile water treated group. Three of the sandwich implant group had the 
most hyperaemic, raised blebs (E). The Healaflow / ilomastat blebs appeared less vascular, however 
were just as “bell shaped” in three of them (F). In this group the blebs appeared to have an opaque 
substance within. In one animal there were white clumps of material that passed down the tube and 
were found to precipitate in the anterior chamber in a similar way to the pseudohypopyon seen in 
phacolytic glaucoma though no anterior uveitis or fibrin in the anterior chamber was seen (see below). 
The ilomastat / Healon GV treated blebs were lower and less bell shaped (G). The blebs of the sterile 
water treated group were the lowest and had the least vascularity (H). 
 
 
Figure 3-84 Precipitation of Healaflow / ilomastat in the anterior chamber. This can be seen at 
the end of the tube. 
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3.5.6 Testing of Bleb functionality using Indocyanine Green 
Under terminal anaesthesia one animal from each treatment group arm, chosen at 
random, and 0.05 mls of ICG was injected into the anterior chamber. To be sure 
there was no artificial IOP rise that might significantly alter the progress of dye into 
the bleb a pressure transducer was inserted into the anterior chamber to monitor 
intracameral IOP and 0.05 mls of aqueous was withdrawn prior to ICG injection 
(Figure 3-85, Figure 3-86).  
ICG injection resulted in the anterior chamber being filled with fluorescent dye. 
However, despite attempts to keep the globe surface dry using tissue and injecting 
the dye from an inferior position, dye was found to contaminate the surface of the 
conjunctiva resulting in a ‘false fluorescence’ from the bleb (Figure 3-87, panel 
within). After 30 minutes no dye was found to have entered the bleb area via the 
tube. Instead a number of blebs exhibited hyperfluorescence related to the dye 
entering the venous system, systemic circulation and bleb vasculature (Figure 3-88).  
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Figure 3-85(A) Transducer (T) and ICG needle (N) insertion into the anterior chamber. (B) 
anterior chamber filled with ICG.  
      
Figure 3-86 Changes in IOP with ICG insertion into the anterior chamber. Data displays 
intracameral IOP measured every 2 seconds and illustrates how IOP changes with transducer needle 
insertion (A), removal of 0.1 mls of aqueous by insulin syringe (B), insertion of syringe containing 
ICG (C) and injection of ICG (0.1mls)(D). 
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Figure 3-87 Fluorescence from ICG dye injected blebs illustrating hyperfluorescence from dye 
leakage onto the conjunctival surface. Pictures display dye and red-free (without dye) from sterile 
water treated group (A and B respectively) and polymer coated implant (C and D respectively). 
Legends: R; hyperfluorescence from ICG dye leakage onto the conjunctival surface, T; tube, I; 
implant. 
 
Figure 3-88 ICG hyperfluorescence in the bleb blood vessels.  Pictures display red-free (E) and 
dye fluorescence (F) from the bleb area of a rabbit treated with dexamethasone / ilomastat implants. 
The implants can be seen in the red-free photograph and the dye hyperfluorescence outlines the 
vasculature, not the bleb interior as anticipated. 
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3.5.7 Histology 
Implants were located in all of the ilomastat and dexamethasone treated groups. 
Where implants were not found at the level of the drainage tube they were found in 
adjacent sections.. In the rabbits treated with the dexamethasone and ilomastat 1 mm 
implants there were a scattering of inflammatory cells and adjacent fibroblasts. 
There were no apparent differences in inflammatory cell distribution between the 
two implants in any single rabbit (Figure 3-89). 
All four of the polymer coated implants were located in the sections either in the 
same plane as the drainage tube or in adjacent sections. Around the pink refractile 
drug remnant there were also associated elongated pieces of clear snake-like 
substance consistent with the polymer. Above and below the polymer coated implant 
there were few inflammatory cells. There were however clusters of inflammatory 
cells at either end of most of the implants associated with gaps in the polymer coat, 
and in one particular section of (1 mm away from the drainage tube of rabbit 21) the 
cluster of inflammatory cells were associated with conjunctival vessel development. 
All three of the Healon GV / ilomastat implant treated blebs had varying degrees of 
inflammatory cell infiltrate located in the region where the implant was placed. 
Numerous polymorphs, macrophages and lymphocytes were seen distributed 
throughout the subconjunctival area. Associated with these were small pink refractile 
islands that had cells including Langhans’ cells associated with them. 
A significant inflammatory infiltrate was seen in three of four of the Healaflow /  
ilomastat treated blebs. In one of the Healaflow / ilomastat treated blebs the 
histology was less clear with the repeated fracturing of the tissue during sectioning. 
The sandwich implant treated blebs had significant inflammatory cell infiltrate in 
three of the four animals. Spaces were found between the significant foci of 
infiltrate. Surrounding the inflammation was an encapsulating band of fibroblasts. 
Sections of blebs in the sterile water group exhibited an inflammatory response 
around the drainage tube. Behind the tube however the conjunctiva had a more open 
morphology. 
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Figure 3-89. Sections of the representative blebs of the ilomastat / dexamethasone (A) and 
polymer coated implant groups (B). Legends: C, conjunctiva; S, sclera; I, implant; T, tube. Scale 
bars 1 mm. A scattering of inflammatory cells was noted around the surface of the polymer coated 
implants. An increased density was seen at either end, most notable in one rabbit 1 mm away (see 
below) 
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Figure 3-90. Representative histological sections of the sandwich implant (C), healaflow / 
ilomastat (D), healon GV / ilomastat (E), sterile water group (F). Scale bar 1 mm. A significant 
inflammatory response was seen in the bleb areas of all hyaluronic acid / ilomastat combinations. The 
sterile water treated group exhibited some inflammation in the proximity of the drainage tube but less 
posteriorly. 
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3.5.8 Discussion 
The results from this experiment found that all combinations of hyaluronic acid / 
ilomastat led to histology demonstrating a significant amount of inflammation at day 
14. The dysmorphic nature of the blebs concurred with the histology. Why should 
this contrast so greatly with the hyaluronic acid /ilomastat combination in the second 
experiment? Is it simply that the time point is earlier, and if a snapshot of histology 
in the previous experiment were taken a similar result would be seen? Apart from 
sectioning at day 30, the other differences between the previous experiment and the 
present one are the type of hyaluronic acid, the method of sterilisation, and the 
proportions of drug and hyaluronic acid used. If we examine each of these in turn:  
Visiol has a lower molecular weight than Healon GV, Healaflow or Revanesse. It is 
possible that the Visiol was cleared more quickly and hence any inflammatory 
reaction to this hyaluronic acid resolved more quickly. However, Healon GV and 
Healaflow are both used in humans without ill effect (inflammation), albeit as a 
buffered gel / solution and not as a freeze-dried preparation. Hydrating freeze-dried 
hyaluronic acid does not revert it to the same physical state as the original 
preparation. An important comparative control would be to use the hyaluronic acid 
preparation but without the drug. Unfortunately due to limitations in animal number, 
and the nature of the experiment being a pilot, a large number of controls was not 
possible.  
The method of sterilisation in this experiment was by ultrafiltration of the drug 
solution, one that has been used successfully by A. Khalili for the sterilisation of 
bevacizumab implants (PhD thesis A Khalili). The sterilisation of the Visiol / 
ilomastat implants in the previous experiments was by exposure to radiation from a 
strontium – 90 probe, typically used as an anti-scarring device in glaucoma surgery 
(Kirwan et al., 2006), and not in any way as intense as that used as a standard for 
sterilisation of medical equipment. Indeed, it would be less surprising if the animals 
in the previous experiment developed an endophthalmitis.  
One factor likely to contribute to the inflammatory difference is the proportion of 
drug to hyaluronic acid, which was far less in the earlier experiment, or indeed that 
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whether the hyaluronic acid was cross-linked and with greater longevity. The 
quantity of ilomastat estimated in the Visiol experiment was 0.5 mg and, although 
the exact mass of hyaluronic acid was unknown, the overall implant had an 
estimated weight of between 8 and 9 mg. In the above experiment the quantities of 
ilomastat and hyaluronic acid were 1 mg and 3 mg respectively for all three arms. A 
lower quantity of hyaluronic acid was used so that not too great a volume of gel 
would be formed on hydration. A higher quantity of drug was used to prolong 
release. It would appear, however, that there was a greater proportion of crystalline 
drug in an undissolved state, despite being dispersed in a hyaluronic acid gel. 
Immune cells recognised the solid crystalline material and mounted a response. That 
islands of crystalline drug are seen in these combinations surrounded by foci of 
immune cells provides support for this. Furthermore, in the sandwich implant where 
drug was not dispersed throughout the hyaluronic acid ilomastat combination, there 
were open spaces not associated with drug in between foci of inflammation. 
The dexamethasone and ilomastat implants exhibited less inflammation than the 
hyaluronic acid combinations at day 14. Indeed the intensity of inflammation seen 
around the implants was similar to that seen around the combination dexamethasone 
ilomastat implants in the previous in vivo experiment. Interestingly there was no 
propensity for more immune cells to be co localised with one implant rather than the 
other, indicating that the anti inflammatory effect of the drug from one implant was 
maintained beyond its own position, or that the antagonistic particulate effect of one 
implant versus the other was not significantly different. Not withstanding these 
findings, however, again the blebs seen in this group were low in comparison to the 
previous experiments and other blebs, and both implants from early on in the 
experiment affected the contour of the conjunctiva of the bleb. Again, interpretation 
of how functional the bleb is at this point is difficult, since spacer effects could 
influence interpretation of the bleb appearance. 
The results of the polymer (provided by Alex Seifalian) coated implants are of 
interest. There was considerably less reactive inflammation in most of the sections 
than that seen in the uncoated pure ilomastat implants in the previous experiments. 
This implies that the foreign body response can be minimised. Islands of 
inflammation, however, were found most often at either end of the implants. In one 
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section the inflammatory reaction was considerable with evidence of a large blood 
vessel. It is likely that in these areas there were defects in the polymer allowing 
access to dendritic or other immune cells. Corroborating these findings were those of 
the detailed SEM images that showed small pits in the polymer coat and crystalline 
material underneath (Figure 3-65).  
What is less clear, however, is how much drug is eluting from these polymer coated 
implants. In vitro release data suggested that polymer coated 2 mm implants are able 
to release drug at a similar rate to uncoated 1 mm implants. Whether the drug 
released is eluted through the coating or through defects such as those seen on the 
SEM is not possible to determine with the samples in this experiment. Analysis of 
the polymer remnants was attempted, however removal of the polymer casings from 
the rigs caused damage to the surface.  
Determining the efficacy of the polymer coated implants, and indeed the other 
implants, in prolonging bleb survival in the animal model remains a challenge. As in 
the dexamethasone / ilomastat implant treated arm, the contours of the blebs in the 
polymer coated arms were affected by the implants within the subconjunctival space. 
An attempt was made to evaluate drainage of aqueous into the bleb using ICG 
injected into the anterior chamber at the time of termination. There was no 
conclusive proof of dye entering the bleb from the tube however. Instead it was 
apparent that the fluorescence seen in blood vessels within the bleb and this was due 
to the dye entering the circulation presumably via the trabecular meshwork. It may 
be that the flow of aqueous through the tube is too slow in the scenario of a 
functioning bleb, or alternatively the bleb has failed. Unfortunately we did not have a 
positive control to compare to such as an MMC treated bleb. 
Further work is required to determine the polymer properties and its behaviour in the 
subconjunctival space. This was the first time this polymer was used for drug 
delivery and much of the previous work was on tracheal stents (Jungebluth et al., 
2011)(Crowley et al., 2014). It is important to compare the tissue response that this 
polymer has to other polymers previously used in this location, for example in 
devices such as the Ahmed or Baerveldt tubes. It may be that there is significantly 
less tissue reaction, but this data needs to be obtained. Of note is that although the 
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polymer is ‘tissue biocompatible’ it is not biodegradable and remnants will remain in 
the subconjunctival space. Is this a benefit or an impediment? The Olagen implant 
uses the spacer effect as its underlying principle to prolong trabeculectomy survival 
(Rao et al., 2009). Longer-term data though is still required to be able to evaluate its 
efficacy. An unknown risk factor is extrusion. Extrusion of the metal Ex-PRESS 
tube, an implant not sutured into place, has been reported (Tavolato et al., 2006), 
although this is of a different material, size and shape. 
A key aim in future experiments will be to develop a uniform coating without 
defects that has a porosity of sufficient size to allow drug dissolution but less than 
will allow immune cell access. It has been shown that membranes with pores of 3 
µm diameter allow lymphocyte migration, but not those of 0.45 µm (Haston et al., 
1982). It will be of interest to examine the release of drug in polymer coats of 
different pore sizes. 
Where a polymer of low immunogenicity has significant promise is in the 
development of a glaucoma drainage device. Currently these are used in the setting 
of patients with failed trabeculectomy or those at high risk of failure. A recent 
randomised trial has suggested that the success rate for the Baerveldt tube in this 
type of patient is significantly greater than trabeculectomy with MMC (Gedde et al., 
2007b; Gedde et al., 2007a; Gedde et al., 2009). Unlike trabeculectomy the 
Baerveldt, Molteno and Ahmed drainage devices rely on the development of a 
fibrous capsule with a lake of aqueous around the drainage plate, or so called 
Tenon’s cyst, to prevent hypotony, yet excessive scarring is still the main cause of 
failure (Rao et al., 2009). Developing a drainage device that has significant 
advantages in tissue biocompatibility, which may entail the integration of an 
antiscarring agent, would fulfil an unmet need. 
The findings of the experiments described in this section indicate that coating a pure 
ilomastat implant with a polymer significantly reduces the inflammatory response 
seen to the naked implant. Hyaluronic acid ilomastat combinations exhibit a foreign 
body response that is considerable and most likely due to the presence of 
undissolved drug. Future work is required to develop a model of testing bleb 
functionality. 
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3.6 Investigation into the use of different polymer coated implants for 
antiscarring therapy 
 
In the previous experiment ilomastat implants coated with polymer provided by Alex 
Seifalian (UCL/Royal Free Hospital) were found to release drug in the rigs within 
the therapeutic range, however a number of defects were noted on the surface of the 
implants when analysed by SEM. Thus it was not clear whether drug was being 
eluted through the polymer or via defects. Furthermore, although less inflammatory 
response was seen around these implants in the in vivo experiment compared to 
previously seen with uncoated implants, pockets of inflammation were noted, 
particularly at either end of the implants. It was therefore necessary to optimise the 
coating of the implants and verify drug release. 
Work performed by Yasmin Rafieim, under the supervision of Professor Seifalian, 
aimed to improve coating a spray coating process, however despite multiple attempts 
using different coating times, and strategies (dip coating vs spraying), defects 
remained in the coated implants. Further experiments performed by myself aimed to 
use pre-fabricated polymer to make a shell before implant insertion. Even using 
polymers made with different porogens to enhance water permeation as used for 
example in gastric drug delivery (Mastropietro et al., 2012), no drug release was 
detected in standard rig experiments (2 mm, 1 mg implants). Further technical 
difficulties also became apparent. Attempts to seal the edges of the pocket using heat 
at 200 0C (the temperature of polymer denaturation) led to inconsistent results, with 
the polymer having variable cohesiveness and would not readily seal. Using 
cyanoacrylate glue was also found not to work (Figure 3-91).  
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Figure 3-91. Attempts to seal a polymer pouch using cyanoacrylate glue (A) and forceps heated 
to 200 0C (B). 
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3.7 Investigation into the use of a hydrophilic polymer coated implants 
An alternative more hydrophilic biocompatible polymer was sought. Vertellus is a 
company that has developed several different phosphorylcholine (PC) polymers for 
use in humans. Their polymers are used in contact lenses and coating of cardiac 
stents. Unlike the polymers used in the previous experiments, they swell on contact 
with water, becoming hydrated. Thus in theory water imbibition will allow drug 
dissolution. In the light of the work performed so far there were two main initial 
questions: 
1) Would it be feasible to coat an ilomastat tablet with a PC polymer uniformly, 
without defects? 
2) If so, would ilomastat elution occur at a therapeutic concentration? 
Vertellus performed the coating process at their laboratory in Basingstoke. The 
polymer solution was prepared using ethanol as a solvent. They optimised the 
polymer concentration in preliminary experiments to establish a consistency that 
would give a smooth coat to the implant surface. Using a dip coating method with a 
polypropylene mesh basket, ilomastat implants were immersed and then allowed to 
dry. Two polymer types were potential candidates for the coating process: “PC 
1059” and “PC1036”. Both polymers are made up of phophorylcholine groups, 
molecules which exhibit bipolar charge, but overall are neutral, similar to the non 
thrombogenic outer membrane of erythrocytes and have been used in clinical 
products. PC 1059 is synthesised without cross linking between polymer chains, 
whilst PC 1036 polymer chains become cross linked after curing at 50 0C. In theory 
the polymer that is more cross-linked should hinder flow of solution more. Implants 
of 2 mm diameter and 1 mg in mass were fabricated at the School of Pharmacy and 
sent to Vertellus for coating. 
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3.7.1 In vitro analysis of Phosphoryl polymer coatings  
3.7.1.1 Appearance of ilomastat implants coated in PC 1036 and PC 1059  
Using a dip coating procedure, initial experiments involved coating ilomastat tablet 
with a single coat of either PC 1036 and 1059. The implants appeared to have 
polymer of variable thickness on the surface. The periphery of the flat surfaces 
revealed greater coating than the edges or centre. Drug crystal shapes were also seen 
in outline.  
 
Figure 3-92. SEMs of implants coated with the polymers PC 1059 (A, B, C) and PC 1036 (D, E, 
F). Implants showed polymer coating with greater thickness at the periphery of the flat edge. Polymer 
PC 1059 thickness was found to be 8.2 +/- 1.8µm (mean +-SD). Polymer PC 1036 coating thickness 
was 6 +/- 2.25 (mean+-SD). The crystalline drug was seen in outline underneath the polymer skin in 
both types of implant. 
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3.7.1.2 Release studies for 1036 vs 1059 
Both implants coated in PC 1036 (cross-linked) and PC 1059 (non cross-linked) 
released ilomastat at a concentration between 10 and 100 µM for 21 days, with a 
greater rate of release from the implants coated in PC 1059 (Figure 3-93, Figure 
3-94). It was not possible to determine the exact quantity of drug present after 
coating by the polymer, however given that the overall mass of the implants was 
similar it is likely that some of the drug dissolved in the solvent used in the coating 
process. The mean peak concentration of ilomastat was 45 µM for implants coated in 
PC 1059 and 21 µM for implants coated in PC 1036.  
 
 
Figure 3-93. Mean concentration of ilomastat released from single coated PC 1059 (non cross-
linked, n = 2) and PC 1036 (cross-linked, n = 2) polymer 2 mm ilomastat implants. Presumed 
mean mass of drug = 1 mg. A higher level of drug concentration was seen with the implants coated in 
the non cross-linked PC 1059. Error bars indicate SD. 
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Figure 3-94. Cumulative release of ilomastat over time from PC 1059 and PC 1036 polymer 
coated implants. A faster release was seen with the implants coated in the non cross-inked polymer 
PC 1059. 
 
3.7.1.3 Appearance and release characteristics of ilomastat implants with 
multiple coatings of PC1059 (3, 5, 7) 
As the rate of drug dissolution was greatest with implants coated in PC 1059, yet 
appeared to have a thicker more even coating, this polymer became the coating of 
choice. Drug dissolution was also likely to be more efficient from this non-cross 
linked polymer. Subsequent experiments aimed to determine whether application of 
multiple coats yielded a smoother surface without drug exposure.  
3.7.1.3.1 Appearance of ilomastat implants coated 3, 5, and 7 times in PC 1059  
Implants exposed to 5 and 7 coating procedures had a greater polymer thickness than 
the implants coated 3 times (Table 3-5, Figure 3-95). The surface of implants coated 
7 times appeared more smooth than those coated 3 or 5 times and with less variation 
in thickness.  
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Table 3-5. Mean coating thickness as determined by SEM for n = 9 measurements. 
Number	of	coats	 Mean	thickness	
(μm)	(n	=	9)	
Standard	
deviation	
Range	(μm)	
3	 24.4	 26.9	 3.5	-	87	
5	 40.7	 30.5	 1.1	-	83	
7	 37.5	 19.3	 4.8	-	66	
 
 
Figure 3-95. Appearance of implants with 3, 5 and 7 coats of polymer PC 1059. Images A and C 
are SEMs of an implant coated 3 times. Images B and E are of an implant coated 5 times. Images D 
and F are of an implant coated 7 times. White arrows represent measurements taken to determine 
polymer thickness. 
3.7.1.4 Appearance of hydrated polymer PC1059 coated implants 
Pure polymer PC1059 was delicate and fragmented easily on handling. As a 
consequence the manipulation required for SEM resulted in some indents in the 
surface. Coated tablets had greater uniformity. Of note however were small pores 
beneath the surface with the polymer having a spongy appearance (Figure 3-96). 
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Figure 3-96 Hydrated polymer PC1059. A smooth surface may be seen with spongy appearance 
beneath. 
 
3.7.1.5 Release studies for implants coated multiple times of PC 1059 
A therapeutic concentration of ilomastat (between 10 and 100 µM) was maintained 
for the duration of the release study (Figure 3-97, Figure 3-98). Implants coated 5 
and 7 times appeared to release ilomastat at a similar rate, and the greatest rate of 
release was from implants coated 3 times. 
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Figure 3-97. Mean concentration of ilomastat released from ilomastat implants coated in PC 
1059 multiple times 3 (n = 3), 5 (n = 3), 7 (n = 3). Presumed mean mass of drug = 1 mg. Error bars 
indicate SD. 
 
Figure 3-98. Cumulative release of ilomastat over time from implants coated 3, 5 and 7 times in 
PC 1059. Error bars indicate SD. 
 
  
0 50 100 150 200 250
0
25
50
75
100
125
150
Time (hours)
C
on
ce
nt
ra
tio
n 
(µ
M
)
Ilomastat coated 1059 x3
Ilomastat coated 1059 x5
Ilomastat coated 1059 x7
0 50 100 150 200 250
0
20
40
60
80
100
Time (hours)
%
 D
ru
g 
re
le
as
e
Ilomastat coated 1059 x7
Ilomastat coated 1059 x3
Ilomastat coated 1059 x5
  
192 
3.7.2 In vivo analysis of polymers coated 7 times in PC 1059 
Implants coated in PC1059 7 times had the most regular and complete coatings 
whilst still releasing drug at a therapeutic concentration, thus were chosen as 
candidates to determine anti-scarring potential. It was postulated that these implants 
would provide antiscarring efficacy with drug elution through the coating, yet 
prevent immune cell access and activation. Because we wished to examine 
distribution of ilomastat in different ocular tissues at the end of the experiment and 
those globes would not be able to be used for histology the treatment arms and n 
number were chosen as follows: 
The experimental arms chosen were: 
1) Ilomastat implants (2 mm 1mg) coated 7 times in PC polymer 1059 (n = 16) 
2) MMC (0.2 mg / ml applied for 3 minutes) (n = 10)  
3) Sterile water (water applied in the same way as MMC (n = 10) 
Two rabbits had to be terminated early: one suffered seizures under anaesthetic 
(sterile water group) and the other had an intractable hyphaema that resulted in tube 
blockage and significantly elevated IOP (PC polymer ilomastat implant group). The 
rabbits treated with MMC had 8 / 10 blebs that were maintained until day 30. Four of 
these were noted to have an avascular edge at day 18. Ten of fifteen rabbits treated 
with implants coated in PC polymer 1059 had blebs that appeared to survive until 
day 30 although the dimensions were smaller than the MMC blebs and in four of 
these the blebs had a morphology where the implant contributed to the appearance. 
The animals treated with sterile water all had blebs that failed by day 15. 
Representative photographs at day 15 and day 24 are shown in Figure 3-99 and 
Figure 3-100, and a survival curve in Figure 3-101.  
  
193 
 
 
Figure 3-99. Representative photos of blebs at day 15 for each of the treatments: mitomycin C 
(A), sterile water (B), ilomastat PC 1059 (C). The appearance of blebs A and B were classed as 
functional and the bleb in C as a failure. The MMC bleb has an avascular edge. 
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Figure 3-100. Representative photos of blebs at day 24 for each of the treatments: sterile water 
(A), mitomycin C (B), ilomastat PC 1059 (C and D). The appearance of ilomastat PC 1059 and 
mitomycin C blebs were classed as functional and the sterile water bleb as a failure. A side view of 
the ilomastat PC 1059 illustrates how the implant contributes to bleb appearance (D).  
 
 
Figure 3-101. Bleb survival of the 3 different groups: ilomastat coated in PC polymer 1059 (n = 
15); MMC 0.2 mg / ml applied for 3 minutes (n = 10); sterile water (n = 9).  
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3.7.3 Intraocular pressure 
Intraocular pressures of rabbits treated with MMC were lower than the other two 
groups at all time points following surgery. The sterile water treated group and 
PC1059 polymer coated implant treated group had an IOP that returned to baseline 
by day 9. There was a significant difference between the groups at day 30 (Kruskall-
Wallis: (H (2) = 11.76, P = 0.0028). There was little difference in intraocular 
pressure in the unoperated eye of the three groups. 
 
 
Figure 3-102 IOP for all 3 groups over time. The eyes that received MMC maintained a lower IOP 
for all postoperative days. Error bars indicate standard error. 
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Figure 3-103 IOP for unoperated eye all 3 groups over time. There was little difference between 
treatment arms. Error bars indicate standard error. 
 
3.7.4 Bleb surface area and height 
Blebs of rabbits treated with MMC and the PC1059 polymer coated implants had 
greater surface area and were classed as ‘higher’ throughout the experiment.  
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Figure 3-104 Bleb surface area for the 3 groups over time. Rabbits treated with the PC1059 coated 
implants and MMC had a greater surface area at each time point than the sterile water treated group. 
Error bars indicate standard error. There was a significant difference between the groups at day 30 
(Kruskall-Wallis: (H (2) = 11.02, P = 0.0041) 
 
 
Figure 3-105 Bleb height for the 3 groups over time. Bleb height was graded as 0, flat; 1, 
shallow/formed; 2, elevated < 2 mm and 3, high > 2 mm. Error bars indicate standard error. There was 
a significant difference between the groups at day 30 (Kruskall-Wallis: (H (2) = 12.42, P = 0.0020) 
3.7.4.1 Bleb vascularity 
PC 1059 polymer coated implant treated blebs maintained greater vascularity than 
the MMC or sterile water treated groups. Little difference in overall vascularity 
could be distinguished between the MMC and sterile water treatment arms (Figure 
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3-106). A Kruskall-Wallis test performed at day 15 found a significant difference 
between the arms (H (2) = 7.68, P = 0.0215). 
 
Figure 3-106 Bleb vascularity. The vascularity was graded as  0 = avascular, 1 = normal, 2 = 
hyperaemic, 3 = very hyperaemic. Data displays vascularity of observed blebs at each time point as 
mean and standard error of the mean. The implant treated blebs were graded as having greater 
vascularity at each time point than the blebs treated with MMC and sterile water. 
3.7.4.2 Histology 
Analysis of the histology for this study was hindered by errors in processing. The 
processing machine that transfers the globes from one concentration of alcohol to the 
next broke down in the UCL Institute of Ophthalmology histopathology laboratory. 
It has subsequently been replaced.  Eight of the globes were found to have had their 
processing interrupted and five of these had extended exposure to air. A number 
(exact total unknown) were processed at a faster rate than expected. 
Of the 29 globes processed for histology, sections could be mounted on slides from 
28 globes. The tissue sections of the 5 that had been exposed to air were more 
compacted, and 4 others were difficult to cut, indicating possible under processing. 
In all 9 globes that received PC 1059 coated implants the remains of the implants 
could be seen as a distinct entities (Figure 3-107, Figure 3-108). An adjacent zone of 
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inflammatory cells was seen, superior to which there was thickened conjunctiva. 
Macrophages with a foamy appearance were the predominant cell found within the 
inflammatory zone. In 4 of the globes inorganic material could be identified and in 
one section red blood cells were seen nearby. 
In the sterile water treated groups the overlying conjunctiva in the bleb area was 
slightly thickened with a scattering of inflammatory cells (Figure 3-107). In all of the 
MMC treated group the conjunctiva was noted to have a paucity of nucleated cells in 
the bleb area. In 3 / 10 of the MMC treated eyes a cavity corresponding to the bleb 
was found. Epithelial interruptions were seen in these 3 together with apoptotic cells. 
 
Figure 3-107 Haematoxylin and Eosin staining of bleb areas from rabbits treated with sterile 
water (A), Mitomycin C (B), PC 1059 coated implants (C) and close (x5) view of PC 1059 (D). 
Legends: Co: conjunctiva, T: drainage tube, S: sclera, I: implant remnants. Surrounding the implant 
remnants were inflammatory cells made up predominantly of macrophages. Scale bars 1 mm.  
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Figure 3-108 Haematoxylin and Eosin staining of all blebs treated with the PC 1059 coated 
implant. Tiles A, B, C, D, E, F, G, H correspond to rabbits 35, 21, 25, 18, 2, 11, 29, 32. Tiles E, F, G 
and H also illustrate how the appearance differs when the globes are not processed to plan. Tiles F and 
G are from globes over exposed to air. 
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3.7.5 Tissue levels of ilomastat 
The concentration of ilomastat in the aqueous, vitreous, bleb conjunctiva, remaining 
conjunctiva, cornea and sclera were determined at day 30 in 6 of the implant treated 
blebs Table 3-6. Although I contributed with dissecting tissues at the time of 
harvesting, Dr Ahmed performed the analysis using facilities at the Royal Free 
Hospital. It was not possible unfortunately to extract aqueous directly from the bleb.  
Table 3-6 Tissue levels of ilomastat at day 30. Tissues where drug was not detected are labelled as 
ND. 
Rabbit	
number		
Aqueous	
humour	
(nM)	
Vitreous	
(nM)	
Bleb	
conjunctiva	
(pg/mg	
tissue)	
Cornea	
(pg/mg	
tissue)	
Sclera	
(pg/mg	
tissue)	
Ilomastat	
remaining	
after	30	d	
(µg)	
4	 14.9	 67.1	 ND	 148.7	 ND	 46.54	
8	 ND	 3.6	 210.7	 30.6	 644.9	 Not	found	
12	 996.5	 5.8	 871.6	 72.1	 15838.9	 Not	found	
22	 57.7	 0.2	 33.7	 8.5	 201.1	 Not	found	
26	 15.3	 ND	 975.6	 53.6	 1958.9	 3.48	
30	 3.9	 0.5	 1503.8	 0.3	 447.1	 4.02	
Mean	±	
SD	
217.7±19
5	
13.4±12.
9	
719.1±267.
6	
52.3±2
1.9	
3818.1±3
51.1	
	
  
3.7.6 Discussion 
These experiments showed that it was possible to formulate a PC polymer coated 
ilomastat implant that would, in theory, allow drug dissolution in an aqueous 
environment to maintain a therapeutic concentration within the bleb. Similar PC 
polymers have been used for coating of cardiac stents (Habara, S, et al. 2011).  The 
seven times coating of the non cross-linked polymer appeared to give the smoothest 
surface, although there was still considerable variability in the coating thickness 
(Figure 3-92, Figure 3-95). No definitive breaches were seen on SEM of the dry 
implant, however a zone of foamy type macrophages was found on histology around 
all implants, and the coating on wet SEM had a somewhat friable appearance.  
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A foreign body type reaction therefore existed, but much less than seen to naked 
ilomastat implants in the first in vivo experiment. Whether the remaining reaction 
was due to the coating becoming spongy and permeable after hydration, allowing 
immune cell access to solid crystalline drug, whether drug during the coating process 
had dissolved in the coating itself and recrystallized with drying, or whether this 
reaction was due to the polymer per se is difficult to say. However, unlike the 
experiment using the POSS PCU polymer, there were no localised collections of 
inflammatory cells, suggesting that the coating was unlikely to have cracks or holes. 
Vertellus tried many different methods in the coating process, comparing dip coating 
in a mesh basket to spray painting, using different concentrations of polymer solution 
and whether to pre clean implants prior to coating with a solvent such as hexane. 
Given the constraints of time a dip coating method, which yielded the smoothest 
coatings, was chosen. Pre-cleaning with a solvent, which may have caused 
significant implant absorption, was deemed not to be necessary. Nonetheless, how 
much drug absorption took place in the coating process is important to determine in 
future experiments in coating optimisation. Certainly some drug was absorbed, given 
that many implants were found to have lost, rather than gained mass after polymer 
coating. Indeed where multiple coats were applied experiments drug loss is likely to 
be greater, as ilomastat is readily soluble in ethanol (1mg / mL) and each time a 
polymer coating, is applied the implant beneath may become wet. Unfortunately 
there was insufficient time and insufficient number of implants to explore this 
relationship.  
Although smoother and thicker, implants coated seven times still had considerable 
variability in thickness. Some of the thinnest points were found on corners, as were 
some of the thickest, suggesting that gravity played a significant influence while the 
polymer was drying. An analogy might be a cake with wet icing, the thinnest icing 
being the superior corners, with the thickest icing being found at the edge at the cake 
bottom next to the cake board. In future experiments alternative methods to dip 
coating such as fine spraying, might lead to a more uniform polymer thickness. 
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Vertellus attempted a more viscous polymer solution but the coverage of this implant 
surface was irregular. 
The kinetics of release for 3 coatings were similar to naked implants of the same size 
and will most likely reflect how thinly coated these implants were. Interestingly, 
although slower, there was little difference between the kinetics of release for the 5 
and 7 coatings. This correlates with the finding that even though variation was 
greater for 5 coats, overall mean polymer thickness was the same. The drug 
concentration differences close to the implants (the boundary layer) are likely to be 
similar for both 5 times and 7 times coatings. 
PC 1059 was the polymer of choice for coating in later experiments rather than PC 
1036 because preliminary coating experiments showed a greater uniformity of 
coating, with drug crystals being less apparent beneath and faster release for implants 
coated in PC 1059. This polymer however is non-crosslinked, which although may 
have benefited drug release created wider spaces within the polymer matrix, allowing 
cellular access. 
The choice of number and types of treatment arms in an in vivo experiment is 
difficult to judge. There are significant advantages and disadvantages for each choice 
and no obvious ‘correct’ answer. In an ideal world where time and money were 
unlimited and rabbit experience was without discomfort, with therefore little ethical 
problems, multiple treatment arms with multiple sampling time points would be used 
(Table 2-5). A negative control, consisting of an implant without active drug, would 
minimise the number of different variables, and discount the ‘spacer effect’ of the 
implant. Multiple time points of harvesting post surgery would be able to answer the 
question of whether negative control arms exhibited greater inflammatory response 
early on, before remodelling had taken place. 
In the real world, however, time and money are limited, and rabbit experience during 
an experiment is less than pleasant. Indeed it is important to question constantly 
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animal use, reducing n numbers to obtain maximum information with minimum 
numbers, refining the experiment to minimise suffering, and replacing animals where 
able with alternative in vitro techniques. In this, as in previous experiments, 
measures were taken to minimise suffering, for example operating on only one eye. 
The choice of 3 arms was made to maximise the n number for each treatment arm, 
and sterile water group chosen as the negative control, because this is similar to a 
patient clinical trial. No clinical trial currently, unless the Olagen implant (a collagen 
implant being trialled as a spacer in human trabeculectomies) gains acceptance, 
would involve insertion of a spacer as a comparator. 
 The disadvantages in not having a spacer, however is that drug effect cannot be 
isolated. The histology, and indeed bleb morphology, would be more interpretable if 
an ethylcelluose arm had been included. If there were minimal macrophage presence 
around a polymer coated ethylcellulose arm one would be able to exclude the 
stimulatory influence as the polymer per se, and something to plan in a future 
experiment 
As it happened, because many globes were affected by an error in histological 
processing, having the greatest n number possible was fortuitous. Interestingly, 
despite difficulty in sectioning the globes that had been either over processed or 
under processed, the slides were interpretable. The theme of cellular response to 
implant was apparent, even though tissues appeared compacted.   
The drug levels found in the different ocular tissues were lower than expected. There 
was also significant variability between one rabbit and another. In the aqueous 
humour the concentration was 0.02 times the therapeutic concentration found to 
inhibit fibroblasts in vitro. It must be remembered, however, that this was aqueous 
drawn from the anterior chamber, and not from the bleb, which may have been 
different. We also do not know the in vivo drug levels required for efficacy, for 
although in vitro gel contraction experiments found that 10 µM to be the lowest 
concentration that would fibroblasts, other experiments have found the Ki for 
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ilomastat to be 20 nM (Grobelny et al., 1992). How toxic ilomastat is to ocular 
tissues is also an unknown. Published data includes concentrations of up to 100 µM 
not being toxic to human Tenon fibroblasts in vitro (Daniels et al., 2003), and no 
significant side effects seen in a phase 1 clinical trial when patients were treated with 
eye drops of  2 mM ilomastat. 
That aqueous was not able to be drawn from the bleb might be either due to the 
tissue architecture being more like a sponge rather than a lake of aqueous. 
Alternatively, the blebs at this point might have failed and there is no aqueous to be 
tapped. It is not possible to be certain of which of these options is correct, however 
an earlier time point might have given a different result. Another test might be to tap 
the MMC blebs. Of interest in 3 of the MMC treated blebs, there was a cavity seen in 
the histological cross section that most likely would correspond to a lake of aqueous. 
These 3 also had fewer cells in their tube although no significant difference in IOP. 
 The observations during the in vivo study deserve careful consideration. As in 
experiments before the observation of a ‘bleb’ did not correlate with other published 
parameters for success. Success according to the Kaplan Meier chart leads one to 
suppose that those rabbits treated with a polymer coated implant exhibited 
statistically similar success rates to MMC, yet the vascularity, an indicator of likely 
failure in humans (Group et al., 2007) was consistently greater in the polymer 
treatment group than either of the other treatment arms. Only the IOP of the MMC 
treated group, the positive control, was consistently lower than the other treatment 
arms. IOP is an indicator of success in clinical trials but frequently unreliable in 
rabbit GFS (Miller et al., 1989). This finding was something that we did not expect. 
Was the surgery more consistent? Or was it just that larger numbers meant that 
pooled data was more accurate? It is difficult to say, however evidence is indicative 
thus that MMC was more successful than polymer treated group and sterile water 
treated group, and question further the validity of success using observation of a bleb 
when a solid implant is used. This will be explored further in the next chapter. 
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These findings show that coating an implant with a PC polymer reduces the 
stimulatory effect that the particulate nature has on the adjacent tissues. The PC 
polymer implant did not prolong glaucoma surgical success, with less scarring than 
negative control as hypothesised, however that the foreign body response was 
ameliorated is an exciting development that opens the opportunity to drug delivery 
for other pathologies, and drainage device implants. 
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3.8 Investigation into bleb functionality 
In all of the in vivo experiments so far, the observational outcome of success has 
been to use the presence of a ‘bleb’. This outcome measure presumes that the bleb’s 
presence is indicative of fluid draining into the subconjunctival space. However, 
where an implant has been used, the histology has contradicted this relationship. 
Indeed the histology of blebs where implants are seen appears, sine qua non, the least 
likely to encourage drainage of aqueous fluid. 
An alternative method to determine bleb functionality is needed. In the experiment 
before last, fluorescent dye was injected into the anterior chamber and the bleb 
watched to see if dye would pass into the bleb area and delineate the bleb anatomy. 
Unfortunately the time taken to enter the bleb via the tube was longer than time taken 
to enter the systemic circulation, with increased bleb fluorescence due to dye in the 
conjunctival and scleral blood vessels. A different tracer not absorbed into the 
systemic circulation might be more successful such as the use of radiolabelled beads, 
however would be likely to contribute to the wound healing process, and as the bleb 
is more like a sponge rather than an open space, a tracer may not enter freely. 
Post cataract surgery, because viscoelastic is used to maintain the anterior chamber 
shape, postoperative elevation of IOP is not uncommon (Jürgens et al., 1997a). 
Ingerborg Stalmans’s group has demonstrated another method through injection of 
Healon into the anterior chamber of rabbits (personal communication). The IOP as 
result increased, enough to test briefly a number of hypotensive drugs, however the 
effect was short lived, probably due to the break down and excretion of the 
hyaluronic acid. Cross linked hyaluronic acid, such as Healaflow, is believed to have 
a longer half-life and has been reported to help maintain bleb structure post filtering 
surgery in humans (Jürgens et al., 1997a; Roy et al., 2012). Injection of Healaflow 
into the anterior chamber of the rabbit, because of its more stable structure could, in 
theory, therefore lead to a permanent disruption of aqueous drainage and persistent 
elevation of IOP. 
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The use of micro beads to elevate IOP in murine models of glaucoma to test 
neuroprotective or neuroregenerative agents has been reported (Sappington et al., 
2010). Little data exists for the use of beads in the rabbit. One type of bead that 
showed promise, used in our group for a murine model to test neuroprotection, is a 
magnetic coated bead. These have the advantage of being able to be directed into the 
drainage angle after injection using a powerful magnet. 
We therefore tested whether injection of magnetic beads and Healaflow into the 
anterior chamber were able to elevate the IOP, in a pilot study of six rabbits. Three 
rabbits received injections of magnetic beads into their left anterior chamber, and 
three rabbits received injections of Healaflow into their anterior chamber. IOP was 
then monitored postoperatively.  
  
3.8.1 Results 
Injection of Healaflow resulted in a postoperative rise in IOP in two of the rabbits: 
one after the first injection (peak IOP 24 mm Hg) and one after the second injection 
(peak IOP 38 mm Hg). This elevation was short-lived however, with IOP returning 
to baseline after 48 hours. Magnetic bead injection revealed no elevation in IOP; 
indeed the IOP of operated eyes followed a lower trajectory than the unoperated, 
although this did not reach statistical significance (Figures 3-110, 3-111).  
The globe size was found to increase in all 3 rabbits treated with Healaflow (limbus 
to limbus horizontal corneal diameter increase of 1 – 2 mm, P = 0.0075 unpaired t 
test). No increase in globe size was seen with magnetic bead injection. 
Representative photographs of eyes treated with Healaflow injection and magnetic 
bead injection are shown below (Figure 3-109). 
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Figure 3-109 The appearance of representative eyes post injection of Healaflow or magnetic 
beads. 
 
Figure 3-110 Graph to show the IOP of Healaflow injected eyes compared to uninjected eyes 
over time. Arrows indicate the points of injection. Postoperatively after the first and second 
injection 1/3 of the rabbits (not the same) showed an increase in IOP. Data shown is the mean ± SD. 
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Figure 3-111 Graph to show the IOP magnetic beads over time. Arrows indicate the points of 
injection. Postoperatively no rabbits showed an increase in IOP. Data shown is the mean ± SD. 
 
3.8.2 Discussion 
These results show that repeated anterior chamber injection of microbeads and cross-
linked hyaluronic acid in this rabbit model do not lead to sustained elevation of IOP. 
Indeed only a few rabbits responded to the challenge of an ocular hypertensive 
stimulant, and in those that did the elevation in IOP was short-lived. That the 
response was so little and variable is discouraging. Our aim had been to disturb and 
disrupt aqueous drainage that would lead to a consistently raised IOP for the duration 
of a 30-day experiment.   
The great variability seen in IOP response to challenge between rabbits illustrates the 
enormous capacity of a healthy rabbit to drain aqueous (Grierson et al., 1986). Even 
though the anterior chamber was filled with occlusive agent there was incomplete 
outflow obstruction and sufficient compensation by the remaining outflow areas. 
This contrasts enormously to experience in humans, where even a little viscoelastic 
causes a rise in postoperative IOP after cataract surgery. Indeed people have 
examined the effect of different viscoelastics used for cataract surgery on the 
postoperative IOP (Jürgens et al., 1997b), despite the aim not leave any in at the end 
of surgery.  
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Other animal models have successfully raised the IOP by injection of beads into the 
anterior chamber   or viscoelastic. The injection of magnetic coated beads has been 
used successfully in the rat to elevate IOP with the aim of testing either 
neuroprotective agents or stem cell regenerative therapies for the optic nerve (Samsel 
et al., 2011).  Unfortunately a rat has an eye so small that inserting even the smallest 
of standard cannulas is too large for glaucoma filtration surgery (personal experience 
with ex vivo rats). 
The development of buphthalmos in several animals not only indicates that there was 
a significant rise in IOP, but also that rabbits of this age react to raised IOP with 
globe enlargement in a similar way to human infants with congenital glaucoma. 
Buphthalmos is seen in children suffering from primary congenital glaucoma up to 
the age of 3 (deLuise and Anderson, 1983). The connective tissues of the sclera and 
cornea are more plastic at a young age and deform. With the rabbits in this 
experiment they too had deformable sclera / corneal tissues. Unfortunately not only 
does this make it more difficult to estimate the intraocular pressure - an enlarged 
globe will have a thinner cornea, but globe enlargement is unlikely to be identical 
between rabbits and therefore will add to greater variation between animals for future 
experiments. Older rabbits may have not had these characteristics. They are 
unfortunately far more expensive and beyond the scope of this experiment. 
The measurement of success for glaucoma filtration surgery in animal models is 
difficult. Unlike human glaucoma patients, that have a raised IOP to begin with, New 
Zealand White rabbits do not. Genetic engineering has allowed such strains to be 
developed (Gelatt, 1977; Lee et al., 1978; Knepper et al., 1991), however they are 
not freely available. The advantage of IOP use as an outcome measure is that it is 
objective, has a scale, and is directly reflective of the aim of surgery. The use of 
observation of the presence of a bleb as an outcome measure is subjective, has no 
numerical scale, and as seen in previous experiments, may not reflect a bleb’s 
functionality.  
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This experiment has shown that it is difficult to raise the IOP of a rabbit artificially. 
Alternative methods of testing glaucoma filtration efficacy may be more successful. 
A column of water attached to a cannula inserted into the anterior chamber could 
artificially raise the IOP, and rate of flow could be related to functionality. 
Alternatively just using sufficient numbers of animals in an experiment may increase 
the accuracy of IOP measurement even in the presence of a low physiological IOPs, 
as seen in the previous experiment. 
 
  
  
213 
 
Chapter 4 Discussion 
The wound healing response is a complex process. Different cellular responses of 
different magnitudes occur at different times according to the type, scale and 
chronicity of insult. A minor insult of short duration leads to tissue restitution. A 
chronic major insult causes scarring as attempts are made by the tissue to preserve 
organ and organism function.  
With most surgery the aim is to achieve the desired effect with maximum restitution 
and minimal scarring. Shorter skin incisions such as ‘key-hole’ surgery for 
cholecystectomy improve both appearance and reduce recovery times. Smaller gauge 
ports for vitrectomy obviate the need for sutures and reduce surgery duration. There 
is even a suggestion that strabismus surgery should be minimally invasive to cause 
less scarring and improve outcomes (Cambridge Ophthalmological Symposium 
2014). 
The concept of successful GFS however contradicts the inherent aim of normal 
wound healing: to return tissues to their normal structure and function. In successful 
GFS there is constant flow of aqueous through a fistula, an abnormal connection 
between the inside of the eye and the sub conjunctival space. A delicate balance 
exists between the constant drive to close this fistula off, and fluid flow maintaining 
fistula patency. In the patient, too much flow results in hypotony and disruption of 
visual function. Too ‘active’ a wound healing process closes off the fistula and halts 
the drainage of aqueous. 
The experiments within this thesis examined the use of implants of antiscarring drug 
placed within the subconjunctival space.  Based on evidence that these would release 
drug over a prolonged period, it was hypothesised that scarring would be reduced 
with an associated delay in wound healing, and functional drainage prolonged.  
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Although our results show that the physical presence of these implants causes an 
opposite effect on scarring to that hypothesised and are inconsistent with the 
previous in vivo data, considerable valuable information has been obtained. It is clear 
that anything particulate, be that suture or undissolved drug, when placed in the 
subconjunctival space, excites a foreign body response that stimulates scarring in the 
tissue’s attempt to heal. This is not restricted to one particular type of drug, as even 
the most potent of steroids, dexamethasone, in its non-dissolved state caused a 
foreign body response. Experiments that made the implants dissolve faster resulted in 
this response lessening, indicating that if the challenge is removed the scarring is 
less, but did not preclude it. 
Of particular interest, however, was the discovery that the foreign body response 
could be tempered when implants were coated with a polymer. Although not masked 
to the point of allowing drug efficacy to overcome the antagonistic particulate effect, 
different formulations of polymer coating were found to reduce the response by a 
significant degree. 
Where this is pertinent is in the development of drainage devices where the presence 
of non host material within the subconjunctival space is necessary.  Control of 
scarring may also help to smoothen the pharmacokinetic profile of sustained release 
implants in other applications and elsewhere in the body.  
The early experiments that demonstrated the efficacy of ilomastat, as an antiscarring 
agent and prolonging bleb survival in GFS, utilised it in solution form by injection. 
Not yet explored is the potential of topical application of the drug for GFS. Would 
topical ilomastat result in therapeutic efficacy? 
Ilomastat has similar properties to a topical drug that is the first line treatment for 
glaucoma patients, latanoprost (Figure 4-1) 
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Both are small molecules: the molecular weight of latanoprost (432.66), and that of 
ilomastat is (388.47). The water solubility of latanoprost is 50 mg / ml. This is the 
same concentration as used by patients. The aqueous solubility of ilomastat is 38 mg 
/ml. Fibroblast mediated gel contraction is inhibited at ilomastat concentrations of 
between 3.8 to 38 mg / ml (10 – 100 mM). The Ki for a fibroblast is in fact far less 
(0.16 ng / ml or 0.4 nM). In vivo experiments have shown that topical application of 
latanoprost results in a concentration of 1.49 ng / mg of drug in the sclera (Sjöquist et 
al., 1998). We do not know what the penetration of ilomastat would be through the 
conjunctiva, but given the lipophilic nature of the drug it is likely to be comparable. 
Would there be any toxic effect of ilomastat to the cornea? It is difficult to determine 
this without performing the experiment, however it was originally designed as a drug 
to reduce keratits in the setting of corneal ulceration (Galardy et al., 1994). 
 
 
Figure 4-1 Chemical structure of latanoprost (A) and ilomastat (B). 
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It is my belief that the anti inflammatory efficacy of ilomastat as a topical medication 
warrants further investigation. Patients, particularly those with glaucoma, are used to 
applying drops to their eye and would far prefer this method of application than the 
discomfort of an injection. Furthermore, they would be able to apply the drug 
themselves, and eliminating the need for all the manpower and inconvenience of 
multiple hospital visits. 
A far wider reaching implication beyond the setting of GFS, if successful, might be 
the use of topical ilomastat to treat other inflammatory ocular diseases and the 
prevention of scarring post procedures such as dacrocystorhinostomy. Indeed it may 
be possible that procedures in other surgical fields would benefit, such as plastic 
reconstructive surgery. At present the only class of effective potent anti-
inflammatory ocular treatments in every day use are steroids. These are not without 
side effects, such as cataract formation and, as discussed before, raised IOP, 
particularly in glaucoma patients. A new class of anti inflammatory, MMPis, may 
even have a synergistic effect if combined with steroids. Unfortunately these 
experiments were beyond the scope of this PhD. 
Interpretation of ‘success’ in experimental animal models is a contentious issue. 
Historically for glaucoma filtration surgery experiments we rely on the appearance of 
a ‘bleb’ and the way it looks on a two dimensional wafer thin histological cross 
section. It is clear that these two parameters are highly dependant on observer 
interpretation and may vary considerably depending on how the first looks and the 
orientation and location of the slice of the second.  
Without complete objectivity it is not possible to retain an unbiased perspective. The 
space shuttle ‘Challenger’ exploded shortly after take off on a cold day when the 
rubber seals in the rocket failed to flex and extend appropriately. The likelihood of 
this happening was well known to the construction workers who made the seals and 
as this information was fed up the chain of command a more and more positive 
interpretation of risk of mechanical failure was taken as juniors wishing to please 
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their superiors painted an optimistic picture (Feynman RP, 1988). The desire to 
achieve success in sending a teacher into space outweighed the more sensible 
decision to delay launch to a warmer day with catastrophic consequences. 
These experiments illustrate the importance of understanding material tissue 
interaction for the development of drug delivery devices. Experimental models are 
key to allowing the development of new treatments and prevent launching into first 
time human use without knowledge of how these might behave within a living 
organism, yet are only useful so long as their limitations are recognised. 
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